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Abstract.
PRH is a transcriptional repressor that regulates development of the haematopoietic 
and vascular systems. VEGF is a mitogen that stimulates cell survival via cell surface 
receptors including VEGFR1 and VEGFR2. This thesis identifies Vegf, Vegfr1, and 
Vegfr2 as bona fide PRH target genes and shows PRH can control cell survival 
through the modulation of VEGF and VEGF receptor signalling. CK2 is a stress-
activated protein kinase with pleiotropic activity and CK2 phosphorylation of PRH 
inhibits its DNA binding activity.  Here I show that CK2 can antagonise PRH induced 
cell death and transcriptional regulation. Furthermore I show that CK2 reduces PRH 
stability and decreases nuclear retention of PRH. The oncogenic BCR-ABL fusion 
protein increases CK2 activity. I show that Inhibition of BCR-ABL in CML cells  results 
in decreased PRH phosphorylation and the down-regulation of PRH target genes. 
Reestablishment of gene control by PRH is  partly responsible for the therapeutic 
effects of BCR-ABL inhibition in CML and that the reestablishment of PRH function 
could be valuable for the treatment of leukaemias with elevated CK2 activity. These 
data show that PRH is a key regulator of the VEGF family and loss of PRH 
transcriptional activity, through elevated CK2, has a role in leukaemogenesis.
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Introduction
1 Introduction.
1.1 Transcription.
1.1.1 Introduction to Transcription.
Humans, and other higher eukaryotes, are complex organisms that are formed from 
several specialized cell types. These cell types are composed of a specific 
combination of proteins that characterize each cell and allow it to perform specific 
functions within a multi-cellular organism. The specific combination of proteins in a 
particular cell is tightly  regulated by numerous endogenous and exogenous signals 
that influence both the regulation of gene expression and protein turnover. Regulation 
of gene expression is a critical process that conveys the cellular response to 
extracellular stimuli. Gene expression is a multi-step process, consisting of gene 
transcription, mRNA processing, mRNA export, protein translation and correct protein 
folding. Gene expression can be regulated at many stages in this process.
Regulation of the transcriptional process is very important in the control of gene 
expression and protein concentration. The process of transcription is complex and 
involves multiple levels of regulation and organization that will be outlined in detail 
over the next section. The RNA that is produced during transcription is a temporary 
copy of the DNA sequence which can either perform a structural role, or be 
transported and processed for protein translation, or act to regulate transcription and 
mRNA stability. The protein product then fulfills its role in the cell, influencing the 
function or phenotype of the cell. 
                                                                                                                     Chapter 1. INTRODUCTION
2
1
1.1.2 Overview of Transcription.
Transcription is the process of synthesizing an RNA sequence transcript from DNA 
nucleotide sequence information. The process of transcription requires a multi-
subunit enzyme called RNA polymerase (RNAP), which catalyses the joining of RNA 
nucleotides from 5ʼ to 3ʼ using DNA as the template sequence.  
Eukaryotic cells have three nuclear RNA polymerases (RNAP I-III). RNAP I and III act 
on a limited profile of genes that encode ribosomal RNA, transfer RNA and small 
nuclear RNAs. RNAP II can potentially transcribe more than 20,000 genes that code 
for proteins (Lander et al., 2001). Transcription of protein coding genes is a highly 
regulated process, with more than 60 polypeptides making up  the 3MDa RNAP II 
holoenzyme complex that is required for transcription initiation (Krishnamurthy and 
Hampsey, 2009). The complexity of the RNAP II holoenzyme provides multiple points 
at which the rate of transcription initiation (and elongation) can be influenced. 
Activation occurs through interactions between activator proteins, such as 
transcription factors, and other proteins within the RNAP II holoenzyme, which 
increase the affinity of the RNAP II holoenzyme with the DNA template. Alternatively 
transcription can be inhibited, through blocking access to the DNA template by the 
RNAP II holoenzyme. This is often achieved by inhibitory interactions between 
repressor proteins and specific subunits of the RNAP II holoenzyme.
The DNA template is divided into a coding region and non-coding regulatory regions. 
Promoter DNA consists of multiple features that assist in the binding of components 
of the RNAP II transcription complex. Examples of these include the TATA box 
(located ~25bp from transcription start site), the initiator (Inr) (at the transcription start 
site) and the downstream promoter element (DPE) (+30 upstream from the 
transcription start site) (reviewed by (Krishnamurthy and Hampsey, 2009)). A single 
promoter can include one or more of these elements however no single promoter 
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element is essential for transcription. These promoter elements assist the formation 
of the transcription pre-initiation complex (PIC) and allow association of the RNAP II 
holoenzyme. Formation of the PIC  is nucleated by the TATA-binding protein (TBP), a 
subunit of TFIID (which includes a further 14 TBP-associated factors [TAFs]) that 
binds to TATA elements. If no TATA element is present then other members of the 
TFIID complex can bind alternative promoter elements (such as the Inr or DPE) 
(Krishnamurthy and Hampsey, 2009).
The RNAP II transcription complex then assembles in a stepwise mechanism in vitro 
(figure 1.1). TFIIB associates with the DNA-TBP complex and binds to the DNA 
surrounding the TATA element. This allows docking of RNAP II and TFIIF, through 
interactions with TFIIB. TFIIE binds to RNAP II and facilitates TFIIH binding to 
complete the PIC (reviewed by (Buratowski, 1994; Lee and Young, 2000)). 
TFIIH, as part of PIC, melts approximately 14 bp  of promoter DNA surrounding the 
transcription start, providing access to the DNA template (Wang et al., 1992). Another 
multi-protein complex, Mediator (MED), provides a bridge between the RNAP II 
complex and transcription factors bound to upstream enhancer elements, which 
enhances the interaction of RNAP II complex with the promoter DNA (Kornberg, 
2005) (figure 1.2). It had been proposed that the RNAP II holoenzyme, consisting of 
MED and the RNAP II transcription complex exists as a pre-assembled complex at 
transcription initiation sites (Greenblatt, 1997). However, this has not been fully 
accepted because subsequent ChIP data demonstrated that recruitment of MED 
precedes RNAP II at gene promoters, which supports a stepwise assembly of the 
RNAP II holoenzyme (Cosma et al., 1999; Bhoite et al., 2001; Kornberg, 2005). Once 
the RNAP II holoenzyme is assembled at the gene promoter RNA synthesis begins. 
RNAP II normally  fails to achieve productive RNA synthesis for several cycles 
releasing short RNA products (2-10 nucleotides in length) (reviewed by (Holstege et 
                                                                                                                     Chapter 1. INTRODUCTION
4
                                                                                                                     Chapter 1. INTRODUCTION
5
TATA Box
TFIIB
RNAP II
TFIIF TFIIE
TFIIH
TFIID
TFIIA
TBP
TAFs
TFIIA
TBP
TAFs
TFIIF
TFIIE
TFIIB
TFIIH
RNAP II
Figure 1.1 - Stepwise mechanism of the assembly of the basal transcription 
machinery.
The diagram illustrates the step by  step process required for the nucleation of the basal 
transcription machinery  around the core promoter. TFIID, including TBP, bind to the TATA 
box with TFIIA. Then TFIIB associates with the promoter, recruiting TFIIF and RNAP II. 
Finally, TFIIE and TFIIH complete the RNAP holoenzyme complex and transcription is 
initiated.
al., 1997)). Once RNAP II succeeds in synthesizing an RNA product greater than 11 
nucleotides in length it will break its interaction with initiation factors and promoter 
DNA to begin translocating along DNA, processively synthesizing RNA (Holstege et 
al., 1997). An RNAP II-DNA elongation complex with stably bound nascent RNA is 
now formed. The C-terminal domain (CTD) of RNAP II is phosphorylated by TFIIH 
subunit and contact with the other GTFs is lost so that transcription elongation can 
continue. The phosphorylated CTD can recruit other factors that are required for 
efficient elongation and mRNA processing (reviewed by (Li et al., 2007; Buratowski, 
2003)). These include; Rad4, a ubiquitin ligase; COMPASS, a Set1 methyltransferase 
complex; FACT, a histone chaperone; and Set2, a methyltransferase (Li et al., 2007). 
Each of these factors play a role in transcription elongation by  providing access to the 
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Figure 1.2 - Model of transcriptional activation through Mediator enhancer 
interactions.
The diagram illustrates the contribution of Mediator for transcriptional activation. Mediator 
promotes the association of the RNAP PIC to promoter DNA through interactions with 
transcription factors (TF) bound to upstream enhancer elements.
Mediator
TF bound 
enhancer
RNAP PIC
DNA template by remodeling the chromatin. After transcriptional initiation and 
elongation, termination of transcription follows to give a messenger RNA product.
1.1.3 Chromatin Structure.
The human genome consists of just over 3 billion base pairs (bp) of DNA and each 
base pair of DNA is 3.4Å thick. Since the average cell is 10µm in length (1µm = 
10000Å) this presents a packaging problem. To overcome this, eukaryotic cells have 
developed a way to increase the amount of DNA that can be packaged into a single 
cell and still allow efficient gene regulation to take place. Approximately 146 bp  of 
DNA is wrapped around a histone octamer to form a DNA-protein particle known as a 
nucleosome (Luger et al., 1997). Nucleosomes condense DNA via nucleosome-
nucleosome interactions to form higher order compaction into nucleosome arrays. 
Nucleosome arrays have been proposed to further fold into a 30nm diameter fiber, 
which could be further folded into large-scale configurations of nucleosomes 
(Tremethick, 2007). In interphase, there are regions of the chromatin that are 
transcriptionally active. Transcriptionally active DNA consists of more accessible 
DNA and less nucleosome-nucleosome interactions to provide space for the 
components of the general transcription machinery (reviewed by (Dehghani et al., 
2005)). However, the most condensed form of DNA is found during the metaphase of 
the cell cycle, where DNA is further condensed into the transcriptionally  inactive 
metaphase chromosome (Dehghani et al., 2005). 
1.1.4 Nucleosomes and Chromatin Remodeling.
Nucleosomes are made up of a histone octamer, consisting of two of each histone 
subunit H2A, H2B, H3 and H4, and these subunits maintain multiple contact points 
with the DNA template (Razin et al., 2007). Since nucleosomes play a key role in 
compaction of DNA, the regulation of nucleosome-nucleosome interactions are 
critical for transcription factor accessibility. Protruding from each nucleosome 
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structure are the N-terminal tails of each of the histones. Histones can be post-
translationally modified by methylation, acetylation, ubiquitination, ADP-ribosylation, 
sumoylation and phosphorylation (reviewed by  (Kouzarides, 2007)). The protruding 
N-terminal tails of histones provide an accessible region of the histone subunits that 
can be modified. When modified these tails can influence chromatin compaction. 
There are three major roles of histone modification:
1. All histone modifications, except for methylation, alter the net charge of the 
nucleosomes and reduce the interaction between DNA and histones. 
2. The post-translational modifications can be recognized by other proteins and 
could control recruitment of transcription factors (e.g. acetylation of histones 
can recruit bromo-domain containing transcription factors and cofactors).
3. Some modifications can influence higher-order chromatin structure (e.g. H4 
K16 inhibits the formation of compact 30nm fibers).
Promoter DNA for active genes have a low nucleosome compaction, providing 
access for transcription factors (Lee et al., 2004). However, there are also examples 
of transcription factors binding to nucleosomal DNA (Adams and Workman, 1995; 
Taylor et al., 1991), prior to nucleosome displacement (Adkins et al., 2004). Once a 
transcription factor is bound to a promoter, the transcription factor can recruit co-
activator complexes, such as histone modifying enzymes that acetylate or methylate 
histone tails. In fact, acetylation of promoter histones H3 and H4 directly correlates 
with the rate of transcription initiation (Pokholok et al., 2005). In some cases 
transcription factors can also recruit additional ATP-dependent chromatin remodeling 
complexes, through direct interactions with the transcription factor or through binding 
to acetylated histones (Hassan et al., 2001). These ATP-dependent chromatin 
remodeling complexes can further impact on the nucleosome density at a promoter 
by altering histone-DNA interactions, by  displacing H2A-H2B dimers or by  sliding 
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nucleosomes along DNA to provide access for further transcription factors (Kassabov 
et al., 2003). These chromatin remodeling complexes are a vital part of transcription 
initiation as they facilitate greater access to DNA for the multi-protein RNAP II 
holoenzyme. However, a large number of promoters could have a partial PIC already 
associated with the promoter, which includes TFIIA, TFIID, TFIIB, TFIIE, and TFIIF 
subunits, but not the TFIIH subunit or RNAP II itself (Zanton and Pugh, 2006). This 
suggests that chromatin remodeling does not always regulate the accessibility  of 
general transcription factors at a promoter, but instead regulates initiation of RNAP 
transcription (Sharma et al., 2003).
1.1.5 Nuclear Architecture.
The nucleus is a complex organelle and consists of several compartments that 
possess specific functions. Many of these functions are not related to RNAP II 
dependent gene transcription, such as the nucleolus which is assembled around 
rDNA genes and is important for coordinating rRNA synthesis. Other characterized 
nuclear compartments include, Cajal Bodies, Clastosome, Cleavage Bodies, Nuclear 
speckles and Paraspeckles although these only occupy a small fraction of the volume 
of the nucleus. These compartments have roles in; snRNP biogenesis, nuclear 
proteasomal activity, mRNA cleavage, splicing factor storage, and RNA-binding 
protein storage respectively (reviewed by (Spector, 2003)).
Few nuclear compartments have been implicated in transcription, likely because the 
majority of the nucleus is used for transcription. However, nuclear organization is 
required for efficient transcription of specific genes encoded in the genome at specific 
points during differentiation. For example, up-regulation of the β-globin genes is 
required during erythrocyte differentiation, however, they need to be inactive up  until 
this point (Ragoczy et al., 2006). Therefore, tight control of active and inactive genes 
is required. Interestingly, active genes may cluster together for transcription, as there 
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are more active RNAP II molecules than there are sites of active transcription (Iborra 
et al., 1996). It is thought that up to 20 active RNAP II proteins are clustered together 
at specific sites of transcription. These clusters are termed transcription factories 
(Carter et al., 2008). It is proposed that these ʻtranscription factoriesʼ nucleate several 
loops of chromatin, and these may involve several genes being transcribed together, 
or even from regions of different chromosomes (Lomvardas et al., 2006). The 
nucleus has two types of chromatin, euchromatin and heterochromatin. Euchromatin 
is located within the centre of the nucleus and contains the active RNAP II 
ʻtranscription factoriesʼ (Spector, 2003; Bolzer et al., 2005). Inactive genes are 
associated with heterochromatin that is found towards the nuclear periphery (Spector, 
2003; Bolzer et al., 2005).  
Genes associated with the nuclear periphery are generally thought to be repressed 
or less active. In fact recent studies have shown that tethering of genes to the nuclear 
periphery can robustly reduce transcriptional activity (Reddy et al., 2008). However, 
there has been significant variation (20%-75%) in the amount of transcriptional 
repression executed by localization to the nuclear periphery (Reddy  et al., 2008; 
Finlan et al., 2008). This suggests that certain genes maybe more susceptible than 
others to repression complexes located at the nuclear periphery. It has also been 
observed that the β-globin gene locus moves from the nuclear periphery to the 
nuclear core when activated (Ragoczy et al., 2006). This movement has suggested 
that the transcription factories maybe relatively immobile and predominantly occupied 
at the nuclear core and that therefore nuclear periphery  localization is a physical 
barrier to transcription. However, localization to the nuclear periphery  is not solely 
associated with transcriptional repression, as active gene transcription has been 
observed to occur at regions associated with the nuclear pore complex (NPC) (Brown 
and Silver, 2007).
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PML nuclear bodies (PNBs) have also been described as a nuclear body (NB) 
associated with transcriptional regulation. PNBs are small nuclear domains that are 
0.1µM-1.0µM in diameter, and PML is a major constituent (Lallemand-Breitenbach 
and de Thé, 2010). PML forms the outer shell of PNBs, with the interior consisting of 
PML partner proteins (Lallemand-Breitenbach and de Thé, 2010). There are now 
around 100 proteins that are known to associate with PNBs, but PML is still thought 
to be the key organizer of PNBs. Sumoylation of PML or the partner protein is 
thought to have a significant role in the recruitment of many of these PNB-associated 
proteins (Lallemand-Breitenbach and de Thé, 2010). PNBs are attached to the 
nuclear matrix (Chang et al., 1995), a nuclear meshwork of insoluble proteins, and 
have been found to correlate with transcriptional repression in some model systems 
(Tsukamoto et al., 2000). However, PNBs are not restricted to playing a roles in 
transcription, a subset of PNBs have a granular core under the electron microscope, 
which is typical of ribonucleoproteins, and PNBs have also been found associated 
with telomeres, with a role in maintaining telomere length (Lallemand-Breitenbach 
and de Thé, 2010).
1.1.6 Transcriptional Regulation.
As illustrated in 1.1.2 the gene promoter region is key in the regulation of a specific 
gene. There are also several other important DNA elements that regulate 
transcription initiation, including enhancers, silencers and insulators. Enhancer 
regions are regulatory sequences that act at a distance (Maston et al., 2006). 
Enhancers can be located several thousand base pairs upstream or downstream of 
the transcription start site (TSS), but they can be shorter distances away as well. As 
with proximal promoter elements these sequences regulate transcription through 
transcription factor association (Maston et al., 2006) and it has been proposed that 
chromatin is looped to cluster these enhancer regions with the core promoter (Cook, 
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2003). In contrast, silencer regions repress transcription in an orientation and 
distance-independent manner and can be considered the opposite of enhancer DNA 
sequences (Maston et al., 2006). Insulator regions are a further level of complexity 
which block the influence of enhancers and silencers by forming insulator bodies at 
the nuclear periphery (Fourel et al., 2004). These insulator bodies collate insulator 
elements preventing association of enhancers or silencers from associating with the 
core promoter (Fourel et al., 2004). These DNA regulatory elements dictate which 
transcription factors that are capable of binding and influencing transcription initiation 
by RNAP II (Orphanides and Reinberg, 2002). 
For transcriptional activation, transcription factors bind to defined binding motifs 
within these DNA sequences. Once bound they can recruit further transcription co-
factors, ATP dependent chromatin remodeling complexes or histone acetyl-
transferase complexes to increase the stability of the interaction between the PIC  and 
DNA (Orphanides and Reinberg, 2002). Ultimately, transcriptional activation can be 
altered by:
1. Increased nuclear concentration of the specific transcription factors and 
certain co- factors or accessory proteins.
2. Post-translational modifications to the gene specific transcription factor 
that allows interaction of other necessary proteins.
3. Reduction of inhibitory/competing transcription factors. 
For example, Nuclear Factor -κB (NF-κB), an important inflammatory response 
transcription factor, is found in the cytoplasm in unstimulated cells. However, upon 
cytokine stimulation, a phosphorylation cascade targets IκB, the inhibitory  subunit of 
NF-κB, for degradation, unmasking the nuclear localization sequence for NF-κB 
(Israël, 2010). This results in a rapid accumulation of nuclear NF-κB that is able to 
activate transcription. In addition NF-κB can be further modified by phosphorylation 
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and acetylation to increase transcriptional activation of specific genes (Chen and 
Greene, 2004). The method used for transcriptional activation is transcription factor 
and gene promoter dependent.
Like transcriptional activation, transcriptional repression is a vital process for tight 
control of gene expression. Transcriptional repressor proteins associate with their 
target genes directly through a DNA-binding domain or indirectly  through other DNA-
bound proteins. Selective transcriptional inhibition by  a transcriptional repressor 
protein can be mediated by:
1. Displacement or blocking of a transcription factor from binding to the gene 
promoter. 
2. Masking the activation domain on a gene specific transcriptional activator.
3. Blocking the interaction of a transcription factor with other components of 
the transcriptional machinery.
4. De-stabilization of the RNAP II holoenzyme.
Transcriptional repression can be transient, through transcription factor binding to 
promoter elements, or stable gene silencing, by methylation of CpG islands. 
Transient transcriptional repression can allow rapid activation or repression of a 
gene. For example, thyroid-hormone and retinoic acid receptors bound to their 
promoter regulatory binding motifs recruit the nuclear receptor co-repressor (N-CoR) 
protein, in their ligand-independent form (Hörlein et al., 1995). N-CoR, a co-
repressor, forms a complex with TBL1 and TBLR1 and recruits HDAC3 to de-
acetylate histones and induce transcriptional repression (Yoon et al., 2003). This 
repression is transient and is distrupted upon ligand binding to the nuclear receptor 
(Perissi et al., 2010). However, stable gene silencing can provide a mechanism for 
longer term silencing of genes, such as silencing of genes during differentiation. CpG 
methylation by  DNA methyl-transferases can lead to the formation of repressive 
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complexes that also reduce access to promoter DNA elements. Methyl-CpG binding 
domain containing proteins, such as MeCP2, bind to these methylated regions and 
again recruit a co-repressor complex that includes HDACs, which maintains 
chromatin in an inaccessible state (Bowen et al., 2004). MeCP2 also competes with 
histone H1 and encourages 30nm chromatin fiber formation, which could be 
important for its transcriptional repression (Ghosh et al., 2010).
1.1.7 Regulation of Transcription Factor Activity.
Controlled gene expression is critical to maintain cellular homeostasis. Regulation of 
transcription factor activity  is controlled through specific post-translational 
modification of the transcription factors. These post-translational modifications can 
influence DNA binding, co-factor association, sub-cellular localization and stability of 
the transcription factor.
Transcription factor activity  relies on sequence specific DNA binding to control target 
gene expression. For example, p53 is a tumour suppressor protein that is activated in 
response to DNA damage and is tightly  regulated by post-translational modifications. 
Upon exposure of cells to UV light or ionizing radiation, p53 is phosphorylated at 
serine residues 33 and 37, by DNA-PK (Sakaguchi et al., 1998). These N-terminal 
post-translational modifications increase site directed acetylation of the C-terminal 
domain of p53 by p300 and P/CAF (Sakaguchi et al., 1998). Acetylation of lysine 320, 
by P/CAF, and lysine 382, by p300, increase p53 sequence specific DNA binding to 
activate specific target genes (Gu and Roeder, 1997; Sakaguchi et al., 1998). 
Phosphorylation and acetylation are the most common post-translational 
modifications to activate transcription factor activity, and these occur in response to 
most inter- or intra-cellular signalling cascades and can promote or inhibit DNA 
binding.
                                                                                                                     Chapter 1. INTRODUCTION
14
Transcription factor association with a co-factor can not only direct transcriptional 
activity  (activation versus repression), but can also limit its transcriptional activity. 
Often accessory proteins are required for transcriptional activation or repression, 
transcription factor binding alone is not sufficient for transcriptional activity. Post-
translational modifications can alter these associations. For example, the orphan 
nuclear receptor, steroidogenic factor 1 (SF-1), is phosphorylated by mitogen 
activated protein kinase (MAPK) in a ligand independent manner (Hammer et al., 
1999). This phosphorylation of serine 203, within the activation function 1 domain, 
stimulates SF-1 transcriptional activity in a luciferase promoter reporter assay 
(Hammer et al., 1999). Transcriptional activation is dependent on co-factor, GRIP1 or 
SMRT, association with SF-1 (Hammer et al., 1999). Mutation of the phosphorylation 
site inhibits GRIP1 or SMRT binding to SF-1 and inhibits transcriptional activation 
(Hammer et al., 1999). Post-translational modifications can alter protein conformation 
to facilitate protein-protein interactions, conversely they can also sterically hinder 
these associations to regulate transcription.
In addition to DNA binding and co-factor association, regulation of nuclear 
localization is an important determinant of transcription factor activity. The signal 
transducers and activators of transcription (STAT) family, of which there are 7 family 
members, is a good example of how post-translational modification can effect nuclear 
localization. Interferon (IFN) stimulation induces expression of immediate-early 
response genes through STATs (Bromberg, 2001). IFN induces a signal transduction 
pathway whereby  Janus kinase (JAK) kinase activity is activated (Bromberg, 2001). 
JAK phosphorylates a single C-terminal tyrosine residue of a STAT protein, this 
induces homo- or hetero-dimerization and nuclear translocation (Darnell, 1997). 
Phosphorylated nuclear STATs are transcriptionally active.
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As transcription factors induce temporal and spatial regulation of gene expression, 
inactivation of transcription factor activity can also be required. Post-translational 
modification of transcription factors are often signals for targeted degradation by the 
proteasome. GATA-1 is a critical haematopoietic transcription factor and tight 
regulation of its transcriptional activity is required for differentiation of haematopoietic 
cells (Orkin, 2000). Acetylation of GATA-1 is necessary for transcriptional activity, 
however, subsequent phosphorylation at multiple residues by MAPK induces poly-
ubiquitination and proteasome dependent degradation (Hernandez-Hernandez et al., 
2006). This targeted degradation of GATA-1 is also induced by erythropoietin (EPO), 
a mitogen that drives erythrocyte maturation (Hernandez-Hernandez et al., 2006).
For efficient and responsive changes in gene expression, intra- and extra-cellular 
signals need to alter transcription factor activity. This section has demonstrated 
examples of altered transcription factor DNA binding, co-factor association, sub-
cellular localization and stability by post-translational modifications in response to 
signal transduction. Each of these plays a significant role in cellular homeostasis. 
1.2 Proline Rich Homeodomain (PRH).
PRH is a transcription factor that belongs to the homeodomain super-family  of DNA 
binding proteins (Soufi and Jayaraman, 2008). It is essential for complete 
development of the embryo, with critical roles in the development of the forebrain and 
foregut maintenance. PRH is also important for the haematopoietic compartment, 
influencing differentiation and growth. 
1.2.1 Homeodomain (HD) Proteins.
The homeobox is a conserved sequence of DNA present within homeotic genes in 
Drosophilia melanogaster and encodes a protein domain termed the homeodomain 
that binds DNA or RNA  (Scott and Weiner, 1984; McGinnis et al., 1984). Further 
homologs of this domain have been identified across species and in humans 299 
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homeodomain-containing genes are listed in the homeodomain resource database 
(Moreland et al., 2009). Homeodomain proteins are a large family of DNA binding 
transcription factors that have roles in many developmental processes. For example 
the Hox genes encode Hox homeodomain proteins and control morphology on the 
main body axis of most metazoans (Lemons and McGinnis, 2006). 
The structure of the homeodomain is well-characterized. It is a DNA binding domain 
composed of 60 amino acids that form a helix loop  helix turn helix secondary 
structure. The N-terminal arm of the homeodomain binds DNA and contacts base 
pairs in the minor groove, whilst the loop  contacts the phosphate backbone of DNA 
(figure 1.3). The recognition helix (helix III) lies in the major groove and interacts 
through contacts from the side chain groups of this helix (Billeter, 1996). Helices I and 
II do not appear to make contacts with the DNA but provide the necessary structure 
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Figure 1.3 - A model of the PRH homeodomain bound to DNA.
The solution NMR structure of the PRH (magenta) homeodomain superimposed on the 
Engrailed (blue), and Oct-2 (yellow) DNA bound structures. The figure was taken from (Soufi 
and Jayaraman, 2008).
for interaction (Billeter, 1996; Neidle and Goodwin, 1994). These interactions provide 
the specificity for recognizing the core ATTA sequence found in many homeodomain 
binding sites.
1.2.2 Structural Properties of PRH and Interaction Motifs.
The human PRH protein consists of 270 amino acids and has a calculated molecular 
weight of 30 kDa, although it shows retarded mobility  on a sodium dodecyl sulfate 
polyacrylamide gel (SDS-PAG) and runs at 36kDa. It is a modular protein composed 
of 3 major regions, a 20% proline-rich N-terminal domain (AAs 1–136), a central 
homeodomain (AAs 137–196), and an acidic C-terminal region (AAs 197–270) (figure 
1.4) (Crompton et al., 1992).
1.2.2.1 PRH N-terminal Domain
The N-terminal domain of PRH has been extensively studied, and this has revealed 
key characteristics that may determine the activity of PRH within the nucleus. The N-
terminal domain allows self-association and is vital for PRH to act as a transcriptional 
repressor (Soufi et al., 2006; Guiral et al., 2001). The composition of the 136 amino 
acids of the N-terminal domain of PRH includes 20% proline residues, 15% alanine 
and 10% glycine residues. The N-terminal domain does not appear to have typical β-
sheet or α-helical structures. Proline residues are known to disrupt α-helix/β-sheet 
secondary structure formation, and as a result this domain probably has a more 
extended structure, which facilitates dimer formation (Soufi et al., 2006). The N-
terminal domain of PRH also appears to be split into 2 regions that have separate 
roles. The first 50 amino acids are vital for PRH dimerization. The second region, C-
terminal to the first 50 amino acids of PRH, are important for associating with a 
partner PRH homeodomain (AAs 132-270) to promote oligomerisation (figure 1.4) 
(Soufi et al., 2006). As well as facilitating oligomerisation, the N-terminal domain can 
repress transcription independently  of the homeodomain when it is fused to another 
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Figure 1.4 - Schematic diagram of the modular structure of PRH.
[A] There are three distinct regions of PRH; the N-terminal domain, the Homeodomain, and 
the C-terminal domain. Regions with key  properties and known interaction sites are marked. 
The diagram has been adapted from (Soufi and Jayaraman, 2008). [B] PRH amino acid 
sequence, showing the N-terminal domain (green highlight), homeodomain (blue highlight), 
and C-terminal domain (golden highlight). The eIF4E (yellow) and TLE (red) interaction 
domains are also shown.
1 " MQYPHPGPAA GAVGVPLYAP TPLLQPAHPT PFYIEDILGR 
41" GPAAPTPAPT LPSPNSSFTS LVSPYRTPVY EPTPIHPAFS 
81" HHSAAALAAA YGPGGFGGPL YPFPRTVNDY THALLRHDPL 
121" GKPLLWSPFL QRPLHKRKGG QVRFSNDQTI ELEKKFETQK 
161" YLSPPERKRL AKMLQLSERQ VKTWFQNRRA KWRRLKQENP 
201" QSNKKEELES LDSSCDQRQD LPSEQNKGAS LDSSQCSPSP 
241" ASQEDLESEI SEDSDQEVDI EGDKSYFNAG
[A]
[B]
PRH Amino Acid Sequence.
DNA binding domain (Guiral et al., 2001).
An enduring theme of most transcriptional processes is the formation of a 
transcriptional complex for activation or repression, with the recruitment of co-factors 
to provide binding specificity and functional output. Similarly PRH has been shown to 
bind with other proteins that could affect the functional activity  of PRH. For example 
PRH contains an Eh-1 motif (FXIXXIL) (Amino acids 31-39 (TFYIEDILG)) (figure 1.4), 
that is also found in the homeodomain proteins Engrailed and Goosecoid. This motif 
is the site of interaction between these homeodomain-containing proteins and a 
family of co-repressor proteins, known as the Groucho/TLE proteins. In PRH, the 
Eh-1 motif mediates the interaction with TLE proteins, the human homologs of 
Groucho. Mutation of the Eh-1 motif results in the loss of association between PRH 
and TLE proteins (Swingler et al., 2004). The N-terminal domain of PRH also 
interacts with the proteosome subunit HC8 (Bess et al., 2003), although the 
significance of this interaction is not fully understood. Proteasome activity does not 
appear to affect the ability of PRH to repress transcription (Bess et al., 2003). There 
are other proteins that also interact with the N-terminal domain of PRH and these 
include; SOX13 (Marfil et al., 2009), which will be discussed later in section 1.2.5; the 
PML protein (interacts with PRH AAs 50-115) (Topcu et al., 1999) and the translation 
factor eIF4E (interacts with PRH AAs 18-24) (Topisirovic et al., 2003a), which will 
both be discussed in section 1.2.6.
1.2.2.2 PRH Homeodomain.
PRH belongs to the NK subclass of homeodomain proteins that contain a Tinman 
(TN) motif located N-terminal to the homeodomain (Banerjee-Basu and Baxevanis, 
2001). PRH contains a motif that resembles this TN decapeptide sequence but lacks 
a conserved arginine residue at position 5 in the homeodomain that all other 
members of the NK family possess and additionally  lacks an NK-specific domain 
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downstream of the homeodomain. Therefore PRH can be considered to have its own 
subclass. Its closest homolog is the Hlx homeodomain protein, which only shares 
56% identity with PRH within the homeodomain region (Crompton et al., 1992).
Homeodomain containing proteins are able to bind to AT-rich DNA sequences in vitro. 
The PRH consensus binding sequence has been determined to be 5ʼ-C/TA/
TATTAAA/G-3ʼ using SELEX experiments but this study only used a C-terminal 
fragment of PRH containing the homeodomain and C-terminal domain of PRH 
(Crompton et al., 1992). Electrophoretic mobility shift assay (EMSA) studies using the 
isolated homeodomain have shown PRH can bind to 5ʼ-ATTAA-3ʼ and 5ʼ-CAAG-3ʼ 
sequences, suggesting a very  poor binding specificity (Pellizzari et al., 2000). To 
date, no SELEX studies have been conducted to characterize the PRH consensus 
binding sequence using the whole PRH protein. Therefore full length PRH binding 
specificity is not well defined, although it is likely PRH binds elements with the core 
sequence ATTA or TAAT.
Recently  PRH has been shown to bind with high affinity to a cluster of five ATTA sites 
in the goosecoid gene promoter (Williams et al., 2008). Moreover high concentrations 
of PRH result in widespread protection of promoter DNA from DNase I treatment in 
vitro (Williams et al., 2008). Binding of PRH to the Goosecoid promoter induces DNA 
distortion and it has been suggested that transcriptional repression by  PRH may 
occur through the compaction of DNA wrapped around a PRH oligomer (Williams et 
al., 2008; Soufi et al., 2006). These studies indicate that it may be the number and 
spacing of potential binding motifs that is important for PRH binding, with co-
operativity  involved in the PRH-DNA association. Thus PRH may have a flexible 
consensus sequence, that only requires a few core ATTA like sequences to initiate 
binding.
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1.2.2.3 PRH C-terminal Domain. 
The C-terminal domain of PRH is a highly  acidic region with four times the number of 
acidic residues than basic residues. PRH can activate or repress gene transcription 
depending on the cell type and promoter environment. The C-terminal domain of 
PRH appears to be necessary for transcriptional activation. The C-terminal domain 
can interact with other transcription factors or co-activators to facilitate gene 
activation. This includes interactions with hepatic nuclear factor 1 alpha (HNF-1α) 
(Tanaka et al., 2005) and serum responsive factor (SRF) (Oyama et al., 2004), these 
interactions will be discussed in detail in section 1.2.5.
1.2.2.4 Oligomerisation of PRH.
Proline residues are often found in protein-protein interaction regions (Kay et al., 
2000), and many of the known protein interactions for PRH are located in the proline-
rich N-terminal domain. Ultracentrifugation experiments have shown that PRH can 
form octamers and larger oligomers for which the proline rich N-terminal domain of 
PRH is critical (Soufi et al., 2006). A model for oligomer formation has been proposed 
(figure 1.5) (Soufi et al., 2006). PRH has a dimerisation domain within the N-terminal 
domain (AAs 1-50; ʻPʼ domain), as well as two other domains that interact with each 
other. These two domains are the transcriptional repression domain (AAs 51-132; ʻRʼ 
domain) and the homeodomain-C-terminal domain (AAs 133-270; ʻHʼ domain). The 
P-P domain interactions occur between monomers and R-H domain interactions 
occur between PRH dimers, giving the potential for higher oligomeric fibres or the 
association of four PRH dimers to form a donut-like ʻclosedʼ structure (figure 1.5) 
(Soufi et al., 2006).
Recently  it has been shown that PRH can bind to long DNA fragments and form 
protein-DNA fibres. This study also demonstrated that PRH oligomers are capable of 
compacting DNA without accessory proteins although this compaction is not sufficient 
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for transcriptional repression (Soufi et al., 2010). This suggests that PRH could be 
functionally and structurally related to the bacterial and archaea proteins, the Lrp/
AsnC  family, which were not previously thought to have eukaryotic equivalents (Soufi 
et al., 2010).
Interestingly  uncontrolled aggregation of PRH proteins does not occur and this could 
in part be due to the rich glycine content in the PRH N-terminal domain as this amino 
acid has been reported to discourage aggregation and key glycine residues can be 
conserved for this purpose (Parrini et al., 2005).
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Figure 1.5 - A model for PRH oligomerization.
The diagram represents a model for the association of PRH monomers into oligomeric 
chains (2D open) or closed donut-like tetramers (3D closed). The P region represents the 
first 50 amino acids, the R region represents amino acids 50-137 and the H region 
represents amino acids 137-270. The figure was taken from (Soufi et al., 2006).
1.2.2.5 Post-translational Modifications of PRH.
PRH can be phosphorylated within the homeodomain at the serine residues 163 and 
177 by protein kinase CK2 (CK2) (Soufi et al., 2009). CK2 promotes survival through 
multiple mechanisms, which will be discussed in more detail later (see section 1.5). 
PRH can interact with the β subunit of CK2, which facilitates the phosphorylation of 
PRH by the CK2 α subunit (Soufi et al., 2009). In vitro experiments demonstrated that 
phosphorylation of the PRH homeodomain inhibits the ability of PRH to bind DNA 
(Soufi et al., 2009). Phosphorylation of PRH by CK2 is therefore very likely to be an 
important mechanism of regulation of PRH transcriptional activity. 
1.2.3 The Role of PRH in Embryonic Development.
PRH expression is critical for embryonic development. Although Prh +/- mice are 
normal and fertile, intercrosses between heterozygous mice give no live offspring. 
Prh -/- embryos show no significant difference to heterozygous littermates until 8.5 
days post coitum (dpc), where a reduction in forebrain is observed. Prh -/- embryos 
begin to die at 11.5 dpc and no live embryos are observed by  15.5 dpc (Martinez 
Barbera et al., 2000). PRH expression is first detected in the primitive endoderm at 
4.5 dpc. PRH expression is then observed in the visceral endoderm (VE) prior to the 
formation of the primitive streak and gastrulation (Thomas et al., 1998). During 
embryonic development the VE differentiates into the anterior VE (AVE), an early 
signalling centre that plays a pivotal role in establishing anterior-posterior polarity of 
the embryo. VE cells expressing PRH are morphologically distinct (Rivera-Pérez et 
al., 2003) and they actively migrate to form the AVE (Srinivas et al., 2004). In addition 
to the role of AVE in axis formation, AVE also has roles in neural patterning by 
signalling to the epiblast before and during gastrulation (Beddington and Robertson, 
1998; Beddington and Robertson, 1999). 
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After gastrulation, Prh is expressed in the anterior definitive endoderm (ADE). The 
ADE develops from the primitive streak and the node signalling centres after 
gastrulation (Wells and Melton, 1999). The ADE replaces the AVE and this is an 
important step for correct head development. PRH expression in the ADE and the 
AVE is required for normal forebrain development (Martinez Barbera et al., 2000). 
Subsequent PRH expression is required for the maintenance of foregut identity and 
liver and pancreas development (McLin et al., 2007).
Development of the haematopoietic and vascular systems originate from a common 
mesodermal progenitor, the haemangioblast (Choi et al., 1998). Blood islands of the 
yolk sac contain haemangioblasts and these consist of haematopoietic stem cells 
(HSCs) and angioblasts (Durand and Dzierzak, 2005). The HSCs form the inner 
regions of these blood islands and the outer cells are the angioblasts (Durand and 
Dzierzak, 2005). Haematopoiesis then occurs within the embryo proper, in the aorta 
gonad mesonephros (AGM) region and the fetal liver (Durand and Dzierzak, 2005). 
Finally, at birth HSCs from the fetal liver migrate and colonize the bone marrow. 
Mature blood cells are produced in the bone marrow in the adult system (Baron, 
2003; Park et al., 2005). The presence of PRH is vital for the development of HSCs 
and is also important for angioblast formation (Guo et al., 2003). Although PRH is 
required for angioblast formation, PRH is not expressed in the angioblast nor is there 
expression in any mature precursor cells of the endothelial lineage (Thomas et al., 
1998). In contrast, PRH is expressed in early  haematopoietic progenitors of all 
linages except T-cell derived lineages (figure 1.6) (Bedford et al., 1993; Manfioletti et 
al., 1995; Jayaraman et al., 2000). PRH expression is then down-regulated during 
terminal differentiation cell of haematopoietic cells and is lost in all mature cells, with 
the exception of granulocytes where PRH expression is maintained (figure 1.6) 
(Manfioletti et al., 1995; Jayaraman et al., 2000). Therefore PRH is likely to control 
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Figure 6 Diagram showing the different steps of haematopoiesis and
vasculogenesis
Haematopoiesis and vasculogenesis begin in the blood islands. The inner part of these blood
islands becomes HSCs, whereas the outer part gives rise to the vascular endothelial pro-
genitors (angioblasts). The endothelial and haematopoietic precursors are thought to originate
from the common mesodermal progenitor, the haemangioblast. HSCs differentiate to all cells
found in the circulating blood, and the angioblasts develop to form the vascular endothelial
system. PRH is expressed in the haemangioblast/haematopoietic stem cell but not in angioblasts
or their derivatives. PRH is expressed in differentiating haematopoietic cells of B-cell lineages
and myelomonocytic and erythroid lineages, but not in T-cell lineages. dpc, days post coitum.
adult life, all mature blood cells are produced in the bone marrow
[49,50].
During early embryonic development, PRH is expressed in
tissues that contribute to both haematopoietic and vascular
systems. In mice, PRH is expressed in extra-embryonic mesoderm
in blood islands of the yolk sac [9,51]. Later after gastrulation,
PRH is expressed in the embryo proper in embryonic mesoderm at
sites where (i) angioblasts are thought to arise and (ii) endocardial
cells develop into the cardiac tubes of the heart [9]. Additionally
PRH is expressed in regions where vessels are known to form,
such as the dorsal aortae and the intersomitic vessels. However,
once cells have differentiated to form committed endothelial
precursors, PRH expression is lost in these cells [9]. The
expression pattern of PRH during embryonic endothelial cell
development is conserved between mouse and species such as
Xenopus [5,9,12,52].
Still later in development, PRH is expressed in the murine fetal
liver (see below) [9,11]. Consistent with the expression studies
outlined above, mice that are homozygous for a disruption of
the Prh gene show defects in haematopoiesis (monocyte develop-
ment) and liver development and die at mid-gestation (E13.5–
E15.5; E is embryonic day) [53,54]. A more recent gene-targeting
experiment has shown that a null mutation of Prh also results in
abnormalities of cardiac and vascular development [27].
Overexpression and knockout studies in different species have
resulted in some apparent discrepancies with regard to the role
of PRH in vasculogenesis. Overexpression of PRH in Xenopus
embryos leads to disorganization of the vasculature and an
increase in vascular progenitors [5] indicating that PRH may
stimulate the proliferation of early endothelial progenitors. Mouse
ES (embryonic stem) cell in vitro differentiation assays with
Prh−/− cells, together with in vivo differentiation assays, and
chimaeric mouse analyses, have revealed that PRH is required
for differentiation of the haemangioblast into haematopoietic
progenitors and, to a lesser extent, endothelial progenitors,
but that formation of the haemangioblast is unaffected [55].
Moreover, Prh−/− endothelial progenitor cells generate lower
numbers of vascular endothelial cadherin-positive cells and form
fewer vascular sprouts compared with those from wild-type cells.
This suggests that PRH also has a role as a positive regulator of
endothelial cell maturation, organization and tube formation [55].
Kubo et al. [56] also showed that Prh−/− ES cells form fewer
committed haematopoietic cells but, in contrast with Guo et al.
[55], they show that Prh−/− cells form larger numbers of haeman-
gioblasts and endothelial progenitors. In addition they demon-
strate that overexpression of PRH leads to reduced numbers of
haemangioblasts, reduced proliferation and decreased VEGFR-2
expression [56]. Consistent with this finding, Prh−/− mice and
ES cells show up-regulation of VEGF-A, a growth factor
that regulates endothelial proliferation [27,55]. Taken together,
these findings support the idea that PRH negatively regulates
proliferation of the haemangioblast and early endothelial progeni-
tors and is required for the differentiation of haematopoietic
progenitors. It has been suggested that the observed discrepancies
between the various studies very probably reflect different
functions of PRH at different stages in vascular development
[56]. The initial role of PRH could be one of a negative regulator
of haemangioblast and endothelial proliferation, and a positive
regulator of haematopoietic differentiation. At later stages, PRH
might positively regulate endothelial cell maturation, organization
and tube formation [56].
The vasculature is made up of endothelial cells and VSMCs that
are not proliferating. In the adult, PRH is not expressed in VSMCs
or endothelial cells. Interestingly, overexpression of PRH in fully
differentiated endothelial cells [HUVECs (human umbilical-vein
endothelial cells)] results in repression of angiogenesis-related
genes including VEGFR-1 (flt-1), VEGFR-2 (flk-1), TIE-1 [TK
with immunoglobulin-like and EGF (endothelial growth factor)-
like domains 1] and TIE-2, and inhibits the ability of these cells
to form endothelial networks in vitro [57]. Thus PRH functions
as a repressor of transcription in these cells and a negative
regulator of angiogenesis. In contrast, elevated PRH expression
activates expression of the embryonic SMemb/NMHC-B gene
in adult VSMCs. The SMemb/NMHC-B gene is a marker of
dedifferentiated VSMCs. PRH is itself up-regulated in VSMCs
after a stent has been placed in the artery, that is during a period
of proliferation and dedifferentiation after injury [45]. Moreover,
overexpression of PRH in embryonic fibroblasts results in the
expression of early, but not late, markers of differentiation into
VSMCs [44]. Thus in adult VSMCs PRH functions as an activ-
ator of gene expression and the induction of PRH expression
in VSMCs appears to be related to the dedifferentiation and
proliferation of the VSMC [45].
The role of PRH in haematopoiesis is complex. Prh−/− ES cells
do not contribute to the formation of lymphoid or myeloid tissues
in chimaeric mouse analyses, indicating that PRH is required
for the formation of the HSCs [55]. Retroviral expression of
PRH in avian blastoderm showed that this protein influences the
proliferation and differentiation of haematopoietic progenitors
[58]. PRH is expressed in early haematopoietic progenitors of
all lineages except that of T-cell lineages [13,14,58]. Although
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Figure 1.6 - PRH expression during haematopoiesis.
The diagram illustrates the process of haematopoiesis, with each box representing a 
distinctive cell type. PRH expression is shown in red. When PRH expression is lost in a 
lineage this is represented in white, for example pre T-cells do not express PRH and PRH 
expression is lost during monocyte differentiation to a mature macrophage. The diagram 
has been adapted from (Soufi and Jayaraman, 2008).
key steps within haematopoietic cell development.
1.2.4 Expression of PRH in the Adult System.
In the adult system PRH has a limited expression profile. PRH expression was first 
observed in avian and human haematopoietic cells (Crompton et al., 1992). PRH is 
often referred to as the human haematopoietically  expressed homeobox (HHEX) in 
the literature (Bedford et al., 1993), but later it was observed that PRH is expressed 
in multiple embryonic tissues and also in the thyroid, lung and liver, as well as in the 
haematopoietic compartment (Soufi and Jayaraman, 2008). In adult liver cells, PRH 
expression is found in adult differentiated liver cells, but not in undifferentiated 
hepatocytes or in undifferentiated liver cell lines (Tanaka et al., 1999). This suggests 
that PRH is important for the maintenance of differentiated liver cells. PRH is 
expressed in adult thyroid cells and is present in both the nuclear and cytoplasmic 
compartments (Bogue et al., 2000). PRH expression is also observed in thyroid 
adenomas, and carcinomas but the localization of PRH is mostly cytoplasmic (D'Elia 
et al., 2002). Furthermore, PRH is expressed in the adult pancreas but its role is 
poorly  understood and although PRH has roles in the development of the heart and 
skin its role in these tissues in the adult system is yet to be characterized (Hromas et 
al., 1993; Bogue et al., 2000; Hallaq et al., 2004; Foley  and Mercola, 2005; Obinata 
et al., 2002). 
1.2.5 Transcriptional Regulation by PRH.
PRH is primarily thought of as a transcriptional repressor (Williams et al., 2008; 
Swingler et al., 2004; Bess et al., 2003; Guiral et al., 2001), however, the number of 
tissues PRH is expressed in and the variety of functions that have been reported for 
PRH suggests that it is likely to act in a context dependent fashion. In fact PRH can 
also activate transcription at some genes (Kasamatsu et al., 2004; Oyama et al., 
2004; Sekiguchi et al., 2001). The mechanisms utilized by PRH for transcriptional 
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regulation are also promoter and context dependent. There are four mechanisms by 
which PRH has been described to regulate gene expression (reviewed by (Soufi and 
Jayaraman, 2008)):
1. PRH can act as a transcriptional repressor that directly associates with 
gene promoter regions.
2. PRH can activate transcription through binding to gene promoter regions.
3. PRH can also repress transcription by indirectly  disrupting the activity of 
another transcriptional regulator. 
4. PRH can activate transcription indirectly through a mechanism other than 
binding to a gene promoter.
Examples of these four mechanisms will be illustrated below. 
Direct transcriptional repression by  PRH is best understood for PRH regulation of the 
Goosecoid gene. Goosecoid is a protein that is expressed during gastrulation in a 
group of cells, called the Spemann Organizer (Niehrs et al., 1993). PRH was first 
described to regulate this gene in Xenopus laevis (Brickman et al., 2000). Recent 
DNase I and chemical footprinting studies have shown that PRH binds directly to the 
promoter of the Goosecoid gene at multiple sites, covering long stretches of the 
promoter and induces DNA distortion (Williams et al., 2008). This study proposes that 
PRH could bind and repress transcription as an oligomer that wraps DNA around its 
oligomeric core (Williams et al., 2008). Another direct target of PRH is the endothelial 
specific molecule 1 (esm-1) gene, here the authors used chromatin 
immunoprecipitation (ChIP) assays to show PRH binds to the esm-1 gene promoter 
(Cong et al., 2006). Electrophoretic mobility shift assays (EMSA) were used to 
determine that the PRH binding sites for the esm-1 gene are conserved 5ʼ C/TA/
TATTAAA/G 3ʼ sequences (Cong et al., 2006). 
                                                                                                                     Chapter 1. INTRODUCTION
28
Although the exact mechanism of PRH induced repression is not fully understood, 
some molecular interactions have been detailed that provide an insight into possible 
modes of action. As described above PRH can interact with proteins of the Groucho/
TLE family of transcriptional co-repressors (Swingler et al., 2004). The TLE family  of 
proteins have no DNA binding capacity and rely  on DNA binding transcription factor 
partners, such as PRH, for localization of their gene targets, this will be discussed in 
more detail later in section 1.3. Recruitment of TLE by PRH has been shown to be 
necessary for transcriptional repression of an artifical promoter, however, the 
significance of this interaction has not yet been shown in vivo at an endogenous 
gene (Swingler et al., 2004). Furthermore, it is not clear whether TLE is a general 
requirement for transcriptional repression by PRH or whether it is important for just 
specific target genes. Also, PRH DNA binding specificity  is yet to be accurately 
characterized, as discussed above (see section 1.2.1), this is further highlighted by 
the fact that PRH has been described to bind to TATA-box sequences and induce 
transcriptional repression. PRH represses the artifical thymidine kinase (tk) reporter 
construct, which contains a TATA-box but no other sequences that resemble PRH 
binding sites (Guiral et al., 2001). Truncations of PRH containing the C-terminal and 
the homeodomain were used in EMSA experiments to show that PRH can bind 
directly to the tk TATA-box (Guiral et al., 2001). This suggests that PRH may  be 
recruited to TATA-box containing genes and block TBP and formation of the PIC 
(Guiral et al., 2001). Therefore this might be another mode of transcriptional 
repression by PRH .
Indirect transcriptional repression by PRH has also been described for a number of 
genes. GATA-2 is a positive regulator of the Vegfr2 gene and binds to specific binding 
elements at the Vegfr2 promoter. PRH can inhibit the GATA-2 dependent activation of 
Vegfr2 through a specific interaction with GATA-2 that disrupts GATA-2 DNA binding 
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(Minami et al., 2004). Furthermore, interactions between the PRH homeodomain and 
the N-terminal domain of jun can decrease jun-dependent transcriptional activation of 
basic fibroblast growth factor (bFGF) (Schaefer et al., 2001). A number of other 
genes are also known to be influenced by PRH expression, including Chordin 
(Brickman et al., 2000), Thyroglobulin (Pellizzari et al., 2000), Vegfr1, Vegfr2, Tie-1, 
Tie-2, Neuropillin-1 (Nakagawa et al., 2003) and Integrin (Kubo et al., 2005; Mack et 
al., 2002). However, it is not yet known whether these genes are directly or indirectly 
influenced by PRH.
PRH can act as a direct transcriptional activator in certain contexts at particular 
genes. PRH has been shown to activate transcription of the ntcp gene through direct 
binding to the gene promoter (Kasamatsu et al., 2004). For this activity the C-terminal 
domain of PRH is reported to be required and truncations of PRH lacking the C-
terminal domain are unable to induce transcriptional activation (Kasamatsu et al., 
2004). PRH also directly  activates the SMemb/NMHC-B gene in vascular smooth 
muscle cells (VSMCs) (Sekiguchi et al., 2001). A promoter element at -481 bp from 
the transcription start site (TSS) is thought to be critical for PRH mediated 
transcriptional activation of this gene (Sekiguchi et al., 2001). 
Indirect transcriptional activation by PRH has also been described. For example, in 
hepatocytes PRH can interact with HNF-1α and stimulate expression of the L-type 
pyruvate kinase (L-PK). In this case, the PRH homeodomain is required to bind to 
HNF-1α and the C-terminal domain is also necessary to enhance L-PK gene 
expression (Tanaka et al., 2005). Similarly, in murine embryonic fibroblasts the 
SM22α gene is activated by SRF and activation is elevated by PRH independent of 
its DNA binding capacity (Oyama et al., 2004). Whereas, during embryogenesis PRH 
blocks SOX13-dependent repression (Marfil et al., 2009). SOX13, with its binding 
partner TCF1, is a repressor of Wnt/TCF signaling. PRH blocks SOX13-dependent 
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repression of Wnt/TCF activity by removing SOX13 from the SOX13/TCF1 complex 
(Marfil et al., 2009). Therefore, PRH acts as an antagonist of Wnt/TCF activity. This 
de-repression was shown to be dependent on the association of the PRH N-terminal 
domain and the LZ-Q domain of SOX13 (Marfil et al., 2009).
1.2.6 Regulation of PRH Activity.
The mechanisms that control the activity of PRH as a transcriptional repressor and a 
transcriptional activator are not fully understood. It is likely  PRH is regulated in vivo 
through post-translational modifications, CK2 phosphorylation is known to inhibit 
DNA binding by PRH in vitro (Soufi et al., 2009). Phosphorylation of PRH could block 
direct regulation and simultaneously promote indirect gene regulation by  enhancing 
interactions with other transcription factors.
1.2.7 The Role of PRH in Haematopoietic Disease.
Since PRH has key roles in the differentiation and proliferation of haematopoietic 
progenitor cells, it is not surprising that dysregulation of PRH expression or activity 
can lead to the progression of malignant diseases such as leukaemia. However, in 
the literature there is conflicting evidence regarding the role of PRH in 
haematopoietic disease. Loss of PRH function or up-regulation of PRH activity can 
lead to the progression of a tumourigenic phenotype. There also appears to be a 
divide in the role of PRH between disease of myeloid or lymphoid origin. In this 
section I will illustrate the conflicting roles of PRH by outlining the current knowledge 
of PRH function in disease of myeloid leukaemias and lymphoid tumours. 
Leukaemias of myeloid origin, which have dysregulated PRH, have reduced PRH 
function (Topisirovic et al., 2003b; Topisirovic et al., 2003a; Jankovic et al., 2008). In 
at least one patient disruption of PRH activity has been demonstrated to result in 
Acute Myelogenous Leukaemia (AML). The patient carries a cytogenetic abnormality 
(t(10;11)(q23;p15) that results in the formation of a NUP98-HHEX(PRH) fusion 
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protein. This fusion protein replaces the N-terminal domain of PRH with that of 
NUP98 but retains the DNA binding activities of PRH. The fusion protein can function 
as a trans-dominant negative over wild-type PRH in repression assays and it has 
been suggested that the fusion protein can compete with endogenously expressed 
PRH and disrupt its cellular roles (Jankovic et al., 2008). A recent study has shown 
that the nucleoporin proteins, including NUP98, are important for the activation of 
some developmental and cell cycle genes. In fact NUP98 is able to activate gene 
expression away from the nuclear pore complex, within the nucleoplasm (Kalverda et 
al., 2010). The region of NUP98 present in the NUP98-Hex fusion protein 
corresponds to the activation domain in NUP98 (Kalverda et al., 2010). Therefore it is 
likely  that the NUP98-HHEX fusion protein present in the patient with AML, has lost 
the N-terminal repression domain from PRH and gained a transcriptional activation 
module in its place resulting in activation of genes normally repressed by PRH in 
myeloid precursor cells. This fusion protein is not sufficient for the development of 
leukaemia as a further mutagenic event is required for full transformation. However, it 
demonstrates that dysregulation of PRH can initiate a malignant phenotype in cells of 
the myeloid lineage.
Previous work has shown that in cells, from human primary AML and chronic 
myelogenous leukaemia (CML) patients, PRH levels are aberrantly low or PRH is 
mis-localized from the nucleus to the cytoplasm (Topisirovic et al., 2003b). The mis-
localization of PRH may be associated with disruption of key regulatory interactions 
with nuclear proteins within nuclear bodies (Topisirovic et al., 2003a). PRH is 
associated with PNBs (Topisirovic et al., 2003a; Topcu et al., 1999), through a direct 
interaction with PML. Amino acid residues 50-115 of the PRH N-terminal domain 
interacts with the RING domain of PML (Topcu et al., 1999). PRH also interacts with 
the eukaryotic translation initiation factor 4E (elF4E), which is a translation factor that 
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has a role in the nucleo-cytoplasmic transport of specific gene transcripts including 
cyclinD1 (Topisirovic et al., 2003a). This interaction between PRH and eIF4E inhibits 
elF4E dependent mRNA transport (Topisirovic et al., 2003a). When this interaction is 
altered by the loss of PRH from the nucleus, increased elF4E-dependent mRNA 
transport of cyclinD1 is observed. This ultimately leads to an increase in cyclinD1 
protein levels, accelerating progression through the G1 cell cycle check-point and 
increasing cell proliferation (Topisirovic et al., 2003a). eIF4E is increased in AML and 
CML leukaemias, where PRH activity is reduced (Topisirovic et al., 2003b). 
Interestingly, PRH and eIF4E co-localize in PNBs (Topisirovic et al., 2003a), 
suggesting that PNB localization of PRH and eIF4E may be important for this 
regulation. Clearly, negative regulation of eIF4E nucleo-cytoplasmic transport of 
cyclinD1 mRNA suggests disruption of this regulation would have a role in myeloid 
leukaemia.
In contrast, the role of PRH appears to be oncogenic in lymphoid tissues. The use of 
AKXD recombinant inbred mice, which develop leukaemias and lymphomas as a 
result of retroviral mediated activation of proto-oncogenes, identified PRH as a 
potential cause of B-cell leukaemias. PRH was found to be significantly up-regulated 
in these leukaemias (Hansen and Justice, 1999). In a follow up study, bone marrow 
cells transduced with retrovirus containing the PRH coding region, and injected into 
mice, lead to the development of tumours originating from T-cell precursor. These 
neoplasms are thought to develop  due to inhibition of differentiation to mature T-cells 
(George et al., 2003). Furthermore, constitutive expression of the LMO2 oncogene in 
the thymus of mice induces the development of overt T-cell acute lymphoblastic 
leukaemia (T-ALL) (McCormack et al., 2010). Over-expression of PRH is sufficient to 
promote self-renewal of thymocytes and McCormack et al suggested this was 
important for the accumulation of subsequent mutations that allow for leukaemic 
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transformation (McCormack et al., 2010). This work is supported by data from Oram 
et al, who demonstrated that LMO2 forms a triad with ERG and FLI1 to bind the +1 
enhancer of the PRH gene promoter (Oram et al., 2010).  
This body of work presents the possibility that the role of PRH is dependent upon the 
environment; hence in certain contexts the loss of PRH results in the loss of 
repression and the elevation of oncogenic genes. Whereas in other environments 
loss of PRH expression may be vital for proper differentiation. Therefore, it is most 
likely  that the determining factor controlling the balance is the time point at which the 
mutation or over-expression occurs during cell maturation. For example, if a mutation 
occurred in the stem cell population it may have a different phenotype compared to 
the same mutation in a myeloid progenitor cell, which may also give a different 
phenotype from the mutation arising in a lymphoid progenitor cell.
1.3 TLE.
Transducin-like Enhancer of split (TLE) proteins constitute a family of transcriptional 
co-repressors that do not bind DNA directly, but associate with DNA binding 
transcription factors (Fisher and Caudy, 1998). TLE dependent repression of gene 
expression requires oligomerization of TLE (Chen et al., 1998). TLE recruitment of 
HDACs (Chen et al., 1999) and its ability to bind to hypo-acetylated histones 
(Palaparti et al., 1997), are also thought to be important for transcriptional repression. 
The TLE family are a widely expressed family  of proteins that have critical roles in 
embryonic development and they are involved in a variety  of signalling pathways in 
the adult system (Buscarlet and Stifani, 2007). 
1.3.1 Role of TLE in Haematopoiesis.
The TLE protein family  are regulators of gene expression during haematopoiesis  and 
there are four homologs of the mammalian TLE protein (Eberhard et al., 2000; 
Linderson et al., 2004; Ren et al., 1999; Levanon et al., 1998; Imai et al., 1998). As 
                                                                                                                     Chapter 1. INTRODUCTION
34
stated in section 1.2, TLE proteins interact with a regulator of haematopoiesis, PRH 
(Swingler et al., 2004), although to date no gene targets have been identified that are 
co-regulated by PRH and TLE proteins. However, TLE proteins can bind to many 
other important haematopoietic factors and regulation by TLE proteins are important 
for lineage commitment (Levanon et al., 1998; Ren et al., 1999; Eberhard et al., 
2000; Linderson et al., 2004). TLE proteins appear to have significant roles in B-cell 
development through interactions with the vital B-cell linage commitment factors, 
Pax5 and PU.1 (Eberhard et al., 2000; Linderson et al., 2004). These interactions are 
important for transcriptional repression of IgH (immunoglobulin heavy chain) and 
Joining (J)-chain genes, which both have B-cell specific cis elements at their 
promoters (Linderson et al., 2004). Interestingly, the TLE homolog Grg4 that was 
investigated in these studies is down-regulated after B-cell activation, suggesting a 
role for TLE proteins in maintaining B-cell precursors (Linderson et al., 2004). 
Furthermore, TLE proteins interact with the PRDI-BFI/Blimp-1 protein, another B-cell 
specific factor, to function as a co-repressor of ifn-β expression (Ren et al., 1999). 
TLE proteins are not limited to roles in the B-cell lineage. TLE also binds to AML1 
and AML2 (Levanon et al., 1998). AML1 binds TLE proteins, through association with 
the VWRPY motif and C-terminal sequences of TLE, recruiting TLE proteins to AML1 
DNA binding sites within the t-cell receptor (tcr) enhancers α and β (Levanon et al., 
1998). AML1 transactivates tcr gene expression in Jurkat T-cells, however, 
recruitment of TLE1 inhibits this activity  (Levanon et al., 1998). TLE1 can also 
counteract LEF-1:β-catenin-dependent transcription of tcr (Levanon et al., 1998), 
demonstrating a role for TLE-1 regulation of gene expression in T-cells as well. As a 
binding partner and negative regulator of AML1 transactivation it is likely that TLE-1 
also has roles in the regulation of myeloid specific genes (Imai et al., 1998; Levanon 
et al., 1998), however none have yet been characterized.
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1.3.2 Structure of the TLE Family.
Understanding the structural features of the TLE family is critical to understanding, 
how these proteins function. TLE proteins are split into two sub-groups of proteins; 
the GRO subgroup, which have five distinct domains (Q, GP, CcN, SP and WD-
repeat domains), and the AES subgroup, which only  contains the Q domain (Chen 
and Courey, 2000). Members of the AES subgroup act as trans-dominant negatives 
over members of the GRO subgroup, which are functional co-repressors of 
transcription. This section will characterize the key structural properties of TLE.
WD-repeat domains are characterized by specifically located tryptophan and 
aspartate residues within ~40 amino acid tandem repeats. This repetitive motif forms 
a β-propeller structure composed of seven β-blades, with each blade consisting of a 
four-stranded anti-parallel β-sheet (Li and Roberts, 2001). This structure is not 
unique to TLE proteins and is found in many proteins with a plethora of cellular 
functions including, signal transduction, vesicular trafficking and transcriptional 
regulation (Stirnimann et al., 2010). Functionally this region is recognized to facilitate 
protein-protein binding and in TLE proteins it functions as a surface for DNA-bound 
transcription factors to bind to TLE (Paroush et al., 1994; Copley, 2005; Jiménez et 
al., 1999). For example, the transcription factors Hairy and Engrailed both bind to 
TLE through the WD-repeat domain (Paroush et al., 1994; Jiménez et al., 1997).
The Q domain is highly conserved between TLE proteins, it is thought to form coiled-
coil structures with two amphipathic α-helices (Miyasaka et al., 1993; Pinto and Lobe, 
1996). These structural elements are vital for the formation of hetero- and homo-
oligomers of the TLE family and point mutations within the α-helices of the Q domain 
disrupt oligomerization (Chen et al., 1998). 
The central region of TLE proteins contains a CcN motif; it is a loosely conserved 
region of ~60 amino acids. Within this region there is a nuclear localization sequence 
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(NLS) and putative phosphorylation motif for CK2 and p34cdc2 kinase (cdc2) (Stifani 
et al., 1992). These phosphorylation sites are important for regulation of TLE activity 
and will be discussed below (section 1.3.4).
The other two central regions are the GP and SP domains and these regions are 
poorly  conserved through the TLE family. The GP domain has a high content of 
glycine and proline residues, whereas the SP domain is rich in serine and proline 
residues.
1.3.3 Mechanism of TLE-mediated Transcriptional Repression.
Although a definitive mechanism of action for TLE induced transcriptional repression 
is yet to be elucidated it is thought that its structural properties are vital for its activity. 
Homo- or hetero-oligomerization of TLE, via Q domain interactions, is important for 
transcriptional repression, and it has been suggested that TLE can form oligomeric 
complexes that associate with chromatin influencing the availability  of binding sites 
for transcriptional activators (Chen et al., 1998). Oligomerization of TLE may also 
repress transcription by spreading over long distances (Martinez and Arnosti, 2008) 
and may contribute to chromatin compaction (figure 1.7) (Sekiya and Zaret, 2007). 
Once recruited to promoter regions TLE can bind to HDACs and induce deacetylation 
of histones (Chen et al., 1999). This interaction requires the SP domain of TLE (Chen 
et al., 1999). Generally, histone deacetylation is considered to repress transcription 
by decreasing transcription factor accessibility  and compaction of DNA (Fuks, 2005). 
Moreover, TLE can bind to hypo-acetylated histone H3 via the N-terminal domain of 
TLE (Palaparti et al., 1997) and possibly further compacts the chromatin structure. A 
role for TLE proteins in masking the availability  of phosphorylation, acetylation and 
methylation sites on histone H3 has been suggested (Palaparti et al., 1997). In 
addition the GP domain has a role in transcriptional repression, although the 
mechanism through which this occurs has not been characterized.
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Figure 1.7 - A model for TLE compaction of chromatin.
The diagram illustrates a model for TLE compaction of chromatin. TLE can bind to hypo-
acetylated histones and oligomerize to compact chromatin structure. This is likely  one of the 
mechanisms of TLE induced repression. The diagram has been adapted from (Sekiya and 
Zaret, 2007).
Interestingly, the AES subgroup of TLE proteins only contain the Q domain and these 
proteins can oligomerize with the TLE proteins from the GRO subgroup  (Ren et al., 
1999). AES proteins have trans-dominant negative activity over the full-length GRO 
proteins and it has been suggested that AES proteins sequester GRO proteins and 
inhibit their ability to bind to DNA-bound transcription factors or associate with other 
co-factors necessary for transcriptional repression (Ren et al., 1999). This suggests 
that the ratio of GRO proteins compared to AES proteins will have a role in balancing 
the repression activity of TLE at target genes.
1.3.4 Phosphorylation of TLE.
Phosphorylation of TLE regulates its nuclear retention and its functional activity as a 
co-repressor (Buscarlet et al., 2009; Hasson et al., 2005; Nuthall et al., 2004; Nuthall 
et al., 2002b; Nuthall et al., 2002a; Eberhard et al., 2000; Husain et al., 1996). TLE is 
phosphorylated following association with a DNA binding partner. Studies by Nuthall 
et al revealed that over-expression of the transcription factor Hes-1 or AML1 (also 
known as RUNX-1), both DNA binding transcription factors that interact with TLE, 
induce hyper-phosphorylation of TLE (Nuthall et al., 2002a). This co-factor activated 
phosphorylation (CAP) of TLE increases the retention of TLE to the chromatin 
fraction and increases transcriptional repression (Nuthall et al., 2002a). Furthermore, 
TLE hyper-phosphorylation is dependent on constitutive phosphorylation of TLE 
proteins by CK2 (Nuthall et al., 2002a). TLE has two CK2 consensus sequences, 
within the CcN domain, at serine residues 239 and 253. Mutation of either or both of 
these serine residues significantly  reduces or abolishes CAP of TLE (Nuthall et al., 
2004). S239 phosphorylation is not dependent on association of TLE with a DNA 
binding transcription factor, however phosphorylation of S239 is vital for 
transcriptional repression (Nuthall et al., 2004). Nuthall et al proposed that S239 is 
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constitutively  phosphorylated by CK2 after translation, priming TLE for subsequent 
hyper-phosphorylation (Nuthall et al., 2004). 
TLE transcriptional activity can also be controlled by  receptor tyrosine kinase (RTK) 
signalling through MAPK (Hasson et al., 2005; Cinnamon et al., 2008). There are two 
potential MAPK phosphorylation sites one within each of the SP and WD40 domains 
(Hasson et al., 2005). In the study by  Hasson et al they showed that upon EGFR 
stimulation TLE is phosphorylated, reducing its co-repressor activities (Hasson et al., 
2005). In addition they demonstrate the ability of EGFR signalling to antagonize 
Notch induced transcriptional output (Hasson et al., 2005). A  follow up study 
identified general activation of MAPK, sufficient to reduce co-repression activity 
(Cinnamon et al., 2008). However, MAPK phosphorylation of TLE does not reduce 
nuclear localization, it only inhibits the transcriptional activity  of TLE (Cinnamon et al., 
2008).
TLE is also hyper-phosphorylated, in the CcN and SP domains, by cdc2 (Nuthall et 
al., 2002b). Cdc2 phosphorylation of TLE occurs during the G2/M phase of the cell 
cycle and reduces the nuclear retention of TLE (Nuthall et al., 2002b). Clearly, 
phosphorylation of TLE is important in determining the transcriptional activity  and 
nuclear retention properties of TLE (Husain et al., 1996; Nuthall et al., 2004; Nuthall 
et al., 2002b; Nuthall et al., 2002a). There are at least four phosphorylation sites on 
TLE1 that affect its activity and therefore multiple combinations of phosphorylated 
residues can arise; it is likely  that different combinations of phosphorylated residues 
have a distinct functional output. This sort of combinatorial regulation suggests TLE is 
tightly regulated to respond to internal and external stimuli as required.
1.4 Vascular Endothelial Growth Factor.
The Vascular Endothelial Growth Factor (VEGF) and its receptors VEGFR1 and 
VEGFR2 are important factors for new blood vessel formation, in the process of 
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angiogenesis (Murukesh et al., 2010). As a result these factors are dis-regulated in 
some diseases such as von Hippel-Lindau syndrome, where they  have a role in 
neovascularization of growing tumors (Harris, 2000).
1.4.1 VEGF.
VEGF belongs to the PDGF superfamily and is a potent mitogen and survival factor 
for endothelial cells (Ferrara and Henzel, 1989; Gerber et al., 1998). However it also 
has other roles, for example it is thought to be a survival factor for haematopoietic 
stem cells (Gerber et al., 2002) and can stimulate monocyte migration (Barleon et al., 
1996). VEGF is secreted as a covalently linked homo-dimer and exists in six 
isoforms; VEGF 121, 145, 165, 183, 189 and 206; with VEGF 121, 165, 183, and 189 
all expressed across a wide range of cell types (Robinson and Stringer, 2001). In 
addition to these isoforms there are another 5 VEGF like mitogens; VEGF-B, VEGF-
C, VEGF-D, VEGF-E, and PlGF; that signal through the VEGF receptors, however, 
these will not be discussed further in this thesis (Robinson and Stringer, 2001).
1.4.2 VEGF Receptors: VEGFR1 and VEGFR2.
The VEGF receptors VEGFR1 and VEGFR2, are receptor tyrosine kinases that can 
bind and be activated by VEGF. The downstream pathways of these receptors 
involve a complex network of signalling cascades that include the p38MAPK, PI3K/
Akt and PLCγ pathways (Roskoski, 2007; Matsumoto and Mugishima, 2006). 
VEGFR1 has a stronger binding affinity for VEGF than VEGFR2 (Waltenberger et al., 
1994), yet VEGFR2 signalling is thought to be more important for endothelial cell 
proliferation and survival (Gille et al., 2001; Bernatchez et al., 1999). The 
physiological role of VEGFR1 described in the literature suggests that it 
predominantly regulates cell migration of both endothelial cells (Kanno et al., 2000) 
and monocytes (Barleon et al., 1996). However, it has also been described to play a 
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role in survival signalling through the Akt pathway (Nishi et al., 2008) and can 
increase cell survival in response to chemotherapeutic agents (Tsuchida et al., 2008). 
1.4.3 Other Receptors for VEGF.
VEGFR1 and VEGFR2 are the most prominent VEGF receptors in the literature, but 
there is also a third receptor, VEGFR3, which is important for lymphatic endothelial 
cell development and function (Olsson et al., 2006). However, VEGFR3 does not bind 
VEGF, but binds VEGF-C and VEGF-D (Ferrara et al., 2003). Additionally there are 
co-receptors that can bind VEGF, neuropilin-1, neuropilin-2, and heparan sulphate 
proteoglycans (HSPGs). These appear to have no catalytic activity  but can increase 
VEGF binding for other VEGF receptors (Soker et al., 1998). Neuropilins are also 
vital for proper vascular development (Kawasaki et al., 1999).
1.4.4 VEGF Signal Transduction.
VEGF induced signal transduction through its receptors VEGFR1 and VEGFR2 
mediate different responses depending on the cellular environment. VEGFR2 
signalling has been well studied and is thought to be primarily responsible for 
endothelial cell proliferation, survival and migration (Gerber et al., 1998; Bernatchez 
et al., 1999). It is also involved in a similar role in many other cell types (Ferrara et 
al., 2003). VEGFR1 in endothelial cells is widely  reported as a decoy receptor, with 
no or few downstream targets (Hiratsuka et al., 1998; Meyer et al., 2006), resulting in 
less VEGFR2 signal transduction. However, in monocytes VEGFR1 signalling 
induces a strong chemotactic response (Barleon et al., 1996). Also, it has been 
shown that VEGFR1 is capable of similar signal transduction responses as those 
induced by VEGFR2 in endothelial cells, when sufficient stimulus is supplied (Knight 
et al., 2000). The following section will review the signalling pathways induced 
through VEGFR2 and VEGFR1 (figure 1.8).
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1.4.4.1 VEGFR2 Signal Transduction.
VEGFR2 signal transduction is initiated by the binding of VEGF to the Ig-like domain 
3 of the extracellular region of VEGFR2 (Lu et al., 2000). Upon ligand binding, 
receptor dimerization is induced and the receptor is activated through auto-
phosphorylation (Dougher and Terman, 1999). There are several important tyrosine 
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Figure 1.8 - VEGF signal transduction.
The diagram illustrates the pathways involved in VEGF signal transduction. The VSP 
induces proliferation, survival and migration, through the PKC, AKT, NOS and RAC 
pathways respectively.
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phosphorylation sites in the cytoplasmic region of VEGFR2, including 
phosphorylation of residue 951 in the kinase-insert domain (Matsumoto et al., 2005), 
residues 1054 and 1059 in the kinase domain (Kendall et al., 1999), and residues 
1175 and 1214 in the C-terminal tail of VEGFR2 (Takahashi et al., 2001). These 
phosphorylated tyrosine kinase residues provide a binding platform for SH2 domain 
containing accessory proteins, which mediate signal transduction. Phosphorylation of 
tyrosine 951 is vital for binding of the T-cell specific adapter (TSAd) protein, this 
interaction is critical for VEGF induced actin reorganization and cell migration but not 
for VEGF induced cell proliferation of endothelial cells (Matsumoto et al., 2005).
The 1054 and 1059 residues have regulatory roles for VEGFR2 and phosphorylation 
of these residues is required for receptor tyrosine kinase activity (Kendall et al., 
1999). Phosphorylation of tyrosine 1175 provides a docking site for phospholipase C 
γ1 (PLCγ1), once bound PLCγ1 is phosphorylated and activated (Takahashi et al., 
2001). Activation of PLCγ1 ultimately leads to Ca2+ influx and activation of the 
calcium-dependent protein kinase C (PKC) (Berridge and Irvine, 1989; Noh et al., 
1995). PKC initiates a signal transduction cascade that results in the activation of the 
extracellular signal-regulated kinase (ERK). Phosphorylated tyrosine 1175 also binds 
the adapter molecules Shb and Sck (Holmqvist et al., 2004; Warner et al., 2000). Shb 
mediates the activation of the phosphoinositide 3-kinase (PI3K) pathway that 
regulates VEGF induced cell migration and survival (Holmqvist et al., 2004; Gerber et 
al., 1998). Activation of PI3K increases phosphatidyl inositol 3 phosphate (PIP3) and 
activates several important intracellular molecules, including Akt and the small GTP-
binding protein Rac. The Akt pathway is fundamental for cell survival (Gerber et al., 
1998).
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1.4.4.2 VEGFR1 Signal Transduction.
Activation of VEGFR1 signalling is very similar to VEGFR2, with the first three Ig-like 
domains required for VEGF binding and receptor dimerization (Barleon et al., 1997). 
The major phosphorylation sites on the VEGFR1 cytoplasmic region are the tyrosine 
residues 1213 and 1242 (Ito et al., 1998). Residues 1327 and 1333 are also auto-
phosphorylated (Ito et al., 1998). PLCγ binds to the phospho-tyrosine residues 1213 
and 1333 of VEGFR1. Other signalling mediators include Grb2, the SH2-containing 
tyrosine protein phosphatase (SHP-2) (Ito et al., 1998) and PI3K (Yu et al., 2001) 
which all bind to 1213. Similar to VEGFR2 signalling, VEGFR1 signalling through the 
PI3K/Akt pathway can be vital for cell survival (Lee et al., 2007b). VEGFR1 signalling 
also appears to be important for Nitric Oxide Synthase (NOS) expression 
(Thirunavukkarasu et al., 2007).
Clearly VEGF can signal via multiple pathways through several receptors to mediate 
its effects. It is likely that the different receptors have alternative effects depending on 
the relative level of expression of these receptors and the relative concentration of 
downstream proteins. In addition, the regulation of VEGF mediated signalling is 
further complicated by cross-talk between several signalling pathways (Olsson et al., 
2006) and heterodimerization between receptors and co-receptors (Waltenberger et 
al., 1994).
1.4.5 The Role of VEGF in Disease.
1.4.5.1 General Role of VEGF in Cancer.
As a regulator of angiogenesis, VEGF is a key molecule in neo-vascularization of 
solid tumours. As stated by Hanahan and Weinberg in their ʻThe hallmarks of cancerʼ 
review:
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“The oxygen and nutrients supplied by the vasculature are crucial for cell 
function and survival, obligating virtually all cells in a tissue to reside within 
100µm of a capillary blood vessel.” (Hanahan and Weinberg, 2000)
This underlines the importance of angiogenesis to a newly developing tumour 
because as the size of the tumour increases the availability  of nutrients and oxygen is 
depleted, therefore inhibiting growth and survival signals they  rely upon. For this 
reason VEGF expression has been proposed as a prognostic marker for many 
tumour types (Poon et al., 2001). Inhibition of VEGF function is currently an area of 
intense research. The development of Bevacizumab, a monoclonal antibody that 
recognizes VEGF, was widely thought to be a big step  in cancer therapy however its 
efficacy as a therapy in isolation has shown little clinical benefit (Robert et al., 2009). 
Yet, in combination with chemotherapy or other targeted therapies Bevacizumab  has 
proven to be significantly beneficial (Miller et al., 2007; Robert et al., 2009). Small 
molecule inhibitors of the VEGF receptors are also in clinical trials and have had 
varying success depending on the cancer type and the combinatorial therapies used 
(Murukesh et al., 2010).
1.4.5.2 Role of VEGF in Normal Haematopoiesis and Haematopoietic Disease.
VEGF is a critical factor for haematopoiesis. In gene knockout experiments for VEGF 
and VEGFR2, blood-island formation was impaired or completely failed, suggesting 
that VEGF is necessary for haematopoiesis (Ferrara et al., 1996; Shalaby et al., 
1995). Expression of VEGF is observed in bone marrow cells (Bautz et al., 2000; 
Janowska-Wieczorek et al., 2001). Whereas, VEGFR2 and VEGFR1 are found on a 
subset of multipotent haematopoietic stem cells (Shalaby et al., 1995; Ratajczak et 
al., 1998). VEGFR1 expression, but not VEGFR2 expression, is up-regulated in more 
mature haematopoietic cells (Ratajczak et al., 1998). Autocrine signalling by VEGF 
through both VEGFR2 and VEGFR1 regulates haematopoietic stem cell survival 
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(Gerber et al., 2002). Autocrine signalling is defined as signalling induced by  a ligand 
secreted from the same cell compared to paracrine signalling which is where the 
ligand is secreted by one cell and bound by a receptor on a nearby cell.
There is a significant amount of literature relating to the role of VEGF and its 
receptors in leukaemia and its roles in regulating leukaemic cell growth and survival. 
VEGF autocrine (Dias et al., 2000) and paracrine (Fiedler et al., 1997) signalling has 
been demonstrated to promote cell survival in leukaemic cells through the induction 
of Bcl-2 (Dias et al., 2002) and VEGF can protect against chemotherapeutic agents 
(Katoh et al., 1998) and radiotherapy (Katoh et al., 1995). The treatment of AML 
patients with an inhibitor of VEGFR1 and VEGFR2, PTK787/ZK222584, showed 
increased apoptosis and inhibited cell proliferation, with an additive effect when used 
with conventional chemotherapy (Barbarroja et al., 2009). Moreover, decreased cell 
growth is observed when VEGF expression is knocked down in CML cells (Ruan et 
al., 2004) and CML patients that express high levels of VEGFR2 have a worse 
survival prognosis (Verstovsek et al., 2003). Additionally, the use of VEGF 
neutralizing antibodies in myelodysplastic syndrome (MDS) has been shown to 
reduce cytokine production and colony-forming unit (CFU)-leukaemia formation in the 
majority of patient samples (Bellamy et al., 2001). These studies therefore suggest 
the therapeutic benefit of targeting VEGF signalling.
1.4.5.3 Role of Angiogenesis in Haematopoietic Disease.
Interestingly, increased angiogenesis of the bone marrow is an associated pathology 
of AML (Padró et al., 2000; Hussong et al., 2000; Rimsza et al., 2002; Matuszewski 
et al., 2007; Lee et al., 2007a; Hatfield et al., 2009; Shih et al., 2009), CML (Aguayo 
et al., 2000), acute lymphoblastic leukemia (ALL) (Perez-Atayde et al., 1997), 
multiple myeloma (MM) (Vacca et al., 1999) and MDS (Aguayo et al., 2000). It is 
thought that the increased angiogenesis of the bone marrow is associated with the 
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up-regulation of angiogenic factors such as VEGF secreted by leukaemic cells 
(Janowska-Wieczorek et al., 2002). For example, in mice transplanted with VEGF 
knock-down CML cells, reduced tumour microvessel density (MVD) is observed 
compared to controls (Ruan et al., 2004). Recently it has been shown that bone 
marrow angiogenesis imaged by dynamic contrast enhanced magnetic resonance 
imaging (DCE-MRI) can predict high-risk patients that may benefit from anti-
angiogenic therapies (Shih et al., 2009). Therefore, therapies are being trialled to 
target VEGF directly or to indirectly reduce VEGF expression (Li et al., 2008).
1.4.6 Transcriptional Regulation of VSP Genes.
1.4.6.1 Regulation of the Vegf Gene.
The Vegf gene in humans is located on chromosome 6p21.3 (Vincenti et al., 1996) 
and has a coding region spanning 14kb  with eight exons (Tischer et al., 1991). 
Regulation of Vegf gene expression is complex (figure 1.9 [A]). Activation of Vegf 
gene transcription in response to hypoxia, is the most thoroughly studied mechanism 
of activation of Vegf in the adult system. The transcription factor, Hypoxia-inducible 
factor 1α (HIF-1α) is a potent regulator of Vegf expression (Forsythe et al., 1996). 
Under normal oxygen conditions conserved proline residues of HIF-1α are 
hydroxylated by prolyl hydroxylase 2 (PHD2) (Berra et al., 2003). Hydroxylation of 
HIF-1α provides a binding platform for the von Hippel-Lindau protein (pVHL) 
(Jaakkola et al., 2001), an E3 ubiquitin ligase that targets HIF-1α for degradation by 
the proteasome (Ohh et al., 2000; Maxwell et al., 1999). In low oxygen conditions 
HIF-1α is stabilized, due to a lack of oxygen for hydroxylation, and it binds to hypoxia 
response elements (HRE) within the proximal promoter region of the Vegf gene to 
induce expression of Vegf mRNA. Vegf expression can also be activated by HIF-2α in 
a similar manner (Takeda et al., 2004). Transcription of the Vegf gene can also be 
directly regulated by a number of other transcription factors that respond to numerous 
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Figure 1.9 - Schematic diagram of transcription factor binding sites for the VSP 
genes.
The diagram illustrates the relative transcription factor binding sites for Vegf [A], Vegfr1 [B], 
and Vegfr2 [C]. The black boxes represent the binding sites relative to the TSS. The 
coloured shapes represent transcription factors that can bind to a specific gene promoter. 
Stacked coloured shapes represent binding of these factors to the same, or proximal to that, 
region of the promoter.
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stimuli. The Sp-1 transcription factor is another important regulator of Vegf gene 
transcription. Sp-1 binds to a cluster of GC  boxes within the Vegf promoter  in 
response to Ras signal transduction, mediated through Erk phosphorylation of Sp-1 
(Tischer et al., 1991; Milanini-Mongiat et al., 2002). However, there are also 
consensus binding sites for other transcriptional activators in this promoter region 
including AP-1, AP-2, and Stat3. Of these transcription factors, AP-1 is important for 
Vegf expression in response to hypoxia and through TGF-β signalling (Damert et al., 
1997; Chua et al., 2000). In addition, there are several reported negative regulators 
of Vegf expression, for example p53 has been reported to bind to the Vegf gene 
promoter and may require Sp-1 for repression (Zhang et al., 2000). p53 also binds to 
and is required for E2F1 dependent repression of Vegf expression (Qin et al., 2006). 
Negative regulators of Vegf expression also include Smad4 (Schwarte-Waldhoff et 
al., 2000), p16 (Zhang et al., 2007), and RB2/p130 (Claudio et al., 2001) but the 
mechanisms for negative regulation of Vegf expression by these proteins are 
unknown and may be indirect. Thus negative reguation of Vegf expression is 
relatively poorly characterized.
1.4.6.2 Regulation of the Vegfr1 Gene.
The Vegfr1 gene locus is located on chromosome 13q12.13 and is more than 200kb 
in size containing 30 exons (Shibuya et al., 1989). Regulation of the Vegfr1 gene is 
less well understood than the Vegf gene but Vegfr1 has recently been targeted for 
investigation (figure 1.9 [B]). Expression of Vegfr1 can be induced by low oxygen 
conditions, in a similar fashion to Vegf expression, as the proximal promoter of the 
Vegfr1 gene contains HRE sites. Although the Vegf gene is regulated by HIF-1α and 
HIF-2α, as described above, the Vegfr1 gene requires HIF-2α for hypoxia-induced 
expression (Takeda et al., 2004). Interestingly, Vegfr1 expression can also be 
activated in response to EGF/FGF2 signalling, which induces recruitment of Ets-1 
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and HIF-2α in a hypoxia-independent manner (Dutta et al., 2008). Whereas Vegf 
expression is repressed by E2F1 through interactions with p53, E2F1 also binds to 
the promoter regions of the Vegfr1 and Vegfr2 genes and correlates with increased 
acetylation of nucleosomes at these promoters (Pillai et al., 2010). This binding of 
E2F1 leads to up-regulation of mRNA expression (Pillai et al., 2010). Daxx acts as a 
negative regulator of the Vegfr1 gene (Murakami et al., 2006), by interacting with 
Ets-1 (Li et al., 2000), but it is unknown whether Daxx acts as a co-repressor or acts 
indirectly by inhibiting DNA binding of Ets-1.
1.4.6.3 Regulation of the Vegfr2 Gene.
The Vegfr2 gene locus is 190kb  in size with a coding region spanning more than 
47kb and contains 28 exons (Yin et al., 1998). The Vegfr2 gene has been extensively 
studied and a variety of transcription factors have been reported to bind to the 
promoter of the Vegfr2 gene (figure 1.9 [C]). The Vegfr2 gene is induced by low 
oxygen conditions through binding of HIF to the HRE within the gene promoter, in a 
similar fashion to HIF binding at the Vegf and Vegfr1 genes. HIF-2α is thought to 
mediate hypoxic induction of Vegfr2 as HIF-2α binds and activates Vegfr2 expression 
in an Ets-1-dependent manner, whereas HIF-1α does not activate transcription in a 
number of cell types (Elvert et al., 2003). Yet in patient samples for cerebral 
arteriovenous malformations, HIF-1α expression is significantly  correlated with high 
Vegfr2 expression, suggesting that HIF-1α might also play a role in some 
environments (Ng et al., 2005). In addition to the hypoxic regulation of Vegfr2 
expression, Vegfr2 is also regulated by a number of other factors. Within the proximal 
promoter of the Vegfr2 gene there are Sp-1 binding sites, which Sp-1 can bind to and 
then activate Vegfr2 expression (Patterson et al., 1997). Sp-3 can act as a negative 
regulator of Vegfr2 expression by inhibiting Sp-1 binding to the promoter (Hata et al., 
1998). The ratio of Sp-1/Sp-3 correlates to expression of Vegfr2 in endothelial and 
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non-endothelial cells (Hata et al., 1998). Furthermore, PPARγ1 can physically 
interact with the Sp-1 and Sp-3 proteins, via the ligand binding site of PPARγ1 
(Sassa et al., 2004). This association can enhance Sp-1 promoter binding, yet 
interaction of PPARγ1 ligand to PPARγ1 inhibits the association of Sp-1 to the Vegfr2 
promoter (Sassa et al., 2004). Within the 5ʼ-untranslated region of the Vegfr2 gene 
there are GATA binding sites through which GATA-1 and GATA-2 can activate Vegfr2 
expression (Minami et al., 2001). Yet, TGF-β signalling, through TGF-β  type I and 
type II receptors, can inhibit Vegfr2 expression even in the presence of over-
expressed GATA-1 or GATA-2 by preventing GATA binding, although the exact 
mechanism is still yet to be determined (Minami et al., 2001). GATA-2 nuclear 
localization and transcriptional activation of the Vegfr2 gene is increased in response 
to mechanical signals of endothelial cells conveyed by increased extra-cellular matrix 
elasticity (Mammoto et al., 2009). The transcription factor TFII-I negatively regulates 
Vegfr2 in this system, where siRNA knockdown of TFII-I under low elasticity 
increases Vegfr2 expression (Mammoto et al., 2009). The Vegfr2 gene promoter also 
contains Nuclear factor -κB (NF-κB) and cAMP response element binding protein 
(CREB) binding sites (Illi et al., 2000). NF-κB can recruit histone acetyl-transferases 
(HATs), p300/CBP and p300/CBP associated factor (P/CAF), to the Vegfr2 promoter 
to activate transcription, but CREB represses Vegfr2 expression (Illi et al., 2000). 
FoxH1 also represses Vegfr2 transcription through a consensus binding site 
approximately  5kb  upstream from the TSS (Choi et al., 2007). HESR1 is a 
transcriptional repressor that acts downstream of Notch signalling and is thought to 
suppress Vegfr2 expression through binding to Sp-1-like factors (Holderfield et al., 
2006).
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1.5 Protein Kinase CK2.
1.5.1 Structure of Protein Kinase CK2.
Protein kinase CK2 is a ubiquitiously expressed serine/threonine protein kinase with 
the minimal recognition consensus sequence determined to be Ser-Xaa-Xaa-Acidic, 
where the acidic residue can be glutamic acid, asparagine, phospho-serine or 
phospho-tyrosine (Meggio et al., 1994). Although even this loose specificity is not 
required for some substrates (Meek et al., 1990). The presence of a consensus 
sequence within a protein does not guarantee phosphorylation (Meggio et al., 1994). 
Structurally CK2 exists as a tetrameric complex consisting of two catalytic CK2α 
subunits, and two regulatory CK2β subunits. There are three distinct CK2 catalytic 
subunits, CK2α, CK2α' (Lozeman et al., 1990) and CK2α'' (Shi et al., 2001), but only 
one regulatory CK2β subunit. CK2 complexes can be formed with two identical 
catalytic subunits or two non-identical subunits (Gietz et al., 1995). CK2α has 
substrates that are independent from substrates for the tetrameric CK2, for example 
calmodulin (Marin et al., 1999). Therefore, there maybe a role for regulated 
disassembly of the tetrameric structure, which drives CK2α and CK2β independent 
functions, although currently none have been described.
In the literature there are few distinctions made between CK2α and CK2α', even 
though they are encoded by separate genes, suggesting that they may have distinct 
biological functions. CK2α and CK2α' are 90% identical in the catalytic domain but 
the C-terminal region has no sequence homology (Litchfield, 2003). This suggests 
that the C-terminal regions of these proteins are important for their biological function, 
especially  as these C-terminal regions are highly conserved through evolution. In 
support of this protein phosphatase 2A (PP2A) has been shown to specifically bind to 
CK2α, but the binding site for this protein is not conserved in CK2α' (Hériché et al., 
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1997). Other proteins including, CKIP-1 (Bosc et al., 2000) and Pin1 (Messenger et 
al., 2002) are also CK2α specific interacting proteins.
CK2β is also highly conserved through evolution, with no amino acid sequence 
changes between birds and mammals and just a single conservative amino acid 
substitution between mammals and Xenopus laevis (Litchfield, 2003). CK2β has 
several key structural elements that are important for the regulation of CK2 activity. 
Amino acid residues 55-64 of CK2β (DLEPDEELED) is similar to auto-inhibitory 
sequences found in other protein kinases (Soderling, 1990). This sequence also 
regulates CK2 activity. Binding of polyamines to this sequence activates CK2 activity 
in vitro (Leroy et al., 1997). Point mutations of this sequence can also increase the 
basal activity of CK2 and inhibit polyamine binding, suggesting it has an auto-
inhibitory role (Leroy et al., 1997). At the C-terminus of CK2β  there is a zinc finger 
structure containing 4 cysteine residues. This structure mediates the dimerization of 
CK2β subunits (Canton et al., 2001). It is thought that the formation of CK2β dimers 
are a prerequisite for CK2α binding (Canton et al., 2001). The amino acid residues 
181-203 of the C-terminal domain of CK2β encompasses a positive regulatory 
domain that is vital for increasing and stabilizing CK2α activity (Marin et al., 1997). In 
addition to these distinct features of CK2β, CK2β is also partly  responsible for the 
selectivity of CK2 substrates. CK2β can act as a docking module for many proteins 
that are phosphorylated by CK2, such as p53 (Appel et al., 1995), and regulators of 
CK2 activity, such as FGF-2 (Bonnet et al., 1996).
1.5.2 Activation of Protein Kinase CK2.
Relatively little is currently known about the mechanisms behind CK2 activation 
under normal physiological conditions. However, CK2 activity can be modulated 
through phosphorylation of the C-terminal domain of CK2α in a cell-cycle dependent 
manner (Bosc et al., 1995). This phosphorylation increases the association with Pin1 
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and subsequently inhibits the CK2 phosphorylation of Topoisomerase IIα (Messenger 
et al., 2002). 
Recent work has also identified CK2 as a downstream target for EGFR signalling (Ji 
et al., 2009). ERK2, which is activated by EGFR signalling, binds to the CK2α subunit 
and phosphorylates CK2α in the C-terminal domain at residues threonine 360 and 
serine 362, which enhances CK2 activity for α-catenin (Ji et al., 2009). 
The best described mode of CK2 activation is in response to stress signals. This can 
occur through an allosteric interaction of CK2 with p38 MAP kinase  and leads to the 
activation of p53, through serine 392 phosphorylation by CK2 (Sayed et al., 2000). 
Activation of p53 by CK2 is observed to occur in response to TNF-α signalling (Sayed 
et al., 2000). Furthermore, UV treatment can activate CK2 through a p38 MAP kinase 
dependent pathway (Kato et al., 2003). CK2 phosphorylation mediates the 
degradation of PML via the proteasome, and this activity is up-regulated by activation 
of the p38 MAP kinase pathway as well (Scaglioni et al., 2008). 
1.5.3 The Role of Protein Kinase CK2 in Disease.
Despite relatively  few studies describing CK2 activation, the role of CK2 is strongly 
correlated with tumourigenesis across most tumour types. In a significant proportion 
of malignant cells, CK2 levels have been found to be elevated compared to normal 
cells of the same type (Tawfic et al., 2001; Trembley et al., 2009). Notably, CK2 is 
known to control the activity of several tumour suppressors (figure 1.10). p53, the 
ʻguardian of the genomeʼ is a known target of CK2, and CK2 phosphorylation of 
MDM2, a negative regulator of p53, can influence the rate of turnover of p53 
(Allende-Vega et al., 2005). PML is another tumour suppressor that is often mutated 
in cancers and phosphorylation by CK2 will target PML for degradation by the 
proteasome (Scaglioni et al., 2006). CK2 can also target the tumour suppressor 
PTEN, which is a key  negative regulator of the Akt survival pathway, and 
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phosphorylation of PTEN by CK2 down-regulates PTEN activity (Silva et al., 2008). 
As well as negatively  regulating tumour suppressor proteins, CK2 can also regulate 
oncogenes such as c-Myc. In this case, CK2 phosphorylation of c-Myc stabilizes the 
protein, reducing its turnover and enhancing c-Myc function (Channavajhala and 
Seldin, 2002). As a result of regulating these pro-survival and pro-proliferation 
proteins, the level of CK2 expression can be indicative of the disease prognosis, with 
high levels of expression often associated with reduced patient survival (Gapany et 
al., 1995; Lin et al., 2010; Kim et al., 2007; Eddy et al., 2005; O-charoenrat et al., 
2004). It has been proposed that tumours can become ʻaddictedʼ to high CK2 
expression due to the number of cellular proteins that are CK2 targets (Ruzzene and 
Pinna, 2010). Interestingly, MM (Piazza et al., 2006), AML (Kim et al., 2007) and T-
ALL (Silva et al., 2008) cells are all susceptible to apoptosis after treatment with CK2 
inhibitors. CK2 has pleiotropic effects on cellular processes but the general trend of 
CK2 action is through the promotion of survival pathways and inhibition of apoptotic 
processes (Trembley et al., 2009).
CK2 is an intriguing protein kinase, unlike most of the kinome, CK2 does not have a 
set of targets in a hierarchical pathway  system based on a specific stimuli, but can 
influence several signal transduction pathways at multiple points within the hierarchy 
(Ruzzene and Pinna, 2010). The three key pathways that CK2 regulates to promote 
survival are the NF-κB pathway, the Wnt pathway and the Akt pathway (reviewed by 
(Ruzzene and Pinna, 2010)). 
CK2 activity can further influence survival through the phosphorylation of key 
components of the apoptosis machinery, such as ARC  (a caspase inhibitor) (Li et al., 
2002), Bid (Desagher et al., 2001), and caspase 9 (where phosphorylation inhibits 
caspase 9 activation, protecting it from cleavage by caspase 8) (McDonnell et al., 
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2008). The ability of CK2 to alter the activity of these factors further underlines why 
activation of CK2 is so important for tumour cells. 
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Figure 1.10 - CK2 action in disease.
The diagram illustrates how CK2 drives proliferation and survival when it is inappropriately 
expressed or activated, by  promoting proliferation and survival whilst protecting from 
apoptosis. These three examples demonstrate the effect of CK2 phosphorylation on protein 
stability and protecting from caspase cleavage.
1.6 Tumour of Haematopoietic Tissues.
In this thesis my focus will be on the role of PRH in the myeloid compartment and 
diseases derived from these cells. Therefore, this next section will briefly discuss 
some of the molecular underpinnings of select haematopoietic diseases that are 
relevant to this thesis.
1.6.1 Acute Myelogenous Leukaemia (AML).
AML is a heterogeneous disease and can arise from a variety of somatic genetic 
alterations, gene mutations, aberrant gene expression and other molecular 
alterations (such as microRNA variation). There is no single underlying cause for 
AML and disruption of a number of genes can lead to AML progression. However, 
perturbed transcription factor activity is a feature for a subset of AML. Common 
transcription factor mutations include the RUNX/AML proteins 1-3 (Grimwade and 
Hills, 2009; Peterson and Zhang, 2004; Elagib and Goldfarb, 2007), PML (Grignani et 
al., 1993; Khan et al., 2001), and EVI-1 (Barjesteh van Waalwijk van Doorn-
Khosrovani et al., 2003; Byrd et al., 2002; Vinatzer et al., 2003; Hirai et al., 2001), 
amongst others. Interestingly, several of these factors are transcriptional repressors 
and demonstrate that perturbed activity of transcriptional repressors has a role in 
AML.
1.6.2 Chronic Myelogenous Leukaemia (CML).
CML is a myeloproliferative disorder that is characterised by  increased proliferation of 
the granulocytic lineage without the loss of the capacity  to differentiate. CML normally 
progresses through three clinical phases; an initial chronic phase; the accelerated 
phase; and finally blast crisis, which is very aggressive and usually fatal. Patients in 
the initial chronic phase have mild symptoms. Once patients progress to the blast 
crisis phase they have high numbers of blast cells (in excess of 30% of total blood 
cells) in the bone marrow and the peripheral blood, with reduced red blood cells and 
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platelets.  About 90% of patients with CML have the Philadelphia (Ph) chromosome, 
which results from a reciprocal translocation between the long arms of chromosomes 
9 and 22, t(9;22)(q34;q11), and encodes the BCR-ABL1 fusion oncogene.
To understand how the BCR-ABL1 fusion protein can initiate leukaemogenesis it is 
important to understand the structural characteristics of the BCR and ABL1 proteins, 
and how the BCR-ABL1 fusion protein forms. Most patients with CML express the 
p210 BCR-ABL1 protein and this is formed through breakpoints around the exons Ia 
and Ib of the Abl1 gene and exons 12-16 of the Bcr gene (Melo, 1996). 
ABL1 is a modular protein containing a central kinase domain preceded by src-
homology domain-2 (SH2) and SH3 domains. The C-terminal end of ABL1 has DNA-
binding and actin-binding domains, with three nuclear localization signal motifs and a 
nuclear export signal motif. ABL1 has two isoforms ABL1a and 1b. ABL1b  is highly 
expressed and has an N-terminal ʻcapʼ domain that is myristoylated (Hantschel and 
Superti-Furga, 2004), and this engages the C-terminal lobe of the ABL1 catalytic 
domain, similar to the conformation of inactivated SRC (Hantschel and Superti-Furga, 
2004; Xu et al., 1997). Forms of ABL1b  that lack the myristoyl moiety  have 
constitutively  active tyrosine kinase activity. The BCR-ABL1 fusion replaces the N-
terminal ʻcapʼ of ABL1 with BCR, therefore removing this auto-inhibitory mechanism. 
BCR has three important domains that act as docking platforms for accessory 
proteins, including (1) a putative calcium-dependent lipid binding site, (2) the central 
pleckstrin homology domain (PHD), and (3) a key tyrosine residue (Ren, 2005). 
Tyrosine 177 is important because it forms a docking site for multiple accessory 
proteins including GRB2, GRB10, 14-3-3 and ABL1 (Ren, 2005). However, it also has 
two other notable domains (1) a serine/threonine kinase domain and (2) a coiled-coil 
oligomerization domain (Ren, 2005). Mutations of the coiled-coil domain, that disrupt 
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oligomerization, will significantly impair the kinase activity  and leukaemogenic 
properties of the BCR-ABL1 fusion protein (Smith et al., 2003). 
The leukaemogenic properties of BCR-ABL1 are facilitated through the signalling 
pathways that are induced (figure 1.11). The BCR-ABL1 fusion protein is a hub  that 
can dock specific accessory proteins and through constitutively active kinase activity 
it can drive oncogenic pathways. Phosphorylation of tyrosine 177 of the BCR module 
is essential for BCR-ABL1-mediated leukaemogenesis (Zhang et al., 2001). 
Phosphorylation of this site facilitates the recruitment of GRB2, which binds a 
guanine-nucleotide exchange factor (GEF) for RAS called Son of sevenless (SOS) 
(Ren, 2005). This complex leads to RAS activation and induction of its downstream 
targets. Also recruited to this complex is the scaffold adapter GRB2-associated 
binding protein 2 (GAB2) (Ren, 2005), which is phosphorylated by  the ABL1 moiety of 
BCR-ABL1 (Sattler et al., 2002). BCR-ABL1-induced phosphorylation of GAB2 
causes constitutive activation of the phosphatidylinositol 3 kinase (PI3K)/AKT 
pathway (Skorski et al., 1995). The importance of GAB2 was demonstrated using 
GAB2-/- mice, as expression of BCR-ABL1 in these animals is unable to transform 
primary myeloid cells (Sattler et al., 2002).
Although the RAS and PI3K/AKT pathways are key oncogenic pathways, BCR-ABL1 
has many other targets as well. BCR-ABL1 can also phosphorylate SRC family 
kinases HCK, LYN and FGR. Phosphorylated HCK activates STAT5 (Ren, 2005; 
Ilaria and Van Etten, 1996), which up-regulates the cell-cycle regulator cyclin D1 
increasing G1 to S phase progression (Nosaka et al., 1999). BCR-ABL1 activates the 
RAC GTPases that include downstream targets such as, CrKL, ERK, JNK and p38 
(Thomas et al., 2007).
Imatinib is a specific inhibitor of BCR-ABL1, v-ABL, and cellular ABL1 (Buchdunger et 
al., 1996). It was shown to be an effective inhibitor of growth of BCR-ABL1 positive 
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Figure 1.11 - Schematic diagram of BCR-ABL1 signalling in CML.
The diagram illustrates how  the BCR-ABL1 fusion protein is able to increase proliferation 
and survival of leukaemic blasts. BCR-ABL1 can initiate signal transduction through multiple 
pathways, including activation of RAS and AKT, two factors that control critical proliferation 
and survival pathways. STAT5 and RAC pathways also have a significant role in the CML 
phenotype.
cells (Druker et al., 1996). Imatinib  is now widely used to treat CML and next 
generation derivatives, Dasatinib and Nilotinib, are also in use in the clinic. However, 
these drugs are not cures, mutations of the ABL kinase pocket can lead to Imatinib 
resistance (Volpe et al., 2009), and Imatinib does not eradicate leukaemic stem cells 
(Chen et al., 2010).
1.6.3 K562 Cells.
The K562 cell line is derived from a patient with CML in blast crisis (Lozzio and 
Lozzio, 1975). K562 cells are positive for the philadelphia chromosome and encode 
the p210 BCR-ABL protein. The majority of cells are undifferentiated blasts, but a 
very  small proportion will spontaneously differentiate down the myeloid linages to 
erythrocytes, megakaryocytes, granulocytes and monocytes. They can also be 
induced to differentiate down the erythroid and megakaryocytic lineages (Osti et al., 
1997; Huang et al., 2004; Bütler et al., 1990). K562 cells are a useful cell line to study 
PRH activity because they express easily detectable levels of endogenous PRH 
protein and mRNA as well as high Vegf and Vegfr1 expression. Therefore, K562 cells 
are ideal for manipulation of PRH expression levels. 
1.7 Aims.
PRH is a known transcriptional repressor, however, few PRH target genes have been 
characterized in adult haematopoietic cells. The Vegf, Vegfr1 and Vegfr2 genes are 
potentially regulated by PRH, although whether this regulation occurs in 
haematopoietic cells and whether they are directly regulated by PRH is unknown. In 
this thesis the transcriptional regulation of the Vegf, Vegfr1 and Vegfr2 genes will be 
investigated. The specific protein-protein interactions and the functional 
characteristics of PRH that are required for transcriptional regulation will also be 
evaluated. PRH has diverse roles in the regulation of cell differentiation, cell survival 
and cell growth that are determined by  its cellular environment. The second aim of 
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this thesis is to investigate the effect of PRH on cell growth and cell survival. 
Manipulation of endogenous PRH levels and introduction of exogenous PRH will be 
used to define the role of PRH in haematopoietic cells. PRH was recently shown to 
be phosphorylated by CK2 in vitro. The final aim of this thesis is to determine whether 
this post-translational modification occurs in vivo and what the functional significance 
of this modification is for PRH induced transcriptional repression and cell survival.
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Materials and Methods
2 Materials and Methods
2.1 Materials.
2.1.1 Chemicals.
Table 1 - Chemicals and Reagents.
Chemical Information
Acrylamide Geneflow A2-0074
30% Acrylamide (37.5:1)
Agarose Sigma A9539
Ammonium Persulphate Sigma A3678
Ampicillin Sigma A9518
Antibodies Anti-Mouse IgG HRP(Santa Cruz 
sc-2005)
Anti-Rabbit IgG HRP (Santa Cruz 
sc-2313)
Anti-Goat IgG HRP (Santa Cruz 
sc-2020)
Anti-Lamin A/C (H-110) (Santa Cruz 
sc-20681) Rabbit Polyclonal
Anti-VEGF (VG76e) Mouse 
Monoclonal
Anti-Phospho PRH (YKN5) Rabbit 
Polyclonal
Anti-PRH Mouse Polyclonal
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2
Chemical Information
Antibodies Anti-Myc tag (9E10) (New England 
Biolabs - Cell Signalling Technology 
#2276) Mouse Monoclonal 
Anti-PanTLE (C-19) (Santa Cruz 
sc-13373) Goat Polyclonal 
Anti-HA (12CA5) (Roche 
11583816001) Mouse Monoclonal
Anti-FLAG (Sigma F7425) Rabbit 
affinity-purified
Bacteriological Agar Sigma A5306
Bactotryptone Sigma
Bovine Serum Albumin (BSA) First Link (UK) Ltd. Cat. 40-00-450
Bradford Reagent Bio-Rad 500-001
Bromophenol Blue Sigma B8026
Calcium Chloride Sigma C1016
Complete EDTA-free (protease 
inhibitor cocktail tablets)
Roche 11 873 580 001
Dimethyl Sulfoxide (DMSO) Sigma D8418
Dithiothreitol (DTT) Park Scientific Ltd
DNA gel loading buffer 6X
DNA markers Fermentas
GeneRulerTM 1Kb DNA Ladder 
(SM0311)
GeneRulerTM 100bp DNA Ladder 
(SM0241)
Dynabeads® Protein A Invitrogen 100-01D
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Chemical Information
Ethanol Fisher Scientific
Ethidium Bromide Fluka 46066
Ethylene glycol-bis(2-
aminoethylether)-N,N,N′,N′-
tetraacetic acid (EGTA)
Sigma E3889
Ethylenediaminetetraacetic acid 
(EDTA)
Sigma E5134
Fetal Bovine Serum (FBS) Sigma F7524
Formaldehyde (36.5%) Sigma F8775
Glycerol Fisher Scientific
Glycine Sigma 241261
Glycogen Calbiochem
HEPES Sigma H3375
Igepal CA-630 (NP-40) Sigma I8896
Magnesium Chloride Sigma M8266
Methanol Fisher Scientific
MG132 (Proteasome inhibitor) Calbiochem 474790
N,N,Nʼ,Nʼ-
Tetramethylethylenediamine 
(TEMED)
Sigma T9281
Penicillin/Streptomycin Sigma P4333
Phenol Sigma P4557
Phenylmethylsulphonyl Fluoride 
(PMSF)
Sigma P7626
Polyoxyethylene Sorbitan 
Monolaurate (Tween 20)
Sigma P1379
Ponceau S solution Sigma P7170
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Chemical Information
Potassium Chloride Sigma P9541
Potassium phosphate (KH2PO4) Sigma P9791
Protein Marker Fermentas
PageRulerTM Plus Prestained Protein 
Ladder (SM1811)
Random Hexamer Primers Fermentas SO142
RPMI 1640 medium Sigma R8758
Sodium Azide Sigma S8032
Sodium chloride Sigma S9888
Sodium deoxycholate Sigma D6750
Sodium dodecyl sulfate Sigma L4509
Sodium fluoride Sigma S7920
Sodium orthovanadate (Na3VO4) Sigma S6508
Sodium pyrophosphate Sigma P8010
Sodium β-glycero phosphate 
Tetracycline Sigma T3258
Thiazolyl blue formazan [1-(4,5-
Dimethylthiazol-2-yl)-3,5-
diphenylformazan] (MTT)
Sigma M2003
Triton X-100 Sigma T8787
Trizma Base Sigma T4661
Yeast Extract Sigma Y1625
β-mercaptoethanol Sigma M6250
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2.1.2 Media.
Table 2 - Media.
Media Information
Luria-Bertani Medium (LB) 1% w/v Bactotryptone
0.5% w/v Yeast Extract
1% w/v NaCl
Luria-Bertani Agar (LB agar) 1% w/v Bactotryptone
0.5% w/v Yeast Extract
1% w/v NaCl
1.5% w/v Bacto Agar
2.1.3 Solutions.
2.1.3.1 Commonly Used Solutions.
Table 3 - Commonly Used Solutions.
Solution Information
1X TAE buffer 40mM Tris-Acetate
1mM EDTA
TE buffer" 10mM Tris-Cl (pH 8.0)
1mM EDTA (pH 8.0)
1X PBS 137mM NaCl
2.7mM KCl
10mM Na2HPO4
2mM KH2PO4
Adjusted to pH 7.4
                                                                                                 Chapter 2. MATERIALS AND METHODS
69
2.1.3.2 Solutions Used in Cell Culture Protocols.
Table 4 - Chromatin Immunoprecipitation (ChIP) Solutions.
Solution Information
ChIP Lysis Buffer 50mM Tris-Cl (pH 8.0)
10mM EDTA
1% SDS
1mM PMSF
Protease Inhibitor Cocktail
ChIP RIPA Buffer 10mM Tris-Cl (pH 8.0)
140mM NaCl
1% v/v Triton X-100
1mM EDTA
0.5mM EGTA
0.1% w/v SDS
0.1% Sodium deoxycholate
Elution Buffer 20mM Tris-Cl (pH 7.5)
50mM NaCl
5mM EDTA
Elution Buffer + 1% SDS 20mM Tris-Cl (pH 7.5)
50mM NaCl
5mM EDTA
1% SDS
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2.1.3.3 Solutions Used in Western Blot Protocols.
Table 5 - Whole Cell Protein Extraction Solutions.
Solution Information
RIPA buffer 50mM Tris-Cl (pH 7.5)
150mM NaCl
1% v/v NP-40
0.5% w/v Sodium Deoxycholate
0.1% w/v SDS
5mM EDTA
Protease Inhibitor Cocktail
1X SDS Loading Buffer 50mM Tris-Cl (pH 6.8)
100mM DTT 
2% SDS
0.1% Bromophenol Blue
10% Glycerol
Table 6 - Post-Nuclear and Nuclear Fractionation of Protein Extracts Solutions.
Solution Information
Buffer A 20mM Tris-Cl (pH7.5)
5mM MgCl2 
1mM DTT
Protease Inhibitor Cocktail
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Solution Information
Buffer B 50mM Tris-Cl (pH 7.5)
500mM NaCl
1% v/v NP-40
0.1% w/v SDS
Protease Inhibitor Cocktail
Table 7 - Immunoprecipitation Solutions.
Solution Information
15X Phosphatase Inhibitor Cocktail 50mM NaF
1mM Na3VO4
10mM Na β-glycero phosphate
1mM EDTA
5mM Na pyrophosphate
Lysis Buffer 50mM Tris-Cl (pH 8.0)
100mM NaCl
20mM NaF
10mM KH2PO4
1% v/v Triton X-100
100µM DTT
10% Glycerol
1X Phosphatase Inhibitors
Protease Inhibitor Cocktail
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Solution Information
Binding Buffer 50mM Tris-Cl (pH 8.0)
100mM KCl
100µM EDTA
0.2% NP-40
1mg/ml BSA
2mM DTT
2.5% Glycerol
1X Phosphatase Inhibitors
Protease Inhibitor Cocktail
Wash Buffer 100mM Tris-Cl (pH 8.0)
200mM NaCl
0.5% NP-40
2mM DTT
Protease Inhibitor Cocktail
Table 8 - SDS Polyacrylamide Gel Solutions.
Solution Information
1X Stacking Buffer 125mM Tris-Cl (pH 6.8)
0.1% w/v SDS
1X Resolving Buffer 375mM Tris-Cl (pH 8.8)
0.1% w/v SDS
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Solution Information
SDS polyacrylamide resolving gel 1X Resolving Buffer (See above)
Acrylamide (% as required for 
molecular weight of proteins being 
resolved)
0.1% Ammonium Persulfate
TEMED
SDS polyacrylamide stacking gel 1X Stacking Buffer (See above)
4.5% Acrylamide 
0.1% Ammonium Persulfate
TEMED
Table 9 - SDS Polyacrylamide Gel Electrophoresis Solutions.
Solution Information
1X Running Buffer 2.5mM Tris-Cl
19.2mM Glycine
0.01% w/v SDS
Table 10 - Transfer of Proteins from SDS-PAG to Immobilon-P Membrane Solutions.
Solution Information
1X Transfer Buffer 10mM Tris-Cl
100mM Glycine
0.005% w/v SDS
20% Methanol
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Table 11 - Antibody Detection Solutions.
Solution Information
PBS-Tween 1X PBS
0.05% Tween 20
Primary blocking solution 1X PBS
3% w/v Bovine Serum Albumin (BSA)
3mM Sodium Azide
2.1.3.4 Solutions Used in Flow Cytometric Protocols.
Table 12 - Apoptosis Assay Solutions.
Solution Information
1X Annexin V Binding Buffer 10mM Hepes/NaOH (pH 7.4)
140mM NaCl
2.5mM CaCl2
2.2 DNA Protocols.
2.2.1 DNA Electrophoresis.
1% agarose gel was made by mixing 1g of agarose with 100 ml of 1X TAE (see 
2.1.3.1). This mixture was heated for 3 minutes in a microwave until the agarose had 
dissolved. To the gel tray 5µl of ethidium bromide (10mg/ml) was added upon which 
the gel solution was poured to allow thorough mixing. Combs were placed in the gel 
to produce the wells. After the gel had set the gel tray was placed into the 
electrophoresis tank (Fisher) and the gel was submerged in 1X TAE. DNA samples in 
loading buffer (diluted with sample to 1X loading buffer) were loaded alongside a 
marker, GeneRuler 100bp DNA Ladder (Fermentas SM0243) or GeneRuler 1kb DNA 
Ladder (Fermentas SM0313). The gel was run at 80-100V (constant voltage) for 
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45-60 minutes or until there was sufficient separation of the DNA fragments as 
determined using a UV trans-illuminator.
2.2.2 DNA Extraction
DNA extraction was performed using a Wizard SV gel purification kit (Promega Cat. 
A9281) according to the manufacturerʼs instructions. 
2.2.3 Polymerase Chain Reaction (PCR)
10ng of plasmid DNA or 100ng of cDNA template was used with 2mM MgCl2, 0.4mM 
dNTPs, 1X RedTaq Polymerase buffer (Sigma D4308), 10 units RedTaq Polymerase 
(Sigma D4308), and 10µM forward and reverse primers in a polymerase chain 
reaction in a final volume of 50µl.
Reactions were performed according to the manufacturerʼs instructions with a hot 
start for 5 minutes at 95ºC, followed by 30-35 cycles of 1 minute at 95ºC, 1 minute at 
55-62ºC (primer dependent), and 1 minute at 72ºC. Samples were separated by 
agarose gel electrophoresis (see 2.2.1) in 1X DNA loading buffer and visualized 
under UV light.
2.2.4 Phenol: Chloroform: Isoamylalcohol (PCI) Extraction and DNA 
Precipitation.
DNA was made up  to a volume of 400µl using autoclaved distilled H2O (dH2O). An 
equal volume of PCI (25:24:1) mixture, taken from the lower layer, was added to the 
DNA solution and vortexed for 1 minute. This was then centrifuged for 5 minutes at 
13,000rpm (Eppendorf 5424). 350µl of the upper (aqueous) phase was carefully 
removed and transferred to a separate eppendorf. A further 50µl of dH2O was added 
to the lower (organic) phase. This was vortexed and centrifuged as described 
previously, and 50µl of the upper phase was added to the first extraction.
10% v/v 3M sodium acetate (pH 5.2) was added to the extracted DNA with 21/2 
volumes of 100% ethanol and 2µl glycogen (10mg/ml) as a DNA carrier. The sample 
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was vortexed, incubated at -20ºC  for 1hour and then centrifuged at 13,000 rpm 
(Eppendorf 5424) for 10 minutes at 4ºC. The supernatant was removed and the pellet 
washed twice with 1ml ice cold 70% ethanol. The DNA pellet was then air-dried for 10 
minutes and resuspended in the required volume of TE buffer.
2.2.5 Restriction Digestion
5µg of plasmid DNA was digested in a final volume of 20µl, in a reaction containing 
1X buffer (enzyme specific) with 10units of enzyme for 1-2 hours at 37ºC  (dependent 
on enzyme efficiency in used buffer). Reactions were separated on an agarose gel 
electrophoresis (see 2.2.1) in 1X DNA loading buffer. The gel was exposed to UV 
light to confirm digestion. 
2.2.6 Phosphatase Reaction
Linearized vector DNA reactions were made up to a final volume of 40µl in 1X Calf 
Intestinal Alkaline Phosphatase (CIAP) buffer with 10 units of CAP enzyme (New 
England Biolabs M0290S) and incubated at 37ºC for 1 hour. Reactions were run 
using agarose gel electrophoresis (see 2.2.1) in 1X DNA loading buffer. The DNA 
fragment was identified under UV light, excised from the gel and transferred to a pre-
weighed eppendorf for DNA extraction (see 2.2.2).
2.2.7 Ligation
Purified DNA insert was used 10 times more than the purified DNA vector in 1X T4 
DNA ligase buffer with 10 units of T4 DNA ligase (Fermentas EL0014) in a final 
volume of 20µl. For sticky end ligations the reaction was incubated at room 
temperature overnight. For blunt end ligations the reaction was incubated on ice left 
at room temperature overnight.
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2.3 Bacterial Protocols
2.3.1 Preparation of competent Escherichia coli (E. coli) XL-1 blue cells.
E. coli XL-1 blue cells were innoculated into 5ml LB broth and incubated at 37ºC 
overnight whilst shaking at 200rpm. 0.5ml overnight culture was innoculated into 
50ml LB broth and incubated at 37ºC until the culture reached an optical density of 
0.5 at 650nm. The culture was incubated on ice for 10 minutes and centrifuged at 
4000rpm (Eppendorf 5810R) for 5 minutes at 4ºC. The pellet was resuspended in 
25ml 0.1M CaCl2 and incubated on ice for 20 minutes. This was centrifuged at 
4000rpm (Eppendorf 5810R) for 5 minutes at 4ºC  and the pellet resuspended in 2ml 
0.1M CaCl2 for 2 hours. 1.4ml 100% Glycerol was added to the cell suspension and 
then 100µl aliquots were either used for transformation (see 2.3.2) or stored at -80ºC.
2.3.2 Transformation of XL-1 blue cells
For plasmid transformation of competent XL-1 blue cells, 50ng of plasmid DNA was 
mixed with 80µl competent XL-1 blue cells (see 2.3.1) and incubated on ice for 20 
minutes. The cells were heat shocked at 42.5ºC for 2 minutes and returned to ice for 
2 minutes. To the cells, 1 ml of LB broth was added before incubating at 37ºC  for 45 
minutes. The cultures were centrifuged at 13,000rpm (Eppendorf 5424) for 15 
seconds, 1ml of the LB broth supernatant was discarded. The cell pellet was 
resuspended in the remaining 80µl and then spread on an agar plate containing the 
appropriate antibiotic (ampicillin = 100mM, kanamycin = 50mM). Plates were 
incubated at 37ºC overnight.
2.3.3 Purification of Plasmid DNA
Plasmid DNA was prepared and purified using Qiagen mini (Qiagen 27104) or maxi 
(Qiagen 12163) prep kits according to the manufacturers instructions.
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2.4 Cell Culture Protocols.
2.4.1 Cell culture
K562 cells were maintained in RPMI 1640 media (Sigma R8758) supplemented with 
10% Fetal Bovine Serum (FBS)(Sigma F7524)(heated to 56ºC for 30 minutes to 
inactivate complement proteins), 100 units/ml Penicillin and 100µg/ml Streptomycin 
(Sigma P4333)(this will be referred to as RPMI media from this point, unless stated). 
Cells were grown at 37ºC in an atmosphere of 5% CO2, 20% O2 and 75% N2. Cells 
were split once every two days or when the culture reached a density of 1 x106 cells/
ml by centrifugation for 5 minutes at 1100 rpm (Eppendorf 5810R), washed in PBS 
and resuspended in the appropriate volume of fresh medium.
2.4.2 Transient Transfection
1x107 K562 cells were centrifuged at 1100 rpm (Eppendorf 5810R) for 5 minutes and 
washed in PBS. The cell pellet was resuspended in 200µl of RPMI media. 10µg 
expression plasmid (or as stated in the text) was added to a Genepulser 0.4 cm 
electroporation cuvette (Bio-Rad 165-2088). The cells were transferred into the 
0.4cm electroporation cuvette onto the expression plasmid to mix. The cells were 
then electroporated using a Bio-Rad Genepulser at 250V, 975µF. Electroporated cells 
were transferred to 4ml of pre-warmed RPMI media in a 6 well plate and incubated 
for 24-48 hours at 37ºC in an atmosphere of 5% CO2, 20% O2 and 75% N2. 
2.4.3 ShRNA Transfection.
5x106 K562 cells were centrifuged at 1100 rpm (Eppendorf 5810R) for 5 minutes and 
washed in PBS. The cell pellet was resuspended in 100µl of solution V (Amaxa 
VCA-1003). 10µg of pRS EGFP (shRNA control) or 5µg pRS PRH49 and pRS 
PRH51 plasmids (or as stated in the text) were added to an Amaxa 0.4 cm 
nucleofector cuvette. The cells were transferred into the 0.4cm nucleofector cuvette 
onto the shRNA plasmid to mix. The cells were then transfected using an Amaxa 
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Nucleofector on program T-016. The cells were transferred to 4ml of pre-warmed 
media in a 6 well plate and incubated overnight at 37ºC. 24 hours post-transfection 
the cells were treated and kept in 5ml RPMI media containing 1µg/ml Puromycin 
(Sigma P8833). Cells were maintained at 37ºC in an atmosphere of 5% CO2, 20% O2 
and 75% N2.
2.4.4 Growth Analysis.
K562 cells were maintained after shRNA transfection under selection until at least a 
cell density  of 3x105 cells/ml in 10ml of RPMI media was attained. At this point all cell 
populations were split to a cell density of 3x105 cells/ml in 10ml of RPMI media. The 
cells were counted daily  using trypan blue exclusion. For this 10µl trypan blue (Fluka 
93595) was mixed with 10µl of cells and then the number of clear cells were counted 
on a haemocytometer (blue cells were not counted). The cell populations were set 
back to 3x105 daily or as required. All dilutions of the cells were recorded and the 
cumulative growth calculated using the equation (conc x vol x dilution factor = total 
number of cells).
An example of this calculation:
Day 1 - 3x105 cells/ml in 10ml (total cells = 3x105 x 10 x 1 = 3x106)
Day 2 - 6x105 cells/ml in 10ml (total cells = 6x105 x 10 x 1 = 6x106) Then split 1 in 2.
Day 3 - 6x105 cells/ml in 10ml (total cells = 6x105 x 10 x (1x2) = 1.2x107) Then split 1 
in 2.
Day 4 - 6x105 cells/ml in 10ml (total cells = 6x105 x 10 x (1x2x2) = 2.4x107) 
2.4.5 MTT assay
Cells were seeded in a 96-well plate at a density  of ~1x104 cells/well in 180µl RPMI 
media. Cells were incubated with VEGF165 (50ng/ml), SU1498 (1µM or 2µM) 
(Boguslawski et al., 2003), anti-VEGF (VG76e) antibody (50µg/ml)(Fraser et al., 
2000) or the equivalent volume of DMSO (Sigma D8418) in each case. Cells were 
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incubated for 72 hours and then 20µl MTT (5mg/ml, Sigma M2003) was added to 
each well and incubated for 3 hours. Cell plates were centrifuged at 4000rpm 
(Eppendorf 5810R) for 5 minutes and the MTT crystals were dissolved by pipetting in 
200µl DMSO. After incubation at 37ºC  for 5 minutes the optical density  (OD) was 
read at 540nm and 650nm (background) using a Versamax (Molecular Devices) plate 
reader. The background OD was subtracted from the reading at 540nm. To calculate 
cell numbers, serial dilutions were made from a known number of cells, and a 
standard curve was produced for calculating cell numbers.
2.4.6 Chromatin Immunoprecipitation (ChIP).
Five transfections of 1x107 K562 cells were transfected with 5µg pMUG1 Myc-PRH 
(or as described in the text)(see 2.4.2) per chromatin preparation. After 24 hours 
incubation at 37ºC, the transfected cells were transferred to a single T25 cell culture 
flask. 48 hours post-transfection cells were washed twice in ice cold PBS and 
resuspended in 500µl PBS. Formaldehyde was added to a final concentration of 1% 
and incubated at room temperature on a rotary  wheel for 8 minutes. Glycine was 
added to a concentration of 0.125M to stop cross-linking reaction and centrifuged at 
13,000rpm (Thermo Scientific Heraeus Fresco 21) for 10 minutes at 4ºC. Cells were 
washed twice in PBS. Cells were resuspended in lysis buffer (see 2.1.3.5) and split 
into fractions of 2.5x106 cells per 130µl volume in an eppendorf. Lysates were 
sonicated in a Biorupter (Diagenode) for 10 minutes on medium power at 4ºC. 
Lysates were cleared by centrifugation at 13,000rpm (Thermo Scientific Heraeus 
Fresco 21) for 10 minutes at 4ºC. To check the efficiency of the sonication, 20µl of 
the chromatin lysate was diluted 1 in 25 in lysis buffer and incubated with 120µg 
Proteinase K at 68ºC for 2 hours. A phenol chloroform isoamyl alcohol (PCI) 
extraction (see 2.2.4) was performed in the presence of 50µg glycogen. 2µg of DNA 
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was separated on a 1.5% agarose gel (see 2.2.1) to check DNA fragmentation was in 
the range of 200-600bp in length. 
Dynabeads® Protein A magnetic beads (Invitrogen 100-01D) were collected by 
applying a magnet and then washed in 500µl ChIP RIPA buffer (see 2.1.3.5). The 
beads were resuspended in 100µl ChIP RIPA buffer per immunoprecipitation. 3µl of 
either anti-Myc antibody (or as stated in the text) or IgGs were added to 100µl of the 
protein A beads and incubated at 4ºC  for 2 hours on a rotary wheel. The chromatin 
lysates prepared above were diluted to 250µg/ml in lysis buffer and 100µl (25µg) of 
chromatin lysate was added to the antibody:bead complex and incubated at 4ºC 
overnight on a rotary wheel. The beads were collected by applying a magnet. Eight 
washes were performed at  room temperature, the first two washes were carried out 
in ChIP RIPA buffer, followed by two washes in ChIP RIPA buffer containing 500mM 
NaCl (see 2.1.3.5), two washes in ChIP RIPA buffer with 0.5% NP40 (see 2.1.3.5), 
and finally  two washes in TE buffer. After the final wash beads were resuspended in 
150µl of elution buffer with 1% SDS (see 2.1.3.5). The beads suspension and 40µg 
Proteinase K was incubated at 68ºC for 2 hours. Beads were collected by applying a 
magnet. The supernatant was retained in a separate eppendorf (bound fraction). 
Beads were resuspended in a further 150µl elution buffer with 1% SDS. Beads were 
collected as before and the supernatant was added to the bound fraction.200µl 
elution buffer (see 2.1.3.5) was added to the bound fraction and a PCI extraction  and 
DNA precipitation (see 2.2.4) was performed using 50µg glycogen. Pellets were 
resuspended in 50µl TE buffer and the concentration of DNA was measured. DNA 
obtained was analysed by qPCR (see 2.6.3).
2.5 Western Blot Protocols.
2.5.1 Whole Cell Protein Extraction.
Whole cell extracts were made from 1x107 K562 cells. The cell pellet was centrifuged 
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at 1100rpm (Eppendorf 5810R) for 5 minutes and then washed in PBS. The pellet 
was resuspended in 150µl RIPA buffer (see 2.1.3.3) and the cell suspension drawn 
up  and down several times through a 3 X Monojet needle (1.1x50mm, 19Gx2”). the 
cell suspension was then incubated on ice for 30 minutes, and then centrifuged at 
13000rpm (Thermo Scientific Heraeus Fresco 21) for 15 min at 4°C. The extracts 
were incubated at 100ºC for 2 minutes in 1X SDS-loading buffer (see 2.1.3.3) and 
separated by electrophoresis (see 2.5.5) or stored at -20ºC. 
2.5.2 Post-nuclear and Nuclear Fractionation of Protein Extracts.
Nuclear and post-nuclear extracts were made as follows: 2x107 K562 cells were 
centrifuged at 1100rpm (Eppendorf 5810R) and the pellet was resuspended in 150µl 
Buffer A  (see 2.1.3.3) at 4°C for 10 minutes. 15µl NP40 (10%v/v) was added to the 
lysate and mixed by vortexing. The lysate was centrifuged at 13,000rpm (Thermo 
Scientific Heraeus Fresco 21) at 4ºC for 1 minute and the supernatant removed and 
stored at -80°C  in 1X SDS-loading buffer (see 2.1.3.3) as the soluble post-nuclear 
fraction. The nuclei in the pellet were resuspended in 150µl Buffer B (see 2.1.3.3) for 
20 minutes at 4°C and then centrifuged at 13,000rpm (Thermo Scientific Heraeus 
Fresco 21) for 1 minute at 4ºC. The supernatant was removed and stored at -80°C in 
1X SDS-loading buffer as the soluble nuclear extract.
2.5.3 Immuno-precipitation (IP).
Whole cell extracts from 2x107 K562 cells were resuspended in 200µl lysis buffer 
(see 2.1.3.4), incubated at 4ºC  for 30 minutes and centrifuged at 13,000rpm (Thermo 
Scientific Heraeus Fresco 21) for 10 minutes at 4ºC. The supernatant was transferred 
to a new eppendorf and binding buffer (see 2.1.3.4) was added at a 1:1 ratio.The 
supernatant was incubated with the primary antibody at 4ºC for 2 hours on a rotary 
wheel. Protein G sepharose beads (30µl per IP)(Sigma P3296) were equilibrated with 
binding buffer and added to the IP. This was incubated for 4 hours at 4ºC on a rotary 
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wheel. The immuno complexes were centrifuged at 13,000rpm (Eppendorf 5424) for 
30 seconds. The pellet was washed in 300µl wash buffer (see 2.1.3.4) three times. 
The precipitate was then resuspended in 30µl of 4X SDS-Loading buffer (see 2.1.3.3) 
and heated to 95ºC for 2 minutes.
2.5.4 Preparation of SDS polyacrylamide gel.
The front and back plates were assembled into the casting brace according to the 
manufacturerʼs instructions (Bio-Rad) and an SDS polyacrylamide resolving gel was 
prepared (see 2.1.3.3) and poured between the gel plates. After the resolving layer 
had set, an SDS polyacrylamide stacking gel was prepared (see 2.1.3.3) and poured 
onto the resolving layer. The well comb was placed into the stacking layer.
2.5.5 Separation of proteins by molecular weight.
The SDS polyacrylamide gel was placed into the separation tank as described in the 
manufacturerʼs instructions (Bio-Rad Mini-PROTEAN Tetra Electrophoresis System). 
Protein samples (as prepared in 2.5.1 and 2.5.2) were loaded onto the gel along with 
PageRuler Plus Prestained Protein Ladder (Fermentas SM1811). The SDS-
polyacrylamide gel was then run at 140V (constant voltage) for 80 minutes or until the 
bromophenol blue dye front had reached the bottom of the gel.
2.5.6 Transfer of proteins from SDS-polyacrylamide gel to Immobilon-P 
membrane.
Immobilon-P membrane (Millipore IPVH00010) was soaked in methanol for 35 
seconds to hydrate, then washed in distilled H2O for 1-2 minutes and equilibrated in 
1X Transfer Buffer for at least 5 minutes. The gel transfer apparatus (Bio-Rad Mini 
Trans-Blot Cell System) and 3MM Whatman filter paper (Whatman 3030917)was 
also soaked in 1X Transfer Buffer. After protein separation the gel was removed from 
the gel plates and the stacking gel was removed. One piece of 3MM Whatman filter 
paper was placed onto the cathode side of the transfer casing. Onto this the gel was 
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placed, followed by Immobilon-P membrane, and then followed by another piece of 
3MM Whatman filter paper. A plastic tube was carefully rolled over the stack of layer 
to remove air bubbles. The transfer casing was locked and assembled into the 
transfer apparatus, and then filled with 1X Transfer Buffer. The apparatus was run at 
270mA for 2 hours and 30 minutes.
2.5.7 Antibody detection of proteins.
After transfer the membrane was transfered into 1X PBS-T and rinsed twice, 
successful protein transfer was detected by staining the membrane with 40ml 
Ponceau S stain for 1-2 minutes. The membrane was washed in 1X PBS-T to 
remove Ponceau S stain and then incubated in a 1X PBS-T solution containing 10% 
(w/v) milk on a rotating platform at room temperature for 18 hours. 
The membrane was washed 5 times for 5 minutes in 1X PBS-T, before a 1 hour 
incubation in primary blocking solution (see 2.1.3.3) with the required primary 
antibody (see table 8). A further five 5 minute washes in 1X PBS-T were performed, 
prior to a 1 hour incubation in 1X PBS-T solution containing 10% (w/v) milk and the 
required secondary antibody. This was followed with a further five washes as 
described above.
ECL Western Blotting detection solutions 1 and 2 (GE Healthcare RPN2106) were 
mixed 1:1 and placed on Saran wrap. Excess PBS-T was removed from the 
membrane before soaking in the mixed ECL detection solution for 1 minute. Excess 
detection solution was removed from the membrane, prior to wrapping in Saran wrap 
and exposing to ECL hyperfilm (GE Healthcare 28-9068-37) for different exposure 
times. These were then developed to reveal the chemiluminescent signal.
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Table 13 - Antibodies.
Antibody Species Working 
Dilution
Information
Anti-Lamin A/C 
(H-110)
Rabbit 
Polyclonal
1 in 10000 Santa Cruz 
sc-20681
Anti-Tubulin Mouse 
Monoclonal
1 in 10000 NeoMarkers
MS-581-P1
Anti-VEGF 
(VG76e)
Mouse 
Monoclonal
1 in 500 Prof. R. Bicknell 
(University of 
Birmingham)
Anti-PhosphoPRH 
(YKN5)
Rabbit 
Polyclonal
1 in 2500 Dr. P-S. Jayaraman 
(University of 
Birmingham)
Anti-PRH Mouse 
Polyclonal
1 in 2000 Dr. P-S. Jayaraman 
(University of 
Birmingham)
Anti-PanTLE 
(C-19) 
Goat 
Polyclonal
1 in 2000 Santa Cruz 
sc-13373
Anti-HA (12CA5) Mouse 
Monoclonal
1 in 5000 Roche
1 583 816 001
2.5.8 Densitometric Analysis.
Densitometric analysis was performed using the open source ImageJ software 
according to the programs documentation. Briefly, Western blot film was scanned and 
opened using ImageJ. Rectangle boxes were drawn to identify the lanes of the gel 
and a lane plot analysis was performed. The area under the plots were calculated 
and quantified. Proteins of interest were compared to loading controls. Untreated or 
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control samples were set to 100%. For half-life calculations the percentages were 
calculated and averaged for three independent experiments. These averages were 
plotted, the equation for the line of best fit was then used to calculate the half-life of 
the protein.  
2.6 Real Time Quantitative PCR (qPCR) Protocols.
2.6.1 mRNA Extraction.
Total RNA was extracted from 2x106 K562 cells. Cells were centrifuged at 1100rpm 
(Eppendorf 5810R) and the cell pellet was used with the RNeasy  mini kit (Qiagen 
74104), according to the manufacturerʼs instructions. The DNase1 digestion step was 
performed using the DNase set (Qiagen 79254). 
2.6.2 cDNA Production.
0.5-1µg RNA was reverse-transcribed to single strand cDNA using random primers 
(Fermentas SO142), 200U of Superscript III reverse transcriptase (Invitrogen 
18080044) and 200U of Ribolock RNase Inhibitor (Fermentas EO0381) in a final 
volume of 20µl. The reactions were incubated at 25ºC for 10 minutes, 42ºC  for 90 
minutes followed by a 72ºC step for 30 minutes.
2.6.3 qPCR.
Real time PCR reactions were performed using the Rotor-gene detection system 
(rotor-gene 6) on an RG-3000 machine. Oligonucleotide primers for Gapdh, Prh, 
Vegf, Vegfr1 and Vegfr2 (see table 9) were used. A 15µl reaction mixture, containing 
0.2µM primers, 1X SensiMix SYBR Green (Quantace QT650-05) and 100-400ng of 
cDNA, was amplified using the following thermal cycler parameters: denaturation at 
95ºC  for 10 minutes prior to 40-50 cycles of 95ºC for 15 seconds denaturation, 
55-62ºC for 20 seconds (annealing primer dependent) and 72ºC for 5 seconds 
extension. A  form of the ∆∆CT method was used to calculate the mRNA levels (Pfaffl, 
2001).
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Table 14 - Primers.
Gene Direction Sequence Annealing 
Temperature
Gapdh FWD 5ʼ-TGA TGA CAT CAA GAA 
GGT GGT GAA G-3ʼ
55ºC for 19 seconds
Gapdh REV 5ʼ-TCC TTG GAG GCC 
ATG TGG GCC AT-3ʼ
55ºC for 19 seconds
Prh FWD 5ʼ-CAC  CCG ACG CCC 
TTT TAC AT-3ʼ
60ºC for 20 seconds
Prh REV 5ʼ-GAA GGC TGG ATG 
GAT CGG C-3ʼ
60ºC for 20 seconds
Vegf FWD 5 ʼ-ATC AGC GCA GCT 
ACT GCC ATC C-3ʼ
62ºC for 20 seconds
Vegf REV 5ʼ-TCT CCT ATG TGC  TGG 
CCT TGG TG-3ʼ
62ºC for 20 seconds
Vegfr1 FWD 5ʼ-TGG CCA TCA CTA AGG 
AGC ACT CC-3ʼ
60ºC for 20 seconds
Vegfr1 REV 5ʼGGA ACT GCT GAT GGC 
CAC TGT G-3ʼ
60ºC for 20 seconds
Vegfr2 FWD 5ʼ-TTA GTG ACC AAC  ATG 
GAG TCG TG-3ʼ
60ºC for 20 seconds
Vegfr2 REV 5ʼ-TAG TAA AGC CCT TCT 
TGC TGT CC-3ʼ
60ºC for 20 seconds
2.7 Flow Cytometric Protocols.
2.7.1 Cell Cycle Profile.
For cell cycle analysis 1x105 K562 cells were washed twice in PBS and resuspended 
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in RPMI media. Ipegal (1% final) and propidium iodide (P.I.; 50µg/ml final) were 
added immedately before running. Data was collected using a FACScalibur 
apparatus (Becton Dickinson) and results were analysed with Becton Dickinson Cell 
Quest software. For each sample at least 10,000 events were collected.
2.7.2 Apoptosis Assay.
For Annexin V analysis ~1x105 K562 cells were washed twice in PBS and 
resuspended in 1x Binding buffer (10mM Hepes/NaOH (pH 7.4), 0.14M NaCl, 2.5mM 
CaCl2). 5µl Annexin V APC (Becton Dickinson, 550474) and propidium iodide (P.I. ; 
5µg/ml final) was incubated for 30 minutes at room temperature. Data was collected 
as above. For EGFP transfected cells a EGFP positive (FL1) gate was applied. FL3 
was used for propidium iodide and FL4 was used for Annexin V APC.
2.7.3 Carboxy-Fluorescein diacetate Succinimidyl Ester (CFSE) Assay.
1x105 K562 cells were incubated at 37ºC for 15 mins in 10µM CellTrace™ CFSE 
(Invitrogen C34554) in PBS. Cells were centrifuged and the dye removed. Cells were 
resuspended in RPMI medium, plated out and incubated for 30 minutes at 37ºC. 
Cells were washed, resuspended in RPMI medium and cultured for 5 days. Samples 
were taken on day 1 and 5. Data was collected and analyzed as above. 
2.8 Plasmids.
pMUG1 Myc-PRH.
This plasmid encodes a fusion protein consisting of amino acids 7-270 of human 
PRH fused to an N-terminal Myc 9E10 epitope. As previously described (Bess et al., 
2003; Swingler et al., 2004).
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pMUG1 Myc-PRH LL23,24AA.
This plasmid was created using a QuikChange® kit (Stratagene) according to the 
manufacturerʼs protocol. pMUG1 Myc-PRH was mutated to replace an alanine at 
residues 23 and 24 instead of a leucine. As previously  described (Desjobert et al., 
2009).
pMUG1 Myc-PRH F32E.
This plasmid was created using a QuikChange® kit (Stratagene) according to the 
manufacturerʼs protocol. pMUG1 Myc-PRH was mutagenised to replace a glutamic 
acid at residue 32 instead of a phenylalanine. As previously described (Swingler et 
al., 2004).
pMUG1 Myc-PRH N187A.
This plasmid was created using a QuikChange® kit (Stratagene) according to the 
manufacturerʼs protocol. pMUG1 Myc-PRH was mutated to replace an alanine at 
residue 187 instead of an asparagine. As previously described (Desjobert et al., 
2009).
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PRH cDNA 810...1604
pBR322 origin 3346...3965
Amp promoter 5050...5022
pMUG1 Myc-PRH
5180 bp
CMV promoter 115...690
Myc-tag 780...809
PRH 3' UTR 1605...2497
Beta-Lactamase resistance gene 4980...4130
Figure 2.1 - Schematic diagram of pMUG1 Myc-PRH.
The diagram illustrates the plasmid features including the beta-lactamase resistance gene 
(for ampicillin resistance), the CMV promoter and the Myc-tag and PRH coding region.
pMUG1 Myc-PRH RR188,189AA.
This plasmid was created using a QuikChange® kit (Stratagene) according to the 
manufacturerʼs protocol. pMUG1 Myc-PRH was mutated to replace alanine residues 
at 188 and 189 instead of arginine residues. As previously  described (Desjobert et 
al., 2009).
pMUG1 Myc-PRH SS163,177EE.
This plasmid was created using a QuikChange® kit (Stratagene) according to the 
manufacturerʼs protocol. pMUG1 Myc-PRH was mutagenised to replace glutamic 
acid residues at 163 and 177 instead of serine residues. As previously described 
(Soufi et al., 2009).
pMUG1 Myc-PRH SS163,177CC.
This plasmid was created using a QuikChange® kit (Stratagene) according to the 
manufacturerʼs protocol. pMUG1 Myc-PRH was mutated to replace cysteine residues 
at 163 and 177 instead of serine residues. Mutagenesis was performed by Hannah 
Williams (University of Bristol) and given as a gift.
pCMV2 Flag-TLE.
The pCMV2 Flag-TLE plasmid expresses Flag-tagged TLE1 and has been previously 
described (Swingler et al., 2004). 
pRc/CMV-CK2.
The plasmids pRc/CMV-CK2α-HA, pRc/CMV-HA-CK2β and pRc/CMV-CK2α-K68M-
HA (Soufi et al., 2009) express HA-tagged CK α and β subunits and a kinase-dead 
CK2α mutant respectively and were a kind gift from Professor David Litchfield 
(University of Ontario).
pEGFP-C1.
The plasmid pEGFP expresses an enhanced green fluorescence protein. The 
plasmid is commercially available from Clontech.
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pEGFP-PRH.
The pEGFP-PRH plasmid was created by inserting the PRH cDNA from a 
pBlueScript clone into the EcoRI and KpnI sites of pEGFP-C1. As previously 
described (Desjobert et al., 2009).
pBJ Flt-1.
The pBJ Flt-1 plasmid is a mammalian expression plasmid that encodes for VEGFR1 
(Flt1) and is a kind gift from D. Bates.
pBJ KDR.
The pBJ KDR plasmid is a mammalian expression plasmid that encodes for VEGFR2 
(KDR) and is a kind gift from D. Bates.
pcDNA3 VEGF165.
The pcDNA3 VEGF165 plasmid is a mammalian expression plasmid that encodes for 
VEGF165 and is a kind gift from D. Bates.
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Figure 2.2 - Schematic diagram of pEGFP-PRH.
The diagram illustrates the plasmid features including the kanamycin/neomycin resistance 
gene, the CMV promoter and the EGFP gene fused to the PRH coding region.
Last AA in EGFP 1327...1329
Enhanced Green Fluorescent Protein Gene 613...1364
PRH cDNA 1375...2187Kanamycin/Neomycin Resistance Gene 3852...4646
pEGFP-PRH
5956 bp
CMV promoter 1...588
PRH 3' UTR 2188...2605
Enhanced Green Fluorescent Protein Gene 2606...2634
SV40 PolyA 2775...2825
f1 ori 2872...3327
SV40 promoter and origin of replication 3501...3803
HSV TK polyA 4882...4900
pUC plasmid replication origin 5231...5874
pRS (shRNA).
The pRS shRNA plasmid constructs were obtained from ORIGENE (Rockville, MD). 
The PRH 49 shRNA plasmid contains the sequence, 5ʼ- CGC GGA CGG TGA ACG 
ACT ACA CGC  ACG CC -3ʼ, to target the N-terminal region of the PRH mRNA with a 
7bp loop followed by the complement of the above sequence. For the PRH 51 
shRNA plasmid contains the sequence 5ʼ- CCA GGA AGA CCT TGA ATC AGA GAT 
TTC  AG -3ʼ to target the C-terminal region of the PRH mRNA. The EGFP shRNA 
plasmid contains the sequence 5ʼ- CAC AAG CTG GAG TAC AAC TAC AAC  AGC 
CA -3ʼ to target EGFP with no human homology (Origene).
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Figure 2.3 - Schematic diagram of pRS plasmid.
The diagram illustrates the plasmid features including the beta-lactamase resistance gene 
(for ampicillin resistance), the puromycin-N-acetyl transferase gene (for puromycin 
resistance) and the U6 promoter (NB/ the shRNA sequence follows the U6 promoter).
Puromycin-N-acetyl transferase 671...1270
3' LTR 1349...1942
pBR322 ORI 2299...2918
Beta-lactamase for ampicillin resistance 3080...3940
5' LTR 4076...4547
pRS
5430 bp
U6 promoter 75...331
SV40 promoter 413...603
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Transcriptional regulation of VSP gene expression by PRH and TLE
3 Transcriptional regulation of VSP gene 
expression by PRH and TLE.
3.1 Introduction
Gene regulation by PRH in haematopoietic progenitor cells is currently poorly 
understood. Although microarray data has revealed potential PRH target genes in 
murine embryonic stem (ES) cells (Guo et al., 2003), the mechanism through which 
PRH is regulating these genes is unknown. This chapter will investigate the 
regulation of genes in the VEGF signalling pathway (VSP), specifically the Vegf, 
Vegfr1 and Vegfr2 genes, by  PRH. Over-expressed wild-type PRH will be compared 
to mutants of PRH to characterize the properties of PRH that are required for 
transcriptional regulation of these genes. Selective knock-down of PRH using 
targeted shRNAs will also be used to validate the targets. Finally, the role of the TLE-
PRH interaction will be evaluated.
3.2 PRH regulation of the Vegf, Vegfr1 and Vegfr2 genes.
It has been shown previously that PRH over-expression down regulates Vegfr1 and 
Vegfr2 expression in HUVECs (Nakagawa et al., 2003). It is unknown whether this 
regulation occurs within haematopoietic progenitor cells, a context where PRH is 
normally highly expressed. It has also been shown that Vegf expression is up-
regulated in PRH -/- ES cells (Guo et al., 2003) and in -/- mice embryos (Hallaq et al., 
2004), but this regulation has not been investigated in any detail. To investigate the 
regulation of all three genes (Vegf, Vegfr1 and Vegfr2) by PRH, K562 haematopoietic 
cells were used. Transcriptional regulation by PRH has been investigated in this 
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K562 cells previously (Swingler et al., 2004). Moreover K562 cells are known to 
express both VEGF and Vegfr1 mRNA (Dias et al., 2000). K562 cells are therefore a 
useful cell line for investigating the regulation of the VSP genes by PRH. In this 
chapter I am going to use PRH over-expression and PRH knockdown to investigate 
the regulation of VSP gene expression by PRH in K562 cells.
3.2.1 PRH over-expression.
To determine the amount of over-expression achieved by  transient transfection and 
whether the amount of exogenous PRH expressed is near to physiological levels, an 
expression plasmid encoding the cDNA for PRH (pMUG1 Myc-PRH) was transiently 
transfected in increasing amounts into K562 cells by electroporation as previously 
described (Bess et al., 2003). The expression plasmid contains a fusion gene 
consisting of a Myc-tag (9E10 epitope) joined to the N-terminus of human PRH 
cDNA encoding amino acids 7-270. In mammalian cells this fusion protein can be 
expressed and it will repress transcription in a similar manner to the wild-type PRH 
(Swingler et al., 2004). Cells were harvested after 48 hours, whole cell protein 
extracts were then prepared and analyzed by Western blotting (see section 2.5 of the 
Materials and Methods). Proteins were separated by a sodium dodecyl sulfate-
polyacrylamide gel (SDS-PAG). After transfer to Immobilon P membrane, proteins 
were detected using specific antibodies. Western blot analysis was performed using 
a PRH antibody (mouse) which can detect both endogenous PRH (figure 3.1 - top 
panel, lower band) and exogenous Myc-PRH (figure 3.1 - top panel, upper band). A 
Lamin A/C antibody  was used as a protein loading control (figure 3.1 - bottom panel). 
Figure 3.1 shows that the exogenous PRH is clearly detectable when 5µg of pMUG1 
Myc-PRH is transfected into K562 cells (top  panel, lane 5). There is a modest 
increase in the level of exogenous PRH present when 10µg pMUG1 Myc-PRH 
plasmid is used and the over-expressed Myc-tagged PRH appears to be expressed 
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at roughly equivalent levels to endogenous PRH (figure 3.1 - top  panel, lane 6). 
Since 10µg of PRH results in expression levels that are within the physiological 
range, subsequently we used 10µg pMUG1 Myc-PRH plasmid for all over-expression 
experiments.
To examine the regulation of Vegf and Vegfr1 expression by over-expressed PRH, 
K562 cells were transfected with pMUG1 Myc-PRH or pMUG1 (CON) and 48 hours 
post-transfection the cells were harvested. RNA was extracted, as described in 
section 2.6.1 of the Materials and Methods chapter. 0.5µg of the extracted RNA was 
reverse transcribed to produce cDNA (see section 2.6.2 for details). The amount of 
cDNA for each gene was then analyzed using quantitative PCR (qPCR) with gene 
specific primers for Vegf, Vegfr1 and Gapdh (internal control gene) (see table 9 in 
section 2.6.3 for details). The relative expression of Vegf and Vegfr1 were analyzed 
using the ΔΔCt method (as modified by Pfaffl (Pfaffl, 2001)). Figure 3.2 [A] shows 
       Chapter 3. TRANSCRIPTIONAL REGULATION OF VSP GENE EXPRESSION BY PRH AND TLE
97
Figure 3.1 - Myc-PRH expression in K562 cells.
Western blot of whole-cell extracts from K562 cells transiently  transfected with increasing 
amounts (0, 0.5, 1, 2, 5, 10µg) of the pMUG1 Myc-PRH plasmid expressing a Myc-tagged 
PRH protein. Protein extracts were made 48 hours post-transfection. Proteins were 
separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and 
transferred to an Immobilon P PVDF membrane. Proteins were stained with a mouse anti-
PRH antibody  (top panel), and a Lamin A/C antibody  (bottom panel). Data representative of 
two independent experiments.
PRH
Myc-PRH
Lamin A/C
Myc-PRH
1 2 3 4 5 6
36
72
55
kDa
that Vegf mRNA expression is repressed (lane 2 compared to lane 1) to 
approximately  60% of its endogenous level by over-expression of PRH. Similarly, 
Vegfr1 mRNA expression is repressed to approximately 40% of its endogenous level 
by over-expression of PRH (figure 3.2 [A] - lane 4 compared to lane 3). The effect of 
PRH over-expression on Vegfr2 expression could not be quantified because although 
expression for Vegfr2 was detectable in untreated cells, the signal for Vegfr2 was 
undetectable in the PRH over-expressed samples. It can be concluded that PRH over 
expression results in down regulation the Vegf, Vegfr1, and Vegfr2 genes in K562 
cells.
To determine whether regulation of VSP mRNA expression by PRH results in 
reduced protein synthesis for each gene, whole cell protein extracts from cells over-
expressing Myc-PRH were made for Western blot analysis. Proteins were separated 
and transferred to Immobilon P membrane for immuno-detection as described above. 
Western blot analysis was performed using the VEGF (VG76e) antibody (Fraser et 
al., 2000) to detect VEGF protein levels (figure 3.2 [B] - top  panel), and a Lamin A/C 
antibody was used as a loading control (figure 3.2 [B] - bottom panel). VEGF protein 
levels are decreased to 27% of the unrepressed state in cells over-expressing PRH 
compared to control cells (figure 3.2 [B] - top panel, lanes 2 and 1, respectively). This 
suggests that repression of Vegf mRNA by PRH is reflected in the level of VEGF 
protein expressed in the cell. The effect of PRH over-expression on VEGFR1 protein 
levels could not be determined with the antibody available (data not shown). The 
VEGFR2 antibodies available were also unable to detect VEGFR2 protein in K562 
cells (data not shown). The lack of a signal for VEGFR1 and VEGFR2 in 
untransfected cells prevented further investigation of VEGFR1 and VEGFR2 protein 
levels.
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Figure 3.2 - The effect  of exogenous PRH on Vegf, Vegfr1 mRNA and VEGF protein 
levels.
[A] Vegf and Vegfr1 mRNA levels in K562 cells 48 h after transfection with 10µg pMUG1 
(lanes 1 and 3, CON) or pMUG1 Myc-PRH (lanes 2 and 4, Myc-PRH). RNA was extracted 
and 0.5µg of extracted RNA was reverse transcribed to cDNA. mRNA levels were 
determined by  using the synthesized cDNA in a qPCR reaction using gene specific primers 
and comparing to qPCR reactions for Gapdh. Values are means and standard deviations 
(SD) (n = 5). [B] Western blot of whole-cell extract from K562 cells transfected with empty 
pMUG1 (lane 1) or pMUG1 MycPRH (lane 2). Protein extracts were made 48 hours post-
transfection. Proteins were separated by SDS-PAGE and transferred to an Immobilon P 
PVDF membrane. Proteins were stained with VEGF (VG76e) antibody  (top panel) or Lamin 
A/C antibody (bottom panel). Data representative of two independent experiments.
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3.2.2 PRH knockdown.
To determine whether the Vegf, Vegfr1 and Vegfr2 genes are regulated by the 
endogenous PRH protein in K562 cells, PRH was knocked down using Prh specific 
shRNAs. Cells transfected with the shRNA plasmids activate the RNA interference 
pathway to knock down the expression of Prh mRNA in a sequence specific manner 
(Paddison et al., 2002; Rao et al., 2009). PRH shRNA 1 targets the Prh mRNA 
sequence in the first exon within the coding sequence, between bases 374 and 402. 
PRH shRNA 2 targets the Prh mRNA sequence within the coding sequence of the 
fourth exon, between bases 789 and 817 (figure 3.3). K562 cells were transfected 
with a single PRH shRNA plasmid (PRH shRNA 1 or PRH shRNA 2), a combination 
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Figure 3.3 - Schematic diagram of the target of PRH shRNAs 1 and 2.
Schematic diagram of PRH shRNA targeting of the Prh mRNA sequence. PRH shRNA 1 
targets the Prh mRNA in the first exon within the coding sequence. PRH shRNA 2 targets 
the Prh mRNA in the fourth exon within the coding sequence.
of these PRH targeted shRNA plasmids (PRH shRNA 1+2), or a GFP targeted 
shRNA plasmid that was used as a control. 24 hours post-transfection the transfected 
cells were selected using 1µg/ml puromycin. After 10 days of puromycin selection the 
knockdown cells were harvested for RNA and protein extraction. 
To determine the level of PRH protein in PRH knockdown cells, whole cell protein 
extracts were extracted and analyzed by Western blot as previously described. 
Western blot analysis was performed using a rabbit anti-PRH antibody (figure 3.4 [A] 
- top  panel) and an anti-Lamin A/C antibody was used as a loading control (figure 3.4 
[A] - bottom panel). Figure 3.4 [A] shows that PRH protein is reduced to 35% and 
55% of endogenous levels for the PRH shRNA 1 and PRH shRNA 2 plasmids 
respectively (figure 3.4 [A] - top  panel, lanes 2 and 3). Combination of PRH shRNA 
plasmids 1 and 2 further reduces the level of PRH expression to 7% of the control 
level (figure 3.4 [A] - top panel, lane 4). The combination of PRH shRNA plasmids 
produced the most significant knockdown and therefore this combination of shRNA 
plasmids was used for all further PRH knockdown experiments. Knockdown of PRH 
protein levels were further confirmed by  Western blot analysis using the mouse anti-
PRH antibody (figure 3.4 [B] - top  panel). In the PRH shRNA sample (lane 1) of the 
top panel of figure 3.4 [B] no band can be clearly identified for the mouse anti-PRH 
antibody, however for the control sample (lane 2), a strong band is observed for the 
mouse anti-PRH antibody. Thus two different PRH antibodies both show a dramatic 
reduction in PRH protein levels in PRH knockdown cells.
RNA was extracted from PRH knockdown and control cells as previously described. 
Reverse transcription of the extracted RNA produced cDNA, which was analyzed by 
qPCR using gene specific primers for Prh and Gapdh (internal control). A significant 
decrease in the level of Prh mRNA was detected in the PRH shRNA knockdown cells 
compared to the control shRNA plasmid cells (figure 3.4 [C] - column 2 compared to 
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Figure 3.4 - Knock-down of PRH protein and prh mRNA by shRNA transfection.
[A] Western blot of whole-cell extracts from K562 cells co-transfected with shRNA plasmids 
control shRNA (lane 1), PRH shRNA 1 (lane 2), PRH shRNA 2 (lane 3), and PRH shRNA 
(1+2) (lane 4). Protein extracts were made 48 hours post-transfection. Proteins were 
separated by  SDS-PAGE and transferred to an Immobilon P PVDF membrane. Proteins 
were stained with rabbit anti-PRH antibody  (top panel) and anti-Lamin A/C antibody  (bottom 
panel). [B] As for [A] except extracts from PRH shRNA 1+2 (lane 1) and control shRNA (lane 
2), using mouse anti-PRH antibody  (top panel) and anti-Lamin A/C antibody  (bottom panel). 
Data representative of three independent experiments. [C] Prh mRNA levels after PRH 
shRNA 1+2 co-transfection. RNA was extracted and 0.5µg of extracted RNA was reverse 
transcribed to cDNA. mRNA levels were determined by  using the synthesized cDNA in a 
qPCR reaction using gene specific primers and comparing to qPCR reactions for Gapdh. 
White bar represent control shRNA cells (lane 1) and grey bar PRH shRNA 1+2 cells (lane 
2). Values are means and SD (n = 5).
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column 1), confirming the knockdown of Prh mRNA as well as PRH protein levels. 
To investigate the regulation of the Vegf, Vegfr1 and Vegfr2 by endogenous PRH, 
protein and RNA was extracted from PRH knockdown cells and control cells for 
analysis. Protein was extracted and analyzed by Western blot as described above. 
Western blot analysis was performed using an anti-VEGF (VG76e) antibody (Fraser 
et al., 2000) (figure 3.5 [A] - top  panel) to detect VEGF protein expression, a rabbit 
anti-PRH antibody (figure 3.5 [A] - middle panel) and an anti-Lamin A/C antibody 
(figure 3.5 [A] - bottom panel) was used as a loading control. In each of the samples 
where PRH is knocked down (figure 3.5 [A] - middle panel, lanes 2-4), VEGF protein 
expression is strongly elevated (figure 3.5 [A] - top panel, lanes 2-4) compared to the 
control cells (figure 3.5 [A] - top  panel, lane 1). This suggests that loss of PRH 
expression de-represses VEGF protein expression.
RNA was extracted from PRH knockdown and control cells as previously described. 
Reverse transcription of the extracted RNA produced cDNA, which was analyzed by 
qPCR using gene specific primers for Prh, Vegf, Vegfr1, Vegfr2 and Gapdh. Prh 
mRNA expression in PRH knockdown cells was approximately 20% of the Prh 
mRNA expression levels in control cells (figure 3.5 [B] - lane 2 compared to lane 1), 
confirming knockdown of Prh mRNA. In PRH knockdown cells Vegf mRNA 
expression is elevated compared to control cells (figure 3.5 [B] - lanes 4 and 3) with 
over four times the expression of Vegf mRNA. Similarly, Vegfr1 mRNA expression in 
PRH knockdown cells is approximately three and a half times greater than the Vegfr1 
mRNA expression in the control cells (figure 3.5 [B] - lanes 6 and 5). Notably, Vegfr2 
mRNA expression is also elevated over two fold in PRH knockdown cells compared 
to control cells (figure 3.5 [B] - lanes 8 and 7). These results show that endogenous 
PRH represses endogenous Vegf, Vegfr1 and Vegfr2 expression in K562 cells.
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Figure 3.5 - The effect of PRH shRNA knock-down on VSP gene expression.
[A] Western blot of whole-cell extracts from K562 cells co-transfected with shRNA plasmids 
control shRNA (lane 1), PRH shRNA 1 (lane 2), PRH shRNA 2 (lane 3), and PRH shRNA 
(1+2) (lane 4). Protein extracts were made 48 hours post-transfection. Proteins were 
separated by  SDS-PAGE and transferred to an Immobilon P PVDF membrane. Proteins 
were stained with anti-VEGF (VG76e) antibody  (top panel), rabbit anti-PRH antibody 
(middle panel) and anti-Lamin A/C antibody  (bottom panel). Data representative of two 
independent experiments. [B] Prh, Vegf, Vegfr1 and Vegfr2 mRNA levels after PRH shRNA 
1+2 co-transfection (PRH KD). mRNA levels were determined as in figure 3.2. White bars 
represent control shRNA cells and grey  bars PRH knockdown cells. Values are means and 
SD (n = 5).
3.3 PRH-TLE interaction is required for Vegf, Vegfr1 regulation.
PRH can regulate gene expression through multiple mechanisms (Soufi and 
Jayaraman, 2008), for example PRH binds via its homeodomain and recruits co-
repressor proteins such as TLE1 to bring about direct transcriptional repression 
(Swingler et al., 2004). PRH can also act post-transcriptionally by interacting with 
eIF4E (Topisirovic et al., 2003a), as outlined in the introduction.
To distinguish between these direct and indirect regulatory  mechanisms, PRH 
mutants in which specific protein interactions or DNA binding are disrupted were used 
and the regulation of Vegf and Vegfr1 genes by these mutated proteins was 
investigated. PRH requires the ability to bind to DNA through the homeodomain for 
direct transcriptional repression (Guiral et al., 2001). Using electrophoretic mobility 
shift assays (EMSA), DNA binding has been shown to be disrupted by a mutation 
within the homeodomain at residue 187 which alters an asparagine to an alanine 
(figure 3.6 - PRH N187A) (Guiral et al., 2001; Desjobert et al., 2009). Interaction 
between PRH and eIF4E can lead to post-transcriptional regulation of mRNA 
transport by PRH. A double mutation at residues 23 and 24 from leucine residues to 
alanine residues has been reported to abrogate this interaction (figure 3.6 - PRH 
LL23,24AA) (Topisirovic et al., 2003a). PRH interacts with the co-repressor Groucho/
TLE through a conserved Eh-1 motif located within the proline-rich N-terminal domain 
of PRH (Swingler et al., 2004). This interaction has been shown to be important for 
transcriptional repression (Swingler et al., 2004). Mutation of the Eh-1 motif in PRH 
from phenylalanine at residue 32 to a glutamic acid residue (figure 3.6 - PRH F32E) 
has previously been shown to abolish binding of TLE to PRH  in pull-down and co-IP 
assays (Swingler et al., 2004). 
K562 cells were transfected with 10µg pMUG1 Myc-PRH, or pMUG1 Myc-PRH 
F32E, pMUG1 Myc-PRH LL23,24AA, pMUG1 Myc-PRH N187A or pMUG1 as a 
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control. After 48 hours the cells were harvested and protein was extracted. Protein 
expression was analyzed by Western blot, as previously described, using an anti-Myc 
(9E10) antibody  (figure 3.7 [A] - top  panel) to detect exogenous Myc-PRH and an 
anti-Lamin A/C antibody was used as a loading control (figure 3.7 [A] - bottom panel). 
Each of the PRH mutant proteins are expressed at approximately  equal levels (figure 
3.7 [A] - top  panel, lanes 3-5 respectively) compared to the wild-type Myc-PRH 
(figure 3.7 [A] - top  panel, lane 2). Therefore, any difference observed in gene 
expression is a consequence of the specific protein mutation and not through 
variations in protein expression levels.
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Figure 3.6 -  Schematic diagram of Myc-PRH point mutations.
Schematic diagram of the PRH protein in pMUG1 Myc-PRH and targeted mutations in the 
protein. The LL23,24AA mutation is defective in eIF4E interaction. The F32E mutation 
reduces PRH binding to TLE. PRH N187A mutant is deficient in DNA binding. The PRH 
RR188,189AA mutant does not localize to the nucleus.
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Figure 3.7 - Characteristics of PRH required for Vegf and Vegfr1 gene regulation.
[A] Western blot of Myc-PRH expression in K562 cells 48 h after transfection with 10 µg 
pMUG1 (lane 1, control) or pMUG1 vectors expressing PRH (PRH {lane 2}, PRH F32E {lane 
3}, PRH LL23,24AA {lane 4}, or PRH N187A {lane 5}). Whole-cell extracts were run on a 
sodium dodecyl sulfate-polyacrylamide gel (SDS-PAG) as described for figure 3.2 and 
stained with Myc and Lamin A/C antibodies. Data representative of five independent 
experiments.[B] Vegf mRNA levels in K562 cells 48 hours after transfection with the vectors 
described for panel [A]. mRNA levels were determined as for figure 3.2. Values are means 
and SD (n = 3). [C] As for panel [B] except that relative levels of expression of Vegfr1 are 
shown. Values are means and SD (n = 3).  
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RNA was extracted from cells transfected with empty expression vector (pMUG1), or 
expression vectors for PRH, or each of the mutants, 48 hours post-transfection. The 
mRNA was reverse transcribed to produce cDNA which was analyzed as described 
above by qPCR. As previously observed (figure 3.2 [A]) the wild-type Myc-PRH 
represses Vegf mRNA expression when compared to the control cells (figure 3.7 [B] - 
lanes 2 and 1). The PRH F32E (figure 3.7 [B] - lane 3) and PRH N187A (figure 3.7 [B] 
- lane 5) mutants both have little or no effect on mRNA expression of Vegf compared 
to the control cells (figure 3.7 [B] - lane 1). In contrast the PRH LL23,24AA (figure 3.7 
[B] - lane 4) mutant represses Vegf mRNA expression as efficiently as the wild-type 
Myc-PRH (figure 3.7 [B] - lane 2) when compared to control cells (figure 3.7 [B] - lane 
1). 
The effect of these PRH mutations was also investigated for Vegfr1 mRNA 
expression, as described for the regulation of Vegf mRNA expression above. Myc-
PRH represses Vegfr1 mRNA expression to approximately  40% of its unrepressed 
state (figure 3.7 [C] - lane 2 compared to lane 1) as previously  observed (figure 3.2 
[A]). However, the PRH F32E (figure 3.7 [C] - lane 3) and PRH N187A (figure 3.7 [C] 
- lane 5) mutants have a substantially reduced capacity to repress Vegfr1 mRNA 
expression, only  repressing Vegfr1 mRNA expression to approximately 80% of the 
unrepressed state (figure 3.7 [C] - lane 1). The LL23,24AA (figure 3.7 [C] - lane 4) 
mutation has no effect on the ability of PRH to repress Vegfr1 mRNA expression, 
repressing mRNA expression as well as the wild-type Myc-PRH (figure 3.7 [C] - lane 
2) when compared to control cells (figure 3.7 [C] - lane 1). It can be concluded that 
both DNA binding and interaction with TLE are required for the repression of the Vegf 
and Vegfr1 genes. However, PRH interaction with eIF4E would appear to have no 
role in the regulation of Vegf and Vegfr1 mRNA expression. This data suggests that 
PRH regulates these genes by a direct transcriptional mechanism.
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To confirm the role of TLE in the regulation of the Vegf and Vegfr1 genes, co-
expression of PRH and TLE-1 was carried out in control and PRH knockdown cells. 
PRH knockdown and control cells were transfected with pMUG1 alone, or pMUG1 
Myc-PRH alone, or pCMV2 Flag-TLE-1 alone, or with pMUG1 Myc-PRH and pCMV2 
Flag-TLE-1. 48 hours post-transfection the cells were harvested and RNA was 
extracted. The extracted RNA was reverse transcribed and analyzed by qPCR as 
detailed above. Figure 3.8 [A] shows that in control cells when PRH is exogenously 
expressed repression of Vegf is observed (lane 2) when compared to control cells 
(lane 1). In control cells when TLE-1 is exogenously expressed, repression of the 
Vegf mRNA expression is also observed (figure 3.8 [A] - lane 3) when compared to 
the control (figure 3.8 [A] - lane 1). However, when both PRH and TLE-1 are co-
expressed, further repression of Vegf is observed (figure 3.8 [A] - lane 4) compared 
to the control (figure 3.8 [A] - lane 1), or indeed compared to PRH or TLE-1 alone 
(figure 3.8 [A] - lane 2 and 3 respectively). In PRH knockdown cells as expected Vegf 
levels are de-repressed compared to control cells (figure 3.8 [A] - lane 5). Re-
introduction of exogenous PRH results in repression of Vegf mRNA expression 
compared to control PRH knockdown cells (figure 3.8 [A] - lanes 6 and 5). In contrast 
with over-expression of TLE-1 in control cells, over-expression of TLE-1 in PRH 
knockdown cells has no significant effect on Vegf mRNA expression compared to 
control PRH knockdown cells (figure 3.8 [A] - lanes 7 and 5). Strikingly, increased 
repression of Vegf mRNA expression is observed when TLE-1 and PRH are co-
expressed in PRH knockdown cells compared to expression of PRH alone in PRH 
knockdown cells (figure 3.8 [A] - lanes 8 and 6). This demonstrates that the presence 
of PRH is required for the repression of the Vegf gene by TLE-1. It is likely  that in 
control cells, the repression observed when TLE-1 is over-expressed alone is through 
binding to endogenous PRH bound at the Vegf gene promoter.
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Figure 3.8 - PRH and TLE co-repression of Vegf and Vegfr1 gene expression.
[A] Vegf mRNA levels in K562 shRNA control cells (CON) and PRH shRNA cells (PRH KD) 
48 hours after transfection with pMUG1-MycPRH (5 µg), pCMV2-TLE1(2.5 µg), or both 
plasmids were determined as for figure 3.2. Values are means and SD (n = 3). [B] As for 
panel [A] except that relative levels of expression of Vegfr1 are shown. Values are means 
and SD (n = 3).
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The role of TLE-1 in Vegfr1 mRNA expression was also investigated in the same 
experiment. As observed for Vegf mRNA expression exogenous expression of PRH 
in control cells results in repression of Vegfr1 mRNA compared to the control (figure 
3.8 [B] - lanes 2 and 1). In control cells when TLE-1 is exogenously expressed, 
Vegfr1 mRNA expression is also repressed compared to the control (figure 3.8 [B] - 
lanes 3 and 1). Co-expression of both PRH and TLE-1 in control cells results in 
further repression of Vegfr1 mRNA expression (figure 3.8 [B] - lane 4) compared to 
the control (figure 3.8 [B] - lane 1), TLE-1 only cells (figure 3.8 [B] - lane 3), or PRH 
only cells (figure 3.8 [B] - lane 2). Again in PRH knockdown cells Vegfr1 mRNA 
expression is elevated. Re-introduction of exogenous PRH into PRH knockdown cells 
results in repression of Vegfr1 mRNA expression compared to control PRH 
knockdown cells (figure 3.8 [B] - lanes 6 and 5). However, unlike over-expression of 
TLE-1 in control cells, over-expression of TLE-1 in PRH knockdown cells has no 
significant effect on Vegfr1 mRNA expression (figure 3.8 [B] - lane 7) compared to 
control PRH knockdown cells (figure 3.8 [B] - lane 5). As seen for Vegf expression, 
increased repression of Vegfr1 mRNA expression is observed when TLE-1 and PRH 
are co-expressed in PRH knockdown cells (figure 3.8 [B] - lane 8) compared to 
expression of PRH alone (figure 3.8 [B] - lane 6). It can be concluded that PRH is 
required for the repression of the Vegfr1 gene by TLE-1. It is likely that in control cells 
TLE-1 expression alone represses Vegfr1 mRNA expression by interacting with 
endogenous PRH bound at the Vegfr1 gene promoter. These data confirm the results 
obtained with the PRH mutants suggesting that recruitment of TLE-1 is essential for 
transcriptional repression by PRH at the Vegf and Vegfr1 promoters.
3.4 PRH is directly associated with the promoters of the VSP genes.
The data above suggests that PRH binds to the Vegf and Vegfr1 promoters to 
repress gene transcription and that TLE-1 is also required for this transcriptional 
       Chapter 3. TRANSCRIPTIONAL REGULATION OF VSP GENE EXPRESSION BY PRH AND TLE
111
regulation. To further investigate whether PRH directly  regulates the Vegf and Vegfr1 
genes through promoter association, chromatin immuno-precipitation (ChIP) 
experiments were performed to determine the regions of PRH binding. ChIP is a 
technique that cross-links proteins to the regions of chromatin they are bound to in 
the cell, the cells are then lysed and sonicated to fragment the chromatin into 
fragments smaller than approximately 800bp. Immuno-precipitation of the protein of 
interest (for example PRH) is performed using a protein specific antibody conjugated 
to a bead. The cross-links are then reversed and the DNA fragments bound to the 
protein of interest are purified. This DNA can be used to determine enrichment of 
specific promoter regions by qPCR.
To perform ChIP experiments the optimum sonication conditions to produce 
chromatin fragments from K562 cells was necessary. For this 2.5x106 or 5x106 K562 
cells were formaldehyde cross-linked before sonication. Cells were either sonicated 
on medium power for 5 minutes or 10 minutes at each concentration. The cross-links 
were then reversed and the DNA was purified. 2µg of purified DNA was run on a 
1.5% agarose gel and visualized under UV light. For 2.5x106 cells sonicated for 5 
minutes on medium power, DNA fragments of between 300 and 600 base pairs in 
length are observed, with an average fragment size of 450bp  (figure 3.9 - lane 1). 
Using double the number of cells, 5x106 cells, and sonicating for 5 minutes on 
medium power, an increase in fragment sizes to between 250 and 900 base pairs 
long is observed, compared to half the number of cells under the same conditions 
(figure 3.9 - lanes 3 and 1). Sonication of 2.5x106 cells on medium power for 10 
minutes gave fragments of between 250 and 600 base pairs in length, with an 
average base pair fragment of 425 base pairs (figure 3.9 - lane 2). Yet sonication of 
5x106 cells for 10 minutes decreases the fragment size to between 200 and 
approximately  600 base pairs in size (figure 3.9 - lane 4), and this gives an average 
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fragment size of 400 base pairs in length. Therefore for all ChIP assays, 5x106 K562 
cells were sonicated on medium power for 10 minutes because this condition 
produces an optimal average fragment size and allows processing of a large number 
of cells.
Previous work has shown that PRH can either regulate gene transcription through 
association with single binding sites or it can bind to multiple binding sites within a 
gene promoter. For example, PRH regulates promoters that contain a TATA box 
sequence and no other SELEX-defined PRH binding sites (Guiral et al., 2001). PRH 
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Figure 3.9 - Optimization of chromatin fragments used for ChIP experiments.
2.5x106 (lanes 1 and 2) or 5x106 (lanes 3 and 4) un-transfected K562 cells were cross-
linked with formaldehyde and sonicated for either 5 (lanes 1 and 3) or 10 (lanes 2 and 4) 
minutes on medium power. The chromatin fragments were purified and separated on a 1.5% 
agarose gel.
M 1 2 3 4
can also bind to multiple adjacent binding sites such as those within the Goosecoid 
promoter and induce transcriptional repression (Williams et al., 2008). In vitro DNase 
1 protection experiments have shown that PRH protects a large region of DNA at 
least 200bp in length suggesting that PRH either spreads along DNA or wraps DNA 
around it (Williams et al., 2008). Therefore, to determine whether PRH binds across a 
small region of DNA or at multiple regions across the Vegfr1 promoter, several 
regions across the promoter were assayed for PRH association.
To investigate where PRH binds to the Vegfr1 promoter, 5µg of pMUG1 Myc-PRH 
was transfected into K562 cells. 24 hours after transfection formaldehyde was added 
to the cells to cross-link DNA bound proteins to chromatin. The cells were then 
sonicated to shear the chromatin into DNA fragments of 200-600bp  in length. 
Chromatin was immuno-precipitated using an anti-myc or anti-IgG antibody, as a 
control. Protein-DNA cross-links were then reversed and the immuno-precipitated 
chromatin was purified. To determine the relative amount of DNA binding by PRH 
across the Vegfr1 promoter, qPCR was performed using primers specific for regions 
within the Vegfr1 promoter and the amount of input DNA was compared to the 
amount of immuno-precipitated DNA. This was then compared to the amount of 
binding by PRH observed at the control Gapdh promoter, which gives the fold 
enrichment of Myc-PRH DNA binding. Figure 3.10 shows the relative position of PCR 
primer pairs that were used to analyze PRH DNA binding at the Vegfr1 gene 
promoter, these primers cover a region of over 9 kilobases from -7500 to +1700 of 
the promoter in relation to the transcription start site (TSS). Enrichment of Myc-PRH 
immuno-precipitated regions of DNA is observed across the Vegfr1 promoter as black 
bars, white bars represent the input DNA and grey bars represent the IgG immuno-
precipitation control (figure 3.10). For regions bound by Myc-PRH the black bar will 
be greater than the white bar (input) and the grey  bar (IgG). For regions not bound by 
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Myc-PRH the black bar will be approximately equal or less than either the white bar 
or the grey bar. Myc-PRH does not bind to the region -7500 bp upstream of the 
Vegfr1 TSS (figure 3.10) compared to the input DNA. However, Myc-PRH is found to 
be weakly associated with the Vegfr1 promoter -5600 bp upstream of the TSS and 
1700 bp downstream of the TSS (figure 3.10). Strong association of Myc-PRH with 
the Vegfr1 promoter is observed at -3500 bp and -1200 bp  upstream of the TSS, in 
addition to the region covering the Vegfr1 TSS (figure 3.10). Therefore, PRH is 
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Figure 3.10 - PRH binds to multiple regions of the Vegfr1 promoter.
Chromatin Immuno-precipitation of Myc-PRH from K562 cells transfected with 5 µg pMUG1 
Myc-PRH. PRH enrichment levels (black bars) were compared to input DNA (white bars) 
and IgG enrichment levels (grey  bars), which were determined by  using purified DNA from 
the immuno-precipitation in a qPCR reaction using promoter specific primers and comparing 
to qPCR reactions for the Gapdh promoter. Dotted line represents the threshold of 
enrichment compared to the input DNA. Values are taken from a single immuno-
precipitation and SD of 3 qPCR reactions. Data representative of 3 sets of chromatin.
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associated with the promoter of Vegfr1 at multiple regions across approximately 7500 
bp of promoter DNA.
To investigate whether mutation of the TLE interaction site in the N-terminal domain 
of PRH or a mutation in the DNA binding domain of PRH affects the binding of PRH 
to the Vegfr1 promoter, 5µg of pMUG1 vector expressing Myc-PRH, or Myc-PRH 
F32E, or Myc-PRH N187A was transfected into K562 cells. 24 hours after 
transfection chromatin was prepared as described above. Chromatin was then 
immuno-precipitated using an anti-Myc antibody or an anti-IgG as a control. Relative 
enrichment was analyzed across the Vegfr1 promoter as described above. The 
binding of Myc-PRH F32E (figure 3.11 [B]) across the Vegfr1 promoter gave a similar 
trend as observed for the wild-type Myc-PRH (figure 3.11 [A]). There was no binding 
observed for Myc-PRH F32E at the -7500bp region upstream from the Vegfr1 TSS or 
at the +1700bp  region downstream of the TSS (figure 3.11 [B]). However, Myc-PRH 
F32E binds to the -5600, -3500 and -1200bp  regions upstream of the TSS and the 
region over the TSS (figure 3.11 [B]). The strongest binding observed for Myc-PRH 
F32E is at the proximal promoter regions, -1200bp upstream and the region covering 
the TSS (figure 3.11 [B]). The Myc-PRH N187A, DNA binding deficient mutant of 
PRH, does not immuno-precipitate any of these 6 regions across the Vegfr1 promoter 
(figure 3.11 [C]). This suggests that mutation of the TLE interaction domain has no 
effect on the ability of PRH to bind to these region of the Vegfr1 promoter, although 
mutation of the DNA binding domain of PRH does prevent association of PRH with 
the Vegfr1 promoter.
To determine whether PRH and TLE both associate at the Vegfr1 promoter, 5µg of 
pMUG1 Myc-PRH, or 5µg pCMV Flag-TLE-1, or 5µg of each of these plasmids was 
transfected into K562 cells. 24 hours after transfection chromatin was prepared as 
described above. Chromatin was then immuno-precipitated using an anti-Myc 
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Figure 3.11 - PRH binding to the Vegfr1 promoter requires a functional homeodomain 
but not interaction with TLE.
[A] Chromatin Immuno-precipitation of Myc-PRH from K562 cells transfected with 5 µg 
pMUG1 Myc-PRH. PRH enrichment levels (black bars) were compared to input DNA (white 
bars) and IgG enrichment levels (grey  bars), which were determined by  using purified DNA 
from the immuno-precipitation in a qPCR reaction using promoter specific primers and 
comparing to qPCR reactions for the Gapdh promoter. Values are taken from a single 
representative immuno-precipitation and SD of 3 qPCR reactions. Data representative of 3 
sets of chromatin. [B] As for panel A except cells were transfected with 5µg pMUG1 Myc-
PRH F32E. [C] As for panel A except cells were transfected with 5µg pMUG1 Myc-PRH 
N187A.
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antibody, or an anti-Flag antibody or an anti-IgG as a control. Relative enrichment 
was analyzed across the Vegfr1 promoter as described above. For the transfections 
involving Flag-TLE-1, immuno-precipitation of Flag-TLE-1 is represented by a dark 
red bar. For regions of the chromatin bound by Flag-TLE-1, the dark red bars will be 
greater than the white bar (input) and the grey bar (IgG). In cells expressing Flag-
TLE-1 alone, Flag-TLE-1 is not strongly associated with the Vegfr1 promoter (figure 
3.12 [B]). However, Flag-TLE-1 does associate with the -1200bp upstream region of 
the Vegfr1 promoter (figure 3.12 [B]). Yet, there is little association across the rest of 
the promoter regions that were assayed. Significantly, in cells expressing Myc-PRH 
and Flag-TLE-1, not only  is binding of Myc-PRH observed across the Vegfr1 
promoter but Flag-TLE-1 is also associated strongly  at the upstream regions, -5600, 
-3500, -1200bp  from the TSS, and at the TSS (figure 3.12 [C]). Although no binding is 
observed for the -7500bp upstream region or the +1700bp  downstream region where 
Myc-PRH is not strongly associated (figure 3.12 [C]). This suggests that PRH and 
TLE-1 bind to the Vegfr1 promoter but TLE is not strongly associated with the 
promoter in the absence of PRH.
To further investigate the recruitment of TLE to the Vegfr1 promoter, chromatin was 
prepared from K562 cells expressing Myc-PRH and Flag-TLE-1, or Myc-PRH F32E 
and Flag-TLE-1, or Myc-PRH N187A and Flag-TLE. Chromatin was then immuno-
precipitated using an anti-Myc antibody, or an anti-Flag antibody or an anti-IgG as a 
control. Relative enrichment was analyzed across the Vegfr1 promoter as described 
above. As described above for figure 3.12, in cells expressing Myc-PRH and Flag-
TLE-1, both proteins immuno-precipitate the same regions of the Vegfr1 promoter 
(figure 3.13 [A]). In contrast, in cells expressing Myc-PRH F32E and Flag-TLE-1, only 
Myc-PRH F32E is found associated with the Vegfr1 promoter and no association is 
observed for Flag-TLE-1 (figure 3.13 [B]). Myc-PRH F32E is strongly  associated to 
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Figure 3.12 - TLE associates with the Vegfr1 promoter in the presence of PRH.
[A] Chromatin Immuno-precipitation of Myc-PRH or Flag-TLE from K562 cells transfected 
with 5 µg pMUG1 Myc-PRH. PRH enrichment levels (black bars) or TLE enrichment levels 
(dark red bars) were compared to input DNA (white bars) and IgG enrichment levels (grey 
bars), which were determined by using purified DNA from the immuno-precipitation in a 
qPCR reaction using promoter specific primers and comparing to qPCR reactions for the 
Gapdh promoter. Values are taken from a single representative immuno-precipitation and 
SD of 3 qPCR reactions. As shown in 3.11. [B] As for panel A except cells were transfected 
with 5µg pCMV Flag-TLE. [C] As for panel A except cells were transfected with 5µg pMUG1 
Myc-PRH and 5µg pCMV Flag-TLE. Data representative of 3 sets of chromatin.
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Figure 3.13 - TLE is not  recruited to the Vegfr1 promoter by PRH mutants that do not 
interact with TLE or bind to DNA.
[A] Chromatin Immuno-precipitation of Myc-PRH or Flag-TLE from K562 cells transfected 
with 5 µg pMUG1 Myc-PRH and 5µg pCMV Flag-TLE. PRH enrichment levels (black bars) 
or TLE enrichment levels (dark red bars) were compared to input DNA (white bars) and IgG 
enrichment levels (grey bars), which were determined by  using purified DNA from the 
immuno-precipitation in a qPCR reaction using promoter specific primers and comparing to 
qPCR reactions for the Gapdh promoter. Values are taken from a single representative 
immuno-precipitation and SD of 3 qPCR reactions. [B] As for panel A except cells were 
transfected with 5µg pMUG1 Myc-PRH F32E. [C] As for panel A except cells were 
transfected with 5µg pMUG1 Myc-PRH N187A. Data representative of 3 sets of chromatin.
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the upstream regions -5600, -3500 and -1200bp from the TSS, as well as at the TSS, 
similar to previous observations in cells expressing Myc-PRH F32E alone (figure 3.11 
[B]). In cells expressing both Myc-PRH N187A and Flag-TLE-1, neither protein is 
associated at any of the regions assayed across the Vegfr1 promoter (figure 3.13 
[C]). These data confirm that the interaction between PRH and TLE-1 within the N-
terminal domain of PRH is vital for the recruitment of TLE-1 to the Vegfr1 gene. 
To determine whether PRH binds at the promoter region of the Vegf gene, the same 
chromatin, as used above, from cells expressing Myc-PRH, or Myc-PRH F32E, or 
Myc-PRH N187A was analyzed as described above, at a single site at the Vegf gene 
promoter. Figure 3.14 [A] shows that in cells expressing Myc-PRH, PRH is bound to 
the Vegf gene promoter -4500bp from the TSS. In cells expressing Myc-PRH F32E, 
PRH F32E protein is also found associated with this Vegf promoter region (figure 
3.14 [A]). However, in cells expressing Myc-PRH N187A, no PRH N187A is found 
associated with the -4.5 kb  region upstream of the Vegf promoter (figure 3.14 [A]). 
This demonstrates that PRH directly binds to the Vegf promoter and that the 
interaction with TLE is not required for DNA binding.
To further establish whether TLE is associated at the Vegf gene where PRH binds, 
chromatin from cells expressing Myc-PRH, or Myc-PRH F32E, or Myc-PRH N187A 
with Flag-TLE-1, as used above, was analyzed as described above, at a single site at 
the Vegf gene promoter. In cells expressing TLE-1 alone no association of TLE is 
observed at the Vegf gene promoter (data not shown). In cells expressing Myc-PRH 
and Flag-TLE-1, PRH and TLE-1 are bound at -4500bp  upstream from the TSS in the 
Vegf gene promoter (figure 3.14 [B]). Yet, in cells expressing Myc-PRH F32E and 
Flag-TLE-1, only PRH F32E protein is also found associated with this Vegf promoter 
region and no association of TLE-1 is observed (figure 3.14 [B]). However, in cells 
expressing Myc-PRH N187A and Flag-TLE-1, neither PRH N187A or TLE-1 are 
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Figure 3.14 - PRH binds to the Vegf and Vegfr2 promoters and recruits TLE.
[A] Chromatin Immuno-precipitation of Myc-PRH from K562 cells transfected with 5 µg 
pMUG1 plasmid expressing Myc-PRH or Myc-PRH F32E or Myc-PRH N187A. PRH 
enrichment levels (black bars) were compared to input DNA (white bars) and IgG 
enrichment levels (grey  bars), which were determined by  using purified DNA from the 
immuno-precipitation in a qPCR reaction using promoter specific primers and comparing to 
qPCR reactions for the Gapdh promoter. Values are taken from a single representative 
immunoprecipitation and SD of 3 qPCR reactions. [B] Chromatin Immuno-precipitation of 
Myc-PRH or Flag-TLE from K562 cells transfected with 5 µg pMUG1 plasmid expressing 
Myc-PRH or Myc-PRH F32E or Myc-PRH N187A and 5µg pCMV Flag-TLE. Enrichment 
levels were determined as for panel A, TLE enrichment is represented by dark red bars. [C] 
As for panel A except using Vegfr2 promoter specific primers. [D] As for panel B except 
using Vegfr2 promoter specific primers.
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found associated with the -4500bp  upstream region of the Vegf promoter. This 
suggests that PRH directly binds to the Vegf promoter and recruits TLE-1 to the 
promoter.
To determine whether PRH also binds to the Vegfr2 promoter, the same chromatin 
from cells expressing Myc-PRH, or Myc-PRH F32E, or Myc-PRH N187A, as above, 
was analyzed as described above, at a single site at the TSS of the Vegfr2 gene. 
PRH is bound to the Vegfr2 gene promoter at the TSS, in cells that express Myc-PRH 
(figure 3.14 [C]). PRH F32E protein also binds to the TSS of the Vegfr2 gene, in cells 
that express Myc-PRH F32E (figure 3.14 [C]). Although PRH N187A is not found to 
associate with the TSS of the Vegfr2 promoter, in cells expressing Myc-PRH N187A 
(figure 3.14 [C]). This data suggests that PRH directly binds to the Vegfr2 promoter 
and that the PRH F32E mutant is able to bind DNA.
To further establish whether TLE can associate with PRH at the Vegfr2 gene, 
chromatin from cells expressing Myc-PRH, or Myc-PRH F32E, or Myc-PRH N187A 
with Flag-TLE-1, as used above, was analyzed as described above, at a single site at 
the TSS of the Vegfr2 gene. Cells that express TLE-1 alone have no association of 
TLE-1 at the Vegfr2 gene TSS (data not shown). In cells expressing Myc-PRH and 
Flag-TLE-1, PRH and TLE-1 are associated with the TSS region in the Vegfr2 gene 
(figure 3.14 [D]). Yet, in cells expressing Myc-PRH F32E and Flag-TLE-1, the PRH 
F32E protein associates with this region of the Vegfr2 gene but no association of 
TLE-1 is observed (figure 3.14 [D]). However, in cells expressing Myc-PRH N187A 
and Flag-TLE-1, neither PRH N187A or TLE-1 associate with the Vegfr2 gene TSS 
(figure 3.14 [D]). This suggests that PRH directly binds to the Vegfr2 gene proximal 
promoter and recruits TLE-1 to the promoter.
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3.5 PRH induces nuclear retention of TLE.
TLE exists in multiple phosphorylation states (Buscarlet et al., 2009; Nuthall et al., 
2004; Nuthall et al., 2002b; Nuthall et al., 2002a; Eberhard et al., 2000; Husain et al., 
1996). Within the haematopoietic compartment TLE can partner with several DNA-
binding proteins including Hes-1 (Fisher et al., 1996), Runx-1 (Aronson et al., 1997) 
and Pax5 (Linderson et al., 2004), as well as PRH (Swingler et al., 2004). It has been 
shown that several of these proteins have a role in regulating TLE phosphorylation 
and modulating its activity (Nuthall et al., 2002a; Eberhard et al., 2000). For example 
expression of Hes1 can induce CK2-dependent hyper-phosphorylation of TLE, which 
can be detected by retarded mobility of TLE proteins on a SDS-PAG (Nuthall et al., 
2002a). Western blot detection of TLE proteins show that there are 2 bands, the 
lower band corresponds to hypo-phosphorylated TLE and the upper band 
corresponds to hyper-phosphorylated TLE (figure 3.15). This phosphorylation 
increases the nuclear retention of TLE proteins (Nuthall et al., 2002a). 
To determine whether over-expressed PRH can alter the phosphorylation status and 
nuclear retention of TLE, pMUG1 or pMUG1 Myc-PRH was transfected into K562 
cells. After 48 hours the cells were harvested, and nuclear and post-nuclear extracts 
were isolated. Post-nuclear extracts contain all cytoplasmic proteins and some 
loosely associated nuclear proteins. The nuclear extracts contain tightly associated 
nuclear proteins. Equal amounts of protein were loaded and run on a SDS-PAG. The 
SDS-PAG was transferred to Immobilon P membrane and Western blotted with an 
antibody that recognizes multiple endogenous TLE proteins (anti-panTLE antibody)
(figure 3.15 - top panel). The blot was stripped of antibody and re-probed with an 
anti-Myc-tag (9E10) antibody (figure 3.15 - upper middle panel) for exogenous Myc-
PRH, or anti-Lamin A/C  antibody (figure 3.15 - lower middle panel) or anti-Tubulin 
antibody (figure 3.15 - bottom panel). Lamin A/C and Tubulin antibodies were used 
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as fractionation and loading controls. In un-transfected K562 cells endogenous TLE 
proteins are primarily localized to the post-nuclear compartment (figure 3.15 - top 
panel, lane 1) and the relative intensity of the two proteins detected by the panTLE 
antibody suggests that the majority of TLE is hypo-phosphorylated (figure 3.15 - top 
panel, lane 1, lower band). However, in Myc-PRH transfected cells, TLE becomes 
equally distributed between the nuclear and post-nuclear compartments (figure 3.15 - 
top panel, lanes 3 and 4). Furthermore, the relative intensity of the two bands 
detected suggests that the majority  of TLE is now hyper-phoshorylated in both the 
nuclear and post-nuclear compartments (figure 3.15 - top panel, lanes 3 and 4, upper 
       Chapter 3. TRANSCRIPTIONAL REGULATION OF VSP GENE EXPRESSION BY PRH AND TLE
125
Figure 3.15 - PRH increases TLE nuclear retention.
Untransfected K562 cells and cells transfected with pMUG1 Myc–PRH were fractionated 
into post-nuclear (PN) and nuclear (N) extracts. The proteins were then separated by  SDS-
PAGE and western blotted for endogenous TLE using a pan-TLE antibody  (top panel), Myc–
PRH using an anti-Myc antibody  (upper middle panel), Lamin A/C (lower middle panel) and 
Tubulin (bottom panel). Data representative of three independent experiments.
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band). Myc-PRH is present in both the nuclear and post-nuclear fractions (figure 3.15 
- upper middle panel, lanes 3 and 4). These results suggests that PRH expression 
increases nuclear retention of TLE proteins, as well as influencing the hyper-
phosphorylation of TLE proteins. 
To investigate whether the interaction of PRH and TLE is required for nuclear 
retention of TLE by PRH, the PRH F32E mutant was expressed in K562 cells. 
Extracts were prepared and run as previously described. The Western blot was 
stained with antibodies to panTLE (figure 3.16 - top panel) and re-probed with an 
anti-Myc-tag (9E10) antibody (figure 3.16 - upper middle panel), or anti-Lamin A/C 
antibody (figure 3.16 - lower middle panel) or anti-Tubulin antibody (figure 3.16 - 
bottom panel). Again Lamin A/C  and Tubulin antibodies were used as fractionation 
and loading controls. As previously observed over-expression of exogenous wild-type 
PRH increases nuclear retention of endogenous TLE (figure 3.16 - top  panel, lane 5) 
compared to control cells (figure 3.16 - top panel, lane 4). However, over-expression 
of PRH F32E is unable to increase the nuclear retention of endogenous TLE (figure 
3.16 - top  panel, lane 6). PRH F32E also has no effect on the phosphorylation status 
of endogenous TLE (figure 3.16 - top panel, lanes 3 and 6) compared to control cells 
(figure 3.16 - top  panel, lanes 1 and 4). Since it has been shown that this mutation 
abolishes the interaction of PRH and TLE we conclude that interaction between PRH 
and TLE is required for the nuclear retention and hyper-phosphorylation of 
endogenous TLE. 
PRH nuclear localization is reported to be mediated by two arginine residues (188 
and 189) in the PRH homeodomain (figure 3.6), within the DNA recognition helix 
(Topisirovic et al., 2003a). In K562 cells this mutation does not influence PRH 
localization (Desjobert et al., 2009) but it does disrupt DNA binding (Unpublished 
observations, Jayaraman et al.). To determine whether DNA binding by PRH is 
       Chapter 3. TRANSCRIPTIONAL REGULATION OF VSP GENE EXPRESSION BY PRH AND TLE
126
required for nuclear retention of endogenous TLE, PRH N187A or PRH 
RR188,189AA were expressed in K562 cells. Extracts were prepared and run as 
previously described. The Western blot was as described above. Lamin A/C (figure 
3.17 - lower middle panel) and Tubulin (figure 3.17 - bottom panel) antibodies were 
used as fractionation and loading controls. The PRH N187A mutant was unable to 
hyper-phosphorylate or retain TLE to the nuclear fraction (figure 3.17 - top  panel, 
lane 7), in contrast to the wild-type PRH (figure 3.17 - top panel, lane 6). Similarly, 
PRH RR188,189AA was unable to hyper-phosphorylate or retain endogenous TLE in 
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Figure 3.16 - PRH requires the TLE binding motif for increased nuclear localization of 
TLE.
Un-transfected K562 cells and cells transfected with pMUG1 containing Myc–PRH and 
Myc–PRH F32E were fractionated into post-nuclear and nuclear extracts. Proteins were 
separated by  SDS-PAGE and transferred to an Immobilon P PVDF membrane. Proteins 
were stained with panTLE (top panel), Myc (upper middle panel), Lamin A/C (lower middle 
panel) and Tubulin (bottom panel). Data representative of three independent experiments.
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the nuclear fraction (figure 3.17 - top panel, lane 8). Since both the PRH N187A and 
PRH RR188,189AA mutants are found in the tightly associated nuclear compartment 
and are defective in DNA binding, it can be concluded that DNA binding by PRH is 
essential for both the nuclear retention and hyper-phosphorylation of endogenous 
TLE.
3.6 Discussion
Considering the importance of the VSP genes in normal physiological processes 
such as angiogenesis and their contribution to malignancy, it is surprising that so little 
is known about direct negative regulators of these genes. This chapter demonstrates 
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Figure 3.17 - PRH DNA binding capacity is required for increased nuclear localization 
of TLE.
Untransfected K562 cells and cells transfected with pMUG1 containing Myc–PRH or Myc–
PRH N187A or Myc-PRH RR188,189AA were fractionated into post-nuclear and nuclear 
extracts. Proteins were separated by  SDS-PAGE and transferred to an Immobilon P PVDF 
membrane. Proteins were stained with panTLE (top panel), Myc (upper middle panel), Lamin 
A/C (lower middle panel) and Tubulin (bottom panel). Data representative of three 
independent experiments.
a direct role for PRH and its co-repressor TLE, as negative regulators of Vegf, Vegfr1 
and Vegfr2. Transcriptional repression of the Vegf and Vegfr1 genes is observed 
when PRH is over-expressed, and knock-down of PRH de-represses Vegf, Vegfr1 
and Vegfr2 expression. Mutations to the DNA binding domain or mutation of the TLE 
interaction motif of PRH prevent transcriptional repression. PRH is known to interact 
with TLE via the Eh-1 motif in the N-terminal domain of PRH, and although this 
interaction has been shown to be significant for the transcriptional repression of an 
artificial promoter (Swingler et al., 2004), it was unknown whether the interaction was 
functional at an endogenous PRH target gene. However, this chapter shows that 
PRH and TLE co-operate to repress both Vegf and Vegfr1 gene expression, and PRH 
and TLE will also bind together at the promoters of these genes. Importantly, TLE is 
not recruited to these promoter regions by  the PRH F32E mutant, which does not 
interact with TLE, but does bind DNA. 
Over-expression of TLE-1 alone represses Vegf and Vegfr1 gene transcription. 
However, TLE-1 repression of Vegf and Vegfr1 is PRH dependent because no 
repression is observed when TLE-1 is expressed in PRH knock-down cells. This 
suggests that TLE maybe a limiting factor for further repression of Vegf and Vegfr1. 
To support this hypothesis over-expression of TLE-1 alone is weakly associated with 
the Vegfr1 promoter, suggesting that the exogenous TLE is binding to the 
endogenous PRH bound at the Vegfr1 promoter. Interestingly, TLE-1 association is 
not observed when Myc-PRH N187A is co-expressed with TLE-1. Immuno-
fluorescence staining of TLE-1 and PRH N187A, has shown that PRH N187A tightly 
binds TLE-1 and they congregate in large foci in the nucleus but not the chromatin 
compartment (Desjobert et al., 2009). Furthermore, the PRH N187A protein acts as a 
trans-dominant negative against wild-type PRH by diminishing available endogenous 
TLE (Desjobert et al., 2009). Therefore, it is likely  that over-expression of PRH 
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N187A sequesters TLE-1 in these foci. Also, TLE-1 is not associated with the Vegfr1 
promoter DNA when co-expressed with PRH F32E. Although, since PRH F32E binds 
to this region it may be that PRH F32E dilutes the amount of endogenous PRH that 
can bind TLE-1 at the Vegfr1 promoter. 
Over-expression of exogenous PRH induces nuclear retention of endogenous TLE 
proteins and this requires PRH DNA binding ability, suggesting that the function of 
PRH and probably the localization of PRH is important for the regulation of TLE. 
Interestingly, the ability of PRH to localize to the nucleus is not affected by mutating 
the DNA binding domain of PRH at residue 187 and so PRH localization to the 
nucleus alone is not sufficient for nuclear retention of TLE. It is most likely that DNA 
binding by  PRH and the association of other proteins, recruited during DNA binding, 
are vital for TLE nuclear retention. In ROS17/2.8 cells, exogenous expression of 
Hes-1 can induce hyper-phosphorylation and induce the nuclear retention of TLE 
(Nuthall et al., 2002a). This hyper-phosphorylation of TLE is CK2 dependent. 
Inhibition of CK2 in cells expressing Hes-1 reduces TLE nuclear retention and this 
CK2 hyper-phosphorylated form of TLE is associated with chromatin. Exogenous 
expression of PRH also induces hyper-phosphorylation of TLE (Desjobert et al., 
2009). Therefore it is likely that the post-translational modification of TLE is required 
for nuclear retention, and this occurs when TLE is recruited to the DNA by 
transcription factors, including PRH.
Out of the three genes, regulation of the Vegfr1 gene is the least characterized. As 
described in the introduction (see 1.4.2.1 and figure 1.7), Vegfr1 is positively 
regulated by HIF-2α and Ets-1 in response to hypoxia or EGF/FGF signalling. 
Interestingly, the binding sites for these proteins are within the first 100 bp  upstream 
of the TSS, with a second HRE around 1 kb upstream of the TSS. ChIP experiments 
show that PRH bound strongly around the TSS and to a region -1.2 kb upstream from 
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the TSS of the Vegfr1 gene. Therefore, it is likely that PRH induced transcriptional 
repression of Vegfr1 could be acting through blocking the binding of transcriptional 
activators. Previous work that showed that PRH only  weakly interacts with the region 
about the TSS of the Vegfr1 gene and more strongly at the -1.2kb  upstream region 
(Noy et al., 2010). This work also showed that when using Vegfr1 luciferase reporter 
constructs the activity of the promoter was elevated if the -700 to -1200 region was 
removed, suggesting endogenous PRH is associated with this region. However, the 
Vegfr1 promoter reporter constructs containing promoter fragments from -700 to 
+155 or -200 to +155 were strongly repressed by exogenous PRH. Strong 
association of endogenous PRH to the -1.2 kb  upstream region of the Vegfr1 
promoter would explain why Vegfr1 expression is elevated in PRH knock-down cells 
and further support ChIP results that demonstrate association of TLE with this region. 
It is now widely  accepted that large multimeric complexes of proteins are required to 
activate transcription, through the formation of the mediator and the RNAP II 
complexes (see 1.1 for details). Large multimeric complexes are also formed for 
transcriptional repression. The region -1 kb upstream of the TSS of the Vegfr1 gene 
contains a cluster of six ATTA or TAAT elements within 500 bp, and the central four 
core homeodomain binding sequences are clustered within 200 bp. The Goosecoid 
promoter is the only other promoter, that PRH represses, that has been analyzed in 
detail, and PRH binds to a region within this promoter that contains 5 ATTA sites 
within a 200 bp region (Williams et al., 2008). It is tempting to suggest that PRH 
regulates this region of the Vegfr1 promoter as an oligomer that wraps the promoter 
DNA around an octameric PRH core, in a similar fashion to that proposed for the 
Goosecoid gene. Using the approximate molecular weight of a PRH octamer, 
Williams et al calculated the length of DNA that could wrap around a PRH octamer 
and found it to be one and a half times the length of DNA a nucleosome wraps 
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around itself (Williams et al., 2008). Therefore a PRH octamer could wrap 
approximately  200 bp fragments of DNA around its circumference (Williams et al., 
2008). Thus suggesting that PRH could preferentially bind to clusters of ATTA DNA 
sequences, as found in the Vegfr1 promoter. Interestingly, there are other ATTA 
clusters in the Vegfr1 promoter including one around -5.6 kb upstream of the TSS, a 
region PRH also binds. 
TLE co-represses Vegfr1 expression, and is capable of forming oligomeric structures 
that are critical for TLE induced transcriptional repression (Chen et al., 1998). TLE 
recruits further factors such as HDACs that can alter and compact the DNA (Chen et 
al., 1999). Consequently, interaction of PRH and TLE would multiply  the depletion 
attraction forces and could contribute to the spreading of TLE (Martinez and Arnosti, 
2008) or possibly facilitating the cooperative binding of PRH to less favourable DNA 
binding sequences. Therefore, PRH repression of the Vegfr1 gene is likely  to be one 
of three potential models for repression (figure 3.18). PRH could binds to single PRH 
binding sites in the promoter and recruit co-repressors to repress transcription. 
Repression would be realized through inhibiting the binding of other transcription 
factors that activate gene expression. In this model PRH would inhibit the 
accessibility of transcription factor binding sites through recruitment of TLE and 
HDACs that increase chromatin compaction. In the second model, PRH could bind to 
clustered core ATTA sites as an oligomer, thus condensing local regions of chromatin 
by wrapping DNA (Soufi and Jayaraman, 2008). In addition PRH could recruit co-
repressors and HDACs to further condense this local structure, again inhibiting 
transcription factor binding sites but over a larger area. This could result in looping of 
DNA, as PRH oligomers bound at distant promoter regions (1-2 kb  away from each 
other), which contributes to condense the higher order chromatin structure. 
Importantly, there would still be accessible promoter DNA within the looped regions. 
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Figure 3.18 - Proposed models for PRH and TLE transcriptional repression.
The diagram illustrates three models for PRH and TLE gene repression. [1] PRH binds to 
single sites within the promoter of the target gene, PRH recruits co-repressors and inhibits 
binding of other transcription factors where PRH is bound. [2] PRH binds as an oligomeric 
complex to the promoter and recruits co-repressors which act together to condense 
chromatin around the binding sites. However, there are loops of DNA that are still accessible 
to other transcription factors but large areas surrounding the PRH binding site are 
inaccessible. [3] PRH binds as an oligomeric complex to the promoter and recruits co-
repressors which act together to condense chromatin and spread condensing large areas of 
DNA even in the absence of specific PRH binding sites.
In the third model, PRH binds to multiple binding sites as an oligomer and wraps the 
DNA around its octameric core. Oligomerization of PRH octamers condenses 
chromatin structure and facilitates cooperative binding to low affinity PRH binding 
sites, allowing PRH to spread along the chromatin fiber. PRH also recruits co-
repressors, which increases the compaction further condensing chromatin structure, 
so the entire promoter is virtually inaccessible for transcription factor binding. 
VEGF and the VEGF receptors, VEGFR1 and VEGFR2, are essential survival factors 
for haematopoietic stem cells (Gerber et al., 2002), and control proliferation and 
survival in endothelial cells (Hoeben et al., 2004). Intriguingly, as shown in this 
chapter, PRH transcriptionally represses all three genes coordinately. Therefore, 
manipulation of PRH activity will directly influence the VSP and its downstream 
targets, potentially controlling cell survival or proliferation. The implications of this 
regulation will not be discussed here as the following chapter will investigate the 
importance of PRH regulation of the VSP genes on cell growth and survival.
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VEGF:VEGF receptor axis controls cell survival
4 VEGF:VEGF receptor axis controls cell 
survival.
4.1 Introduction
The role of PRH on the regulation of cell growth, differentiation and survival has pre-
dominantly been investigated during development. PRH controls the differentiation 
and proliferation of blast colony-forming cells (BL-CFC) produced from embryonic 
stem cell-derived embryoid bodies, BL-CFC  have similar characteristics to the 
haemangioblast present in the early embryo (Kubo et al., 2005; Guo et al., 2003). Yet 
the influence of PRH on the adult system is less well characterized and the role of 
PRH on the proliferation of the myeloid haematopoietic compartment is not well 
understood. This chapter will characterize the role of PRH in growth and survival of 
human haematopoietic cells of myeloid lineage through perturbing the expression 
level of PRH. In addition the contribution of VEGF signalling to growth will be 
assessed using drugs to manipulate VEGF signalling and by over-expressing 
components of the VSP.
4.2 PRH inhibits cell growth
To investigate the effect of PRH expression on cell growth, K562 cells were 
transfected with 5µg pMUG1 Myc-PRH or 5µg pMUG1 (as a control). Cells were 
counted, using trypan blue exclusion (as described in section 2.4.4 of the Materials 
and Methods chapter), at 24, 48 and 72 hours post-transfection. After 72 hours there 
is a significant decrease in cell growth for the PRH over-expressed cells (figure 4.1 
[A] - lane 2) compared to the control cells (figure 4.1 [A] - lane 1). This data shows 
that PRH is decreasing the growth of K562 cells.
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To further investigate the effect of PRH on cell growth, K562 cells were transfected 
with pEGFP in addition to pMUG1 Myc-PRH or pMUG1 (control). The expression of 
EGFP was observed using fluorescence assisted cell sorting (FACS) at 24, 48 and 
72 hours post transfection. The number of EGFP expressing cells at 24 hours was 
set as 100% for both populations of cells. Both control and PRH expressing cells had 
equivalent transfection efficiencies. Figure 4.1 [B] shows that cells expressing PRH 
have a strong reduction in EGFP expression over 72 hours and express 50% less 
EGFP by 72 hours post-transfection. However, control cells maintain 90% expression 
of EGFP over 72 hours after transfection (figure 4.1 [B]). This data indicates that PRH 
expression may be altering cell proliferation or survival.
To determine whether PRH inhibits cell cycle checkpoint progression, EGFP and 
PRH expressing cells or EGFP control cells were permeabilized and stained with 
propidium iodide, 24 hours post-transfection, and analyzed using FACS. Propidium 
iodide stains the DNA and can be used to analyze the proportion of cells in each 
phase of the cell cycle. The amount of DNA in a cell doubles during S phase, 
therefore the amount of DNA in the cell indicates which phase of the cell cycle the 
cell is in. In FACS cells are first identified by  their morphology, using forward scatter 
(FSC) and side scatter (SSC) parameters, and the DNA content of cells is then 
analyzed by the intensity  of propidium iodide staining (FL3). Figure 4.2 shows a 
representative set of data for cells expressing PRH and control cells. There is little 
difference in the distribution of cells throughout the cell cycle in PRH transfected cells 
compared to control cells. Thus PRH does not appear to be influencing cell cycle 
progression.
To determine whether PRH alters cell survival by increasing the amount of apoptosis, 
the PRH transfected and control cells were co-stained with an Annexin V APC 
antibody and propidium iodide, 24 hours post-transfection and analyzed using FACS. 
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Figure 4.1 - The effect of PRH on cell number.
[A] Cells transfected with pMUG1 (lane 1) or pMUG1-Myc-PRH (lane 2). Total number of 
cells, counted using trypan blue exclusion, 72 hours after transfection. Values are means 
and standard deviation (n=3). [B] Cells transfected with pEGFP alone or pEGFP and 
pMUG1-Myc-PRH. The percentage of EGFP-expressing cells 24 h post-transfection was set 
as 100%, and the change from this was tracked over 72 h. Values are means and standard 
deviation (n = 3).
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Figure 4.2 - Cell cycle for K562 cells transfected with PRH.
Cells transfected with pEGFP and pMUG1 or pMUG1 Myc-PRH. 24 h post-transfection cells 
were treated with Igepal and propidium iodide and analyzed by flow cytometry. Propidium 
iodide staining determines the phase of the cell cycle. One representative histogram of 3 is 
shown.
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In this case the cells were identified on their morphology (FSC  vs SSC) and by 
expression of EGFP (FL1). EGFP positive cells were sorted into cells that stain with 
propidium iodide alone (FL3), Annexin V APC alone (FL4), or stain with both. Early 
during apoptosis phosphatidylserine is translocated from the inner plasma membrane 
to the outer plasma membrane of the cell. The Annexin V protein has a strong affinity 
for phosphatidylserine, therefore cells in early apoptosis display Annexin V on the 
surface of the cell. This allows the use of Annexin V as a cell membrane marker for 
apoptotic cell death. Whereas cells that are dying necrotically, stain with propidium 
iodide and do not display Annexin V on their cell surface. This produces four distinct 
cell populations; live cells (propidium iodide and Annexin V APC negative cells), cells 
undergoing necrosis (propidium iodide positive, Annexin V APC negative cells), cells 
in early apoptosis (propidium iodide negative, Annexin V APC positive cells), and 
cells in late apoptosis (propidium iodide positive, Annexin V APC positive cells). 
Figure 4.3 shows a representative set of data for cells expressing PRH (lower panel) 
and control cells (upper panel). The PRH expressing cells have a significant increase 
in early  and late apoptotic cells, 18.2% and 17.8% respectively (figure 4.3 - lower 
panel), compared to the control cells, 14.7% and 2.1% respectively (figure 4.3 - upper 
panel). There is a reduction in the number of live cells for the PRH expressing cells 
(figure 4.3 - lower panel) compared to the control cells(figure 4.3 - upper panel). 
There is little difference in the level of necrosis between PRH expressing (figure 4.3 - 
lower panel) and control cells (figure 4.3 - upper panel). It can be concluded that 
elevated PRH expression in cells increases cell apoptosis rather than reducing cell 
proliferation.
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Figure 4.3 - The effect of PRH on apoptosis. 
EGFP and empty  vector (upper panel) or EGFP and Myc-PRH (lower panel) expressing 
cells were dual stained with propidium iodide (PI)/Annexin V APC antibody  (AV) and 
analyzed by  flow cytometry. The dot plot shows the percentages of live cells (PI- AV-), 
necrotic cells (PI+), early apoptotic cells (AV+), and late apoptotic cells (AV+ PI+) after 
gating for EGFP positive cells. One representative dot plot of 3 is shown.
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4.3 DNA binding and interaction with TLE are required for PRH 
dependent for cell apoptosis.
To determine whether transcriptional regulation by PRH has a role in regulating cell 
growth, cells co-expressing EGFP and PRH or EGFP with either PRH F32E or PRH 
LL23,24AA or PRH N187A or empty vector were analyzed using FACS at 24, 48 and 
72 hour time points. In each case the percentage of EGFP expression at 24 hours 
was calculated and set as 100%. All transfections had equivalent transfection 
efficiencies. The number of cells expressing EGFP at 48 and 72 hours was 
calculated relative to the 24 hour time point. Figure 4.4 [A] compares the percentage 
of cells expressing EGFP at 72 hours in the absence or prescence of PRH. As 
previously shown in figure 4.1, the percentage of cells expressing EGFP in the PRH 
transfected cell population (figure 4.4 [A] - lane 2) is approximately half that observed 
for the control cells (figure 4.4 [A] - lane 1). In contrast expression of PRH N187A 
(figure 4.4 [A] - lane 5) has no effect on the percentage of cells expressing EGFP. 
Similarly expression of PRH F32E (figure 4.4 [A] - lane 3) also has no effect on the 
percentage of EGFP positive cells. Interestingly, expression of PRH LL23,24AA 
(figure 4.4 [A] - lane 4) results in 40% fewer EGFP positive cells than the control cells 
(figure 4.4 [A] - lane 1). These data suggest that the interaction of PRH with TLE and 
with DNA are important requirements for the regulation of cell growth. They also 
suggest that the interaction with eIF4E has a relatively  minor role in the regulation of 
cell growth in this case.
To determine whether transcriptional regulation by PRH plays a role in inducing 
apoptosis, EGFP and PRH transfected or control EGFP cells were stained with 
propidium iodide and Annexin V APC antibody 24 hours after transfection and 
analyzed by FACS. As before transfected cells were identified by morphology and 
expression of EGFP. EGFP positive cells were isolated and examined for apoptosis 
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Figure 4.4 - Characteristics of PRH required to induce apoptosis.
[A] Percentage of EGFP positive cells in co-transfection experiments. K562 cells were 
transfected with pEGFP and either pMUG1 (Control) or pMUG1 vectors expressing PRH 
(PRH), PRH F32E (F32E), PRH LL23,24AA (LL23,24AA), or PRH N187A (N187A), and the 
percentage of EGFP positive cells was measured 72 hours post-transfection. Values are 
means and SD (n = 3). [B] K562 cells were transfected as for [A] and dual stained with PI/
AV antibody  24 hours post-transfection for analysis by  flow cytometry. Total apoptosis shown 
(n = 3).
[A]
0
25
50
75
100
P
er
ce
nt
ag
e 
of
 t
ra
ns
fe
ct
ed
 c
el
ls
C
on
tr
ol
P
R
H
F3
2E
LL
23
,2
4A
A
N
18
7A
1 2 3 4 5
[B]
0
5
10
15
20
P
er
ce
nt
ag
e 
ap
op
to
tic
 c
el
ls
C
on
tr
ol
P
R
H
F3
2E
LL
23
,2
4A
A
N
18
7A
1 2 3 4 5
or necrotic cell death by staining with propidium iodide and Annexin V APC as 
described above. As observed previously cells expressing PRH (figure 4.4 [B] - lane 
2) have approximately  twice as many apoptotic cells (early and late) compared to the 
control cells (figure 4.4 [B] - lane 1). In contrast cells expressing PRH N187A (figure 
4.4 [B] - lane 1), show no change in the total number of apoptotic cells compared to 
the control cells (figure 4.4 [B] - lane 5). A small increase in cells undergoing 
apoptosis is observed for cells expressing PRH F32E (figure 4.4 [B] - lane 3) 
compared to control cells (figure 4.4 [B] - lane 1), however, there is substantially less 
apoptosis than the wild-type PRH cells (figure 4.4 [B] - lane 2). Cells expressing PRH 
LL23,24AA (figure 4.4 [B] - lane 4) have more cells in apoptosis than the control cells 
(figure 4.4 [B] - lane 1), although still less than the wild-type PRH cells (figure 4.4 [B] - 
lane 2). These results show that mutations that block DNA binding by PRH and 
perturb the recruitment of the PRH co-repressor dramatically reduces the pro-
apoptotic effects of PRH. Whereas mutations that block post-translational regulation 
by PRH have a relatively  minor effect on the pro-apoptotic function of PRH. This 
further supports the hypothesis PRH induces apoptosis through transcriptional 
repression of genes that require the PRH-TLE interaction for repression.
4.4 Knockdown of PRH increases cell survival
Expression of VEGF and its receptors are associated with or contribute to several 
haematopoietic malignancies (Dias et al., 2000; Dias et al., 2002). Since both VEGF 
ligand and its receptors are up-regulated in the PRH knockdown cells, it is expected 
that the PRH knockdown cells will either proliferate faster or have a survival 
advantage compared to the control cells. 
To investigate the role of endogenous PRH on cell growth and survival, PRH was 
knocked down using Prh specific shRNAs. 5x106 cells were transfected with a control 
shRNA or PRH shRNA 1+2 (as described in Chapter 3). Transfected cells were 
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Figure 4.5 - Knock-down of PRH increases cellular growth.
[A] Cumulative growth curves for K562 cells transfected with control shRNA (CON) or PRH 
shRNA 1+2 (PRH KD). Cells were selected with puromycin 24 hours post-transfection. After 
7 days, 3 x106 cells of each cell type were plated out and counted over 11 days. Values are 
means and SD (n = 3). [B] Graph of the doubling time for K562 cells transfected with SVC 
shRNA or PRH shRNA (1+2) (grey bar). Values are means and SD (n = 3). 
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selected using 1µg/ml puromycin, 24 hours post-transfection. After 7 days of 
puromycin selection the cells were diluted to 3x105 cells/ml and counted every 24 
hours. The cells were diluted to 3x105 cells/ml every day or 2 days as required. The 
cumulative growth was then calculated as described in section 2.4.4 of the Materials 
and Methods. As shown in figure 4.5 [A] PRH knockdown (PRH KD) cells grow 
substantially faster than control (CON) cells over 11 days, with approximately  2-3 
times the cumulative number of cells by day 11. From these data the mean doubling 
time for each of the cell populations was calculated. Figure 4.5 [B] shows that the 
doubling time for the PRH knockdown cells is approximately 5 hours less than the 
control cells. 
To further investigate this growth difference between PRH knockdown cells and 
control cells, the cell cycle profile was analyzed for each population. The populations 
of cells were permeablized using 1% Igepal and the DNA was stained with 50µg/ml 
propidium iodide  before analyzing by FACS. Viable cells were gated according to 
their morphology (FSC vs SSC) and were analyzed by the intensity of propidium 
iodide stain (FL3), which reflects the stage the cells are at in the cell cycle. The PRH 
knockdown cells and control cells have the same proportion of cells in G1 and S 
phase (figure 4.6), 43% and 17.5% respectively. However, in the PRH knockdown 
population of cells there is a small but significantly (p=0.003) increase of cells in the 
G2/M phase with an average of 28.5% compared to 23.5% for the control cells 
population (figure 4.6). There is also a slight but significant (p=0.008) decrease of 
cells in the Sub G0/G1 phase for the PRH knockdown population (6% of the total 
cells) compared to the control population (9.5% of the total cells)(figure 4.6). Results 
were taken from three independent PRH knockdown experiments. A reduction in the 
sub  G0/G1 phase of the cell cycle indicates that there are less cells that are 
undergoing apoptosis. The increase of cells in the G2/M phase of the cell cycle could 
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suggest that PRH plays a role in the G2 cell cycle check point. As there is no change 
in the G1 and S  phases of the cell cycle PRH does not appear to have any effect on 
DNA replication.  
To investigate whether the PRH knockdown cells cycle through the cell cycle faster 
than the control cells, PRH knockdown and control cells were treated with CFSE. 
CFSE is an inter-membrane fluorescence collating agent; the intensity of the 
fluorescence emitted is proportional to the cell number and reduces through each cell 
division. Therefore, if the PRH knockdown cells have an increased rate of cycling 
through the cell cycle there will be a distinct decrease in fluorescence in the PRH 
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Figure 4.6 - Cell cycle profile for PRH knock-down cells.
Percentage distribution of cells in each stage of the cell cycle. Propidium Iodide staining of 
K562 cells transfected with control shRNA (CON) or PRH shRNA 1+2 (PRH KD) is shown (n 
= 3).
p<0.003
p<0.008
knockdown population compared to the control cells. PRH knockdown and control 
cells were established as previously described above. After treatment with CFSE the 
cells were grown for a further 5 days. On days 1 and 5 a sample of the cell population 
was analyzed by FACS. On day 1 both the control cells (figure 4.7 [A] - dashed black 
line) and PRH knockdown cells (figure 4.7 [A] - dashed blue line) had more than 98% 
of the population in a single peak for the 1st generation of cells stained with CFSE. 
By day 5 the population of cells were predominantly spread out between the 3rd, 4th 
and 5th daughter cell populations (figure 4.7 [A] - black and blue solid lines). The PRH 
knockdown cells contain approximately 10% more cells in the 5th daughter cell 
population than the control cells (figure 4.7 [B]). This suggests that there is little 
difference in the rate of cycling through the cell cycle. Thus the increased growth of 
PRH knockdown cells appears to be through a decrease in apoptosis.
To confirm that apoptosis is reduced in PRH knockdown cells, PRH knockdown and 
control cells were stained with propidium iodide and Annexin V  APC antibody and 
analyzed by FACS. Viable cells were sorted for staining of propidium iodide and 
Annexin V APC. Figure 4.8 shows a representative set of data from three 
independent experiments for PRH knockdown cells (lower panel) and control cells 
(upper panel). The PRH knockdown cells have a reduction in early  and late apoptotic 
cells, 14.1% and 1.4% respectively (figure 4.8 - lower panel), compared to the control 
cells, 17.5% and 3% respectively (figure 4.8 - upper panel). There is also an increase 
in the number of live cells in the PRH knockdown population (figure 4.8 - lower panel) 
compared to the control population (figure 4.8 - upper panel). There is little difference 
in the level of necrosis between PRH knockdown cells (figure 4.8 - lower panel) and 
control cells (figure 4.8 - upper panel). This 25% reduction of total apoptosis in PRH 
knockdown cells very likely contributes considerably to the growth of these cells. 
These data confirm that PRH controls cell growth by influencing apoptosis.
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Figure 4.7 - The rate of proliferation of PRH knock-down cells.
[A] CFSE staining of control shRNA (CON) or PRH shRNA 1+2 (PRH KD) at day  1 (right 
hand peak) and day 5 (left hand peak). Representative histogram of 3 independent 
experiments. [B] Graph of the percentage of K562 cells transfected with SVC shRNA (white 
bars) or PRH shRNA (1+2) (grey bar) in each of the daughter cell populations. Values are 
means and SD (n = 3). 
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Figure 4.8 - The level of PRH knock-down cells undergoing apoptosis.
PRH knockdown (lower panel) and control cells (upper panel) were dual stained with 
propidium iodide (PI)/Annexin V APC antibody (AV) and analyzed by flow  cytometry. The dot 
plot shows the percentages of live cells (PI- AV-), necrotic cells (PI+), early  apoptotic cells 
(AV+), and late apoptotic cells (AV+ PI+). One representative dot plot of 3 is shown.
4.5 Cell survival induced by VEGF signalling is dependent on PRH 
levels
VEGF paracrine signalling is essential for proliferation and survival of endothelial 
progenitors (Zachary, 2003). Autocrine VEGF signalling through its receptors is 
known to be an essential mechanism for cell survival in haematopoietic progenitors 
(Gerber et al., 2002; Katoh et al., 1995; Katoh et al., 1998; Dias et al., 2002), and 
more recently has also been shown to be involved in regulating proliferation and 
survival in endothelial cells (Bates et al., 2003; Gee et al., 2005).
To investigate the role of VEGF signalling in haematopoietic progenitor cell survival, 
all three VSP genes, VEGF, VEGFR1 and VEGFR2 were co-expressed in K562 cells 
either with EGFP or exogenous EGFP-PRH. As control samples, cells expressing 
EGFP alone or EGFP-PRH alone were used. Cells were then assessed for cell death 
using Annexin V staining and propidium iodide as outlined above. As before viable 
transfected cells were identified according to their morphology  and expression of 
EGFP. EGFP positive cells were then examined for propidium iodide and Annexin V 
APC staining. In cells expressing VEGF, VEGFR1, and VEGFR2 (figure 4.9 [A] - lane 
2) there is a significant reduction (p=0.05) in the level of total apoptosis (early  and 
late apoptosis) compared to the control cells (figure 4.9 [A] - lane 1). As previously 
observed, cells expressing PRH alone (figure 4.9 [A] - lane 3) are more apoptotic 
than control cells (figure 4.9 [A] - lane 1). However, cells expressing PRH together 
with VEGF, VEGFR1 and VEGFR2 (figure 4.9 [A] - lane 4) have significantly 
(p=0.005) reduced apoptosis in comparison to cells expressing PRH alone (figure 4.9 
[A] - lane 3). This suggests that increased expression of genes in the VEGF 
signalling pathway is sufficient to induce survival signalling and block apoptosis even 
in the presence of PRH.
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Figure 4.9 - Contribution of VSP to PRH induced apoptosis.
[A] K562 cells transfected with 3µg pEGFP (white bars) or pEGFP-PRH (grey bars), with or 
without 3 µg of each of the vectors expressing VEGF, VEGFR-1, and VEGFR-2 (bars 2, and 
4). 24 hours post-transfection the cells were dual stained with PI/AV antibody  for analysis by 
flow cytometry. The graph shows the means and SD (n = 3).[B] K562 cells transfected with 
SVC shRNA (CON - white bars) or PRH shRNA 1+2 (PRH KD - grey bars) were 
retransfected with 3 µg of each of the vectors expressing VEGF, VEGFR-1, and VEGFR-2 
(bars 2, and 4). Cells were analyzed as in panel [A]. The graph shows the means and SD (n 
= 3).
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To determine whether increased expression of VEGF, VEGFR1 and VEGFR2 are 
important for cell survival in the absence of PRH; VEGF, VEGFR1 and VEGFR2 were 
expressed in PRH knockdown and control cells. Propidium iodide and Annexin V 
APC staining was performed and cell death was analyzed by FACS as previously 
described. Control cells expressing VEGF, VEGFR1 and VEGFR2 (figure 4.9 [B] - 
lane 2) have a significant (p=0.005) decrease in total cell apoptosis compared to 
control cells alone (figure 4.9 [B] - lane 1). PRH knockdown cells (figure 4.9 [B] - lane 
3) have reduced apoptosis compared to the control cells (figure 4.9 [B] - lane 1). 
However, PRH knockdown cells co-expressing VEGF, VEGFR1 and VEGFR2 (figure 
4.9 [B] - lane 4) show no change in the level of apoptosis compared to the PRH 
knockdown cells alone (figure 4.9 [B] - lane 3). Thus, VEGF and its receptors are only 
able to counteract apoptosis caused by PRH in cells that express PRH. This strongly 
suggests that down-regulation of VSP gene expression and VEGF signalling 
mediates PRH induced apoptosis in K562 cells.
To confirm that VEGF signalling in the PRH knockdown cells is important for cell 
survival, PRH knockdown and control cells were treated with exogenous VEGF165 
protein or an equivalent volume of DMSO. Cells were seeded into 96 well plates and 
treated with 50 ng/ml VEGF165 protein or DMSO and grown for 72 hours. Cell 
numbers were measured using a 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) assay, a colorimetric assay for viable cells that measures the activity 
of mitochondrial reductase enzymes which reduce MTT to give a purple formazan 
dye. Reactions were performed in quadruplicate and readings were taken at 0 hours 
to ensure equal loading of cells. Data shown is the mean and standard error from a 
set of four from a single experiment and is representative of five independent 
experiments. As expected, the PRH knockdown population (figure 4.10 [A] - lane 3) 
have significantly more cells (p=0.01) than the control cell population (figure 4.10 [A] - 
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Figure 4.10 - Role of VEGF signalling in PRH knock-down cell growth. 
[A] K562 cells were transfected with SVC shRNA (CON - white bars) or PRH shRNA 1+2 
(PRH KD - grey  bars) and then incubated with 50 ng/ml VEGF (bars 2 and 4) or an equal 
volume of DMSO  (bars 1 and 3) for 72 hours. An MTT assay  was then used to calculate cell 
numbers. Values are means and SD (n = 4). [B] As for panel A except that cells were 
incubated with 50 µg/ml anti-VEGF antibody. Values are means and SD (n = 4). Data 
representative of five independent experiments.
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lane 1). Untreated control cells (figure 4.10 [A] - lane 1), and control cells treated with 
VEGF165 (figure 4.10 [A] - lane 2) have an equal number of cells. However, the PRH 
knockdown cells treated with VEGF165 (figure 4.10 [A] - lane 4) have significantly 
more cells (p=0.02) than the PRH knockdown untreated population (figure 4.10 [A] - 
lane 3). This demonstrates that VEGF can stimulate cell growth or survival better in 
the PRH knockdown cells than the control cells and suggests that there is increased 
VEGF signalling in the PRH knockdown cells.
To further investigate the importance of VEGF signalling in the PRH knockdown cells, 
PRH knockdown and control cells were established as previously described, and 
treated with 50µg/ml of a VEGF specific antibody  or an equivalent volume of DMSO. 
Cell numbers were calculated using an MTT assay after 72 hours of treatment. Data 
shown is the mean and standard error from a single experiment performed in 
quadruplicate and is representative of five independent experiments. As observed in 
figure 4.10 [A] there are more PRH knockdown cells (lane 3) than control cells (lane 
1). Treating PRH knockdown cells with an anti-VEGF antibody (figure 4.10 [B] - lane 
4) reduces cell growth significantly (p<0.0001) compared to untreated PRH 
knockdown cells (figure 4.10 [B] - lane 3) and negates the growth advantage of the 
PRH knockdown cells relative to control cells (figure 4.10 [B] - lane 2). Clearly PRH 
knockdown cells respond more dramatically to VEGF antibodies than control cells 
suggesting that de-repression of Vegf in PRH knockdown cells contributes to cell 
survival.  
To investigate the role of the VEGF receptors in PRH knockdown cell survival, PRH 
knockdown and control cells were treated with either DMSO or 2mM Sutent 
(SU11248); a receptor tyrosine kinase inhibitor which inhibits VEGFR2 signalling 
(Sun et al., 2003) and potentially VEGFR1 signalling (Barbarroja et al., 2009), 
PDGFR (Sun et al., 2003; Abrams et al., 2003), KIT(Abrams et al., 2003), and FLT3 
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signalling (Deeks and Keating, 2006). Cell numbers were calculated using an MTT 
assay after 72 hours of treatment. Data shown is the mean and standard error from a 
single experiment performed in quadruplicate and is representative of three 
independent experiments. PRH knockdown cells treated with Sutent (figure 4.11 [A] - 
lane 4) have significantly (p=0.01) reduced cell growth compared to untreated PRH 
knockdown cells (figure 4.11 [A] - lane 3), whereas Sutent has no effect on control 
cells (figure 4.11 [A] - lane 1 and 2). Treating PRH knockdown cells with Sutent 
(figure 4.11 [A] - lane 4) also reduces the growth advantage of the PRH knockdown 
cells compared to the control cells (figure 4.11 [A] - lane 2). This evidence suggests 
that signalling through tyrosine kinase receptors, including the VEGF receptors is 
important for cell survival and that de-repression of Vegfr1 and Vegfr2 in PRH 
knockdown cells contributes to the observed increase in cell growth.
To distinguish between the effect of VEGF receptor signalling and the effect of other 
receptor tyrosine kinases, control and PRH knockdown cells were also treated with 
2mM Sugen (SU1498), a receptor tyrosine kinase inhibitor, which specifically inhibits 
VEGFR2 receptor signalling (Strawn et al., 1996), or an equivalent volume of DMSO. 
As described above the cell numbers were calculated using an MTT assay after 72 
hours of treatment. Data shown is the mean and standard error from a single 
experiment performed in quadruplicate and is representative of three independent 
experiments. PRH knockdown cells treated with Sugen (figure 4.11 [B] - lane 4) have 
significantly (p=0.0001) reduced cell growth compared to untreated PRH knockdown 
cells (figure 4.11 [B] - lane 3). Treating PRH knockdown cells with Sugen (figure 4.11 
[B] - lane 4) also removes the growth advantage of PRH knockdown cells compared 
to the control cells (figure 4.11 [B] - lane 2). This suggests that VEGF signalling 
through VEGFR2 is important for cell survival and that de-repression of Vegfr2 in 
PRH knockdown cells is responsible for increased cell growth.
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Figure 4.11 - The role of VEGF receptor signalling in PRH knock-down cell growth.
[A] K562 cells were transfected with SVC shRNA (CON - white bars) or PRH shRNA 1+2 
(PRH KD - grey  bars) and then incubated with 2 mM SU11248 (bars 2 and 4) or an equal 
volume of DMSO  (bars 1 and 3) for 72 hours. An MTT assay  was then used to calculate cell 
numbers. Values are means and SD (n = 4). [B] As for panel A except that cells were 
incubated with 2 mM SU1498 (bars 2 and 4). Values are means and SD (n = 4). Data 
representative of three independent experiments.
[B]
0
4500
9000
13500
18000
N
um
b
er
 o
f c
el
ls
-- + +
CON PRH KD
Sugen
1 2 3 4
p=0.0001
[A]
0
4500
9000
13500
18000
N
um
b
er
 o
f c
el
ls
-- + +
CON PRH KD
Sutent
1 2 3 4
p=0.01
4.6 Discussion
As demonstrated in this chapter PRH is a regulator of cell survival. Increased survival 
is observed in PRH knock-down cells, and over-expression of PRH induces 
apoptosis. PRH regulation of cell survival has not previously  been described. 
However, inhibition of cell proliferation by PRH has been described in the myeloid 
compartment (Jayaraman et al., 2000; Topisirovic et al., 2003b). In U937 cells, a 
myeloid cell line displaying monocytic characteristics, PRH induces G1 cell cycle 
arrest by inhibiting eIF4E mRNA recruitment of cyclin D1 to the ribosome (Topisirovic 
et al., 2003a). PRH has also been shown to inhibit cell transformation by E26 Myb-
Ets expressing viruses infected into multi-potential progenitors (MEPs) (Jayaraman et 
al., 2000). Therefore, an important question is why does PRH induce apoptosis in 
K562 cells, yet PRH inhibits cell proliferation in other myeloid-derived cell lines and 
model systems. It is likely  that the role of PRH is dependent on its cellular 
environment. K562 cells contain the Philadelphia chromosome and the resulting 
BCR-ABL fusion protein activates a variety of signalling pathways that activate cell 
cycle controlling proteins (Kurzrock et al., 2003). For example, activation of the Ras 
pathway, leads to MEK/ERK activation, resulting in increased cyclin D1 expression, 
CDK2-cyclin E activation and rapid G1 phase progression (Keenan et al., 2001; Lents 
et al., 2002; Phillips-Mason et al., 2000). Over-expression of a mutant of PRH (PRH 
LL23,24AA), which disrupts the interaction with eIF4E, has little effect on cell growth 
and apoptosis compared to wild-type PRH in K562 cells. This suggests that 
translational repression of cyclin D1 mRNA transport by PRH, may only  have a small 
effect in K562 cells because of the constitutive activation of the Ras pathway. PRH 
knock-down cells proliferate slightly faster than control cells but this effect is not as 
significant as the regulation of survival in these cells. It is possible that this slight 
increase in proliferation is because a decrease in PRH results in increased eIF4E 
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mRNA transport of cyclinD1. The key characteristics of PRH in K562 cells is the 
ability  of PRH to bind DNA and interact with the co-repressor TLE. These features 
significantly reduce PRH induced apoptosis. Therefore transcriptional regulation by 
PRH is critical for PRH regulation of K562 cell survival. 
This chapter illustrates the role of VEGF signalling in the control of myeloid cell 
survival. Increased cell survival through VEGF signalling was shown here using over-
expression of VEGF, VEGFR1 and VEGFR2 in K562 cells. This supports previously 
published data demonstrating VEGF autocrine signalling induces survival of 
haematopoietic stem cells (Gerber et al., 2002). Also, work carried out by Ruan et al, 
showed that VEGF expression in K562 cells is vital for cell growth in culture and solid 
tumour formation in nude mice (Ruan et al., 2004). In addition PRH antagonizes 
VEGF survival signalling through transcriptional regulation. This was demonstrated in 
cells treated with a VEGF neutralizing antibody or VEGF receptor inhibitors, where 
PRH knockdown cells were more sensitive to depletion of VEGF or inhibition of 
VEGF receptor signalling than control cells. In addition, over-expression of VEGF and 
its receptors from PRH-independent promoters antagonizes the effects of PRH over-
expression. One explanation of these results is that PRH knockdown cells are reliant 
on the VSP for their increased survival. In support of this idea is data showing that 
PRH knockdown cells have enhanced survival when grown in the presence of 
exogenous VEGF, whereas control cells are unresponsive to exogenous VEGF.
In this chapter over-expression of both VEGFR1 and VEGFR2 were found to 
increase survival of K562 cells. The role of VEGFR1 induced signalling versus 
VEGFR2 induced signalling is controversial in endothelial cells, where it has been 
suggested that VEGFR1 may only act as a decoy receptor (Hiratsuka et al., 1998). 
However, in the haematopoietic compartment VEGFR1 signalling is vital for 
macrophage migration (Hiratsuka et al., 1998), as well as monocyte migration 
                                     Chapter 4. VEGF:VEGF RECEPTOR AXIS CONTROLS AML CELL SURVIVAL
159
(Barleon et al., 1996). In addition both VEGFR1 and VEGFR2 are able to promote 
cell survival through autocrine signalling in haematopoietic stem cells (Gerber et al., 
2002). A recent study treated AML patient samples and AML cell lines with a VEGF 
receptor inhibitor, with specificity  for both VEGFR1 and VEGFR2, and observed 
increased apoptosis (Barbarroja et al., 2009), similar to evidence shown in this 
chapter. Also, Barbarroja et al show that combined VEGFR inhibitor and 
chemotherapy has a better therapeutic efficacy  than chemotherapy alone (Barbarroja 
et al., 2009), demonstrating the importance of VEGF signalling for haematopoietic 
cell survival. In this chapter we used a low specificity small molecule receptor 
tyrosine kinase inhibitor, SU11248, and a VEGFR2 specific inhibitor, SU1498, which 
reduced PRH knock-down cell growth significantly. This data suggests that VEGFR2 
signalling is important for K562 cell survival. However, it is important to note SU1498 
was selected for specificity against VEGFR2 and checked for PDGF specificity, but 
its activity against VEGFR1 has not been determined (Strawn et al., 1996). 
Therefore, it cannot be ruled out that VEGFR1 may also be inhibited by this 
compound. Both VEGFR1 and VEGFR2 are thought to activate several similar 
pathways including the Akt survival pathway, therefore it is likely  there are 
redundancies between these receptors and they both contribute to PRH knock-down 
cell survival signalling.
As a transcriptional regulator of VSP genes, which control cell survival, it is tempting 
to suggest a role for PRH in myeloid-derived leukaemic disease. It is known that 
dysregulation of PRH activity, such as aberrantly  low levels of PRH or mis-
localization of PRH, has been observed in a subset of human AML and CML patient 
samples (Topisirovic et al., 2003b). Although a correlation between increased VEGF-
induced survival signalling and PRH activity in primary AML or CML samples has not 
been investigated, there is a body of previous work that has validated the 
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significance of VEGF survival signalling in malignant haematopoietic cells. For 
example, it is known that VEGF and the VEGF receptors, VEGFR1 and VEGFR2, are 
up-regulated in many haematopoietic malignancies (Dias et al., 2002). Leukaemia 
samples and leukaemic myeloid-derived cell-lines express VEGF and functional 
VEGFR2, where autocrine signalling stimulates cell survival and proliferation (Dias et 
al., 2000). In addition, VEGF has been shown to promote cell survival by  protecting 
haematopoietic cells from apoptosis induced by  gamma-ray irradiation and 
chemotherapeutic drugs, etoposide and doxorubicin (Katoh et al., 1995; Katoh et al., 
1998). Therefore, it is possible that CML and AML patients that have perturbed PRH 
activity  are likely to have a higher tolerance of chemotherapeutic agents and 
increased survival signalling. Furthermore, in HL60 leukaemic cells, VEGF was found 
to up-regulate Hsp90 and induce Bcl-2 expression, leading to apoptosis inhibition 
(Dias et al., 2002). It has also been reported that MCL1, a BCL2 family member, is 
up-regulated after VEGF treatment, with reduced caspase 3 activity (Katoh et al., 
1998). This suggests that VEGF is a key factor for haematopoietic stem cell survival 
through control of the Bcl-2 family genes, although it is likely multiple pathways 
including activation of the Akt pathway (as discussed in the introduction). There is 
strong evidence that supports a role for VEGF signalling in haematopoietic 
malignancies and deregulation of PRH activity could be a key step in the regulation 
of these VSP genes.  
The role of PRH in regulating cell growth within the haematopoietic compartment 
appears to be complex. In this chapter PRH is shown to be a regulator of myeloid cell 
survival through transcriptional regulation of the VSP genes. However, PRH can also 
regulate cell proliferation within the myeloid compartment, as I have previously 
described above (Topisirovic et al., 2003b; Topisirovic et al., 2003a)(Jayaraman et al., 
2000). This suggests that PRH has a general role in myeloid cells as a tumour 
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suppressor. In contrast, in the lymphoid compartment, PRH can act as an oncogene. 
For example, expression of PRH under the control of a T-cell specific promoter 
results in increased proliferation of T-cells (Mack et al., 2002) and PRH was found to 
be up-regulated in some B-cell leukaemias (Hansen and Justice, 1999). Also, over-
expression of PRH is sufficient for self-renewal of thymocytes and accumulation of 
subsequent mutations that allow for leukaemic transformation (McCormack et al., 
2010). These observations suggest a myeloid-lymphoid divide for PRH control of cell 
growth and survival, suggesting that tissue specific factors are important in controlling 
the PRH induced response.
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Role of CK2 phosphorylation of PRH
5 Role of CK2 phosphorylation of PRH.
5.1 Introduction.
Protein kinase CK2 (CK2) is a ubiquitously expressed protein kinase that is activated 
in response to stress signals (Sayed et al., 2000). There are multiple targets of CK2 
phosphorylation, including components of the Akt signalling pathway and regulators 
of apoptosis. CK2 is therefore defined as a pro-survival factor (Ahmed et al., 2002). 
Unsurprisingly, CK2 is commonly  activated in malignant diseases of most cell types, 
including AML and CML (Kim et al., 2007; Mishra et al., 2007). In vitro studies 
identified PRH as a binding partner of CK2β. It was further established that CK2 
phosphorylates the serine residues 163 and 177 of the PRH homeodomain, which 
inhibits DNA binding in vitro (Soufi et al., 2009). However, the significance of CK2 
phosphorylation of PRH in cells is unknown. Evidence that CK2 phosphorylates PRH 
in vivo and the effect of phosphorylation on PRH transcriptional activity and stability 
will be presented in this chapter. The clinical significance of CK2 activity and 
regulation of PRH by CK2 will also be discussed. 
5.2 Phosphorylation of PRH in vivo.
It has been demonstrated previously by Soufi et al that antibodies generated in 
mouse and rabbit preferentially recognize the unphosphorylated and phosphorylated 
conformations of PRH, respectively (see figure 2B (Soufi et al., 2009)). These 
antibodies were utilized to investigate whether endogenous PRH is phosphorylated 
by CK2 in vivo.
To determine whether PRH is phosphorylated in vivo by CK2, K562 cells were treated 
with increasing amounts of a specific CK2 inhibitor 2-Dimethylamino-4,5,6,7-
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Figure 5.1 - In vivo phosphorylation of PRH by CK2.
[A] K562 cells were treated with 10µM, 20µM, 40µM, 80µM DMAT or the equivalent volume 
of DMSO. The proteins were then separated by  SDS-PAGE and western blotted for 
endogenous phosphorylated PRH using a rabbit anti-PRH antibody  (top panel), total 
endogenous PRH using a mouse anti-PRH antibody  (upper middle panel), CK2 
phosphorylated XRCC1 using an anti-phospho-XRCC1 antibody  (lower middle panel) and 
Lamin A/C was used as a control (bottom panel). Data representative of two independent 
experiments. [B] K562 cells were treated with 80µM DMAT (lane 2) or 160µM TBB (lane 4) 
or the equivalent volume of DMSO (lanes 1 and 3). The proteins were then separated by 
SDS-PAGE and western blotted as for panel A. Data representative of two independent 
experiments.
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tetrabromo-1H-benzimidazole (DMAT) (Pagano et al., 2004) for 24 hours. Whole cell 
protein extracts were made from treated and untreated cells. Equal amounts of 
protein were separated by SDS-PAGE, and the proteins were transferred onto an 
Immobilon P membrane. Western blot analysis was performed by staining the 
membrane with the rabbit anti-pPRH antibody (figure 5.1 [A] - top  panel) for 
phosphorylated PRH (pPRH). The blot was stripped of antibody  and re-probed with 
the mouse anti-PRH antibody (figure 5.1 [A] - upper middle panel) for 
unphosphorylated PRH (PRH), or an anti-pXRCC1 antibody (figure 5.1 [A] - lower 
middle panel). XRCC1 protein is known to be phosphorylated by CK2 and serves as 
a CK2 phosphorylation specific control. Blots were also probed with an anti-Lamin A/
C antibody, as Lamin A/C  is used as a loading control (figure 5.1 [A] - bottom panel). 
In untreated K562 cells, a strong pPRH band can be observed at 36kDa (figure 5.1 
[A] - top panel, upper band, lane 1) and the strength of this band decreases with 
increasing DMAT concentration (figure 5.1 [A] - top  panel, upper band, lanes 2-5). 
However, the level of unphosphorylated PRH protein is unchanged by DMAT 
treatment (figure 5.1 [A] - upper middle panel, lanes 1-5). The pPRH rabbit antibody 
also detects a band at 27kDa (figure 5.1 [A] - top  panel, lower band, lane 1) and will 
be discussed later in section 5.7 of this chapter. To confirm that DMAT inhibits CK2 
activity  the membrane was re-probed with an antibody against CK2 phosphorylated 
XRCC1 (pXRCC1). Figure 5.1 [A] lower middle panel, lanes 1-5, show a gradual 
decrease in pXRCC1 staining with increased DMAT concentration. 
To further confirm that PRH is phosphorylated by CK2, K562 cells were treated with 
80µM DMAT or 150µM TBB, a second CK2 specific inhibitor, or the equivalent 
volume of DMSO. After 24 hours the cells were harvested and whole cell protein 
extracts were made. Western blot analysis was performed as above, using the rabbit 
anti-pPRH antibody (figure 5.1 [B] - top panel), or the mouse anti-PRH antibody 
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(figure 5.1 [B] - middle panel), or an anti-Lamin A/C antibody (figure 5.1 [B] - bottom 
panel). As previously observed, K562 cells treated with DMAT have reduced staining 
down to only 25% of the untreated levels of pPRH (figure 5.1 [B] - top panel, lane 4 
compared to lane 3). K562 cells treated with an alternative CK2 inhibitor, TBB, also 
have reduced levels of pPRH (figure 5.1 [B] - top panel, lane 2), 18% expression 
compared to untreated K562 cells (figure 5.1 [B] - top  panel, lane 3). The level of 
unphosphorylated PRH is unaffected by  either treatment (figure 5.1 [B] middle panel). 
This shows that PRH is phosphorylated in K562 cells by CK2. 
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Figure 5.2 - Transcriptional repression of Vegf and Vegfr1 expression by CK2 
inhibition.
K562 cells were treated with 80µM DMAT or the equivalent volume of DMSO for 24 hours. 
RNA was extracted and reverse transcribed the cDNA. mRNA levels were determined by 
using the synthesized cDNA in a qPCR reaction using gene specific primers and comparing 
to qPCR reactions for Gapdh. Values are means and standard deviations (SD) (n = 3).
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5.3 CK2 phosphorylation of PRH regulates gene expression of Vegf 
and Vegfr1.
To investigate the role of CK2 phosphorylation on the regulation of Vegf and Vegfr1 
gene expression, K562 cells were treated with 80µM DMAT or an equivalent volume 
of DMSO. After 24 hours of treatment the cells were harvested, RNA was extracted 
and reverse transcribed to cDNA. The amount of cDNA for each gene was then 
analyzed using qPCR with gene specific primers for Vegf, Vegfr1 and Gapdh. Gapdh 
was used as an internal control gene, therefore all qPCR data was normalized 
against Gapdh mRNA expression (figure 5.2 - lanes 1 and 2). Relative to Gapdh 
levels, Vegf gene expression is down-regulated by  approximately  50% in the DMAT 
treated cells (figure 5.2 - lane 6) compared to the untreated cells (figure 5.2 - lane 5). 
The expression of Vegfr1 is also repressed by approximately 60% in the cells treated 
with DMAT (figure 5.2 - lane 4) compared to cells that have not been treated (figure 
5.2 - lane 3). Evidently, CK2 activity plays a role in the regulation of Vegf and Vegfr1 
gene expression. CK2 activity could potentially increase the amount of 
unphosphorylated PRH which can bind DNA and repress the Vegf and Vegfr1 genes.
To determine whether CK2 regulation of Vegf gene expression is dependent on 
endogenous PRH, PRH was knocked down using Prh specific shRNAs, as described 
previously. PRH knockdown and control cells were treated with 80µM DMAT or the 
equivalent volume of DMSO for 24 hours. mRNA levels were measured as outlined 
above to determine gene expression levels. In cells treated with DMAT, the level of 
Vegf expression is repressed by approximately 50% (figure 5.3 [A] - lane 2) when 
compared to untreated cells (figure 5.3 [A] - lane 1). When PRH protein levels are 
knocked down by specific shRNAs (figure 5.3 [A] - lane 3) Vegf expression is 
elevated compared to the control cells (figure 5.3 [A] - lane 1), as previously 
described. However, in the PRH knockdown cells, treatment with DMAT (figure 5.3 
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Figure 5.3 - Repression of Vegf, Vegfr1 by CK2 inhibitors requires PRH expression.
[A] Vegf mRNA levels in K562 shRNA control cells (CON) and PRH shRNA cells (PRH KD) 
24 hours after treatment with 80µM DMAT or the equivalent volume of DMSO. RNA was 
extracted and 0.5µg of extracted RNA was reverse transcribed to cDNA. mRNA levels were 
determined by  using the synthesized cDNA in a qPCR reaction using gene specific primers 
and comparing to qPCR reactions for Gapdh. Values are means and standard deviations 
(SD) (n = 3). [B] Vegfr1 mRNA levels from the same cells as in panel A.
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[A] - lane 4) has no effect on the level of Vegf gene expression compared to 
untreated PRH knockdown cells (figure 5.3 [A] - lane 3). This demonstrates that PRH 
is necessary for CK2 induced regulation of Vegf gene expression.
Analysis of Vegfr1 expression levels in knockdown and control cells treated with 
DMAT shows that in control cells Vegfr1 expression is reduced to approximately 40% 
(figure 5.3 [B] - lane 2) of its unrepressed state (figure 5.3 [B] - lane 1). ShRNA 
knockdown of PRH (figure 5.3 [B] - lane 3) results in elevated expression of Vegfr1 
compared to the control cells (figure 5.3 [B] - lane 1), as previously described in 
Chapter 3. However, in PRH knockdown cells that are treated with DMAT (figure 5.3 
[B] - lane 4) there is no effect on the level of Vegfr1 gene expression compared to 
untreated PRH knockdown cells (figure 5.3 [B] - lane 3). Again this demonstrates that 
PRH is necessary for CK2 induced regulation of Vegfr1 gene expression.
To determine how CK2 phosphorylation of PRH regulates PRH function as a 
transcriptional repressor protein, mutations were made at serines 163 and 177. To 
mimic phosphorylation of these residues these two serines were mutated to glutamic 
acid residues (figure 5.4). In addition, these serines were also mutated to cysteines 
(figure 5.4), to prevent phosphorylation and to imitate unphosphorylated serine 
residues. Mutagenesis was performed by Hannah Williams and the plasmids were 
gifted to me for these studies.
To further investigate the role of CK2 regulation of Vegf gene expression through 
PRH; PRH, a PRH mutant that cannot be phosphorylated by CK2 (PRH 
S163C,S177C), and the PRH phospho-mimic (PRH S163E,S177E) were expressed 
in K562 cells alone or with CK2 α and β. 48 hours post-transfection, RNA was 
extracted and reverse transcribed to produce cDNA which was analyzed as 
described above by qPCR. As previously observed, when PRH is expressed, Vegf 
gene expression is repressed (figure 5.5 [A] - lane 2) when compared to the 
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Figure 5.4 -  Schematic diagram of Myc-PRH CK2 phosphorylation site point 
mutations.
Schematic diagram of the PRH protein in pMUG1 Myc-PRH and targeted mutations in the 
protein. The PRH S163E,S177E mutant mimics CK2 phosphorylated PRH. The PRH 
S163C,S177C mutant is unable to be phosphorylated. 
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Figure 5.5 - Regulation of Vegf, Vegfr1 expression by CK2 phosphorylation mutants of 
PRH. 
[A]Vegf mRNA levels in K562 cells 48 h after transfection with 5 µg pMUG1 (lane 1) or 
pMUG1 vectors expressing PRH (PRH [lane 2], PRH S163C,S177C [lane 3], or PRH 
S163E,S177E [lane 4]) alone or with 3µg pRc/CMV-CK2α-HA, and 5µg pRc/CMV-HA-CK2β. 
mRNA levels were determined by  using the synthesized cDNA in a qPCR reaction using 
gene specific primers and comparing to qPCR reactions for Gapdh. Values are means and 
SD (n = 3). [B] Vegfr1 mRNA levels in K562 cells 48 hours after transfection with the vectors 
described for panel [A]. Values are means and SD (n = 3). 
[A]
Vegf
0
0.5
1.0
1.5
R
el
at
iv
e 
m
R
N
A
 le
ve
ls
- + +- - - + CK2
PRH PRH 
(CC)
PRH 
(EE)
1 2 3 4 5 6 7
[B]
Vegfr1
0
0.5
1.0
1.5
R
el
at
iv
e 
m
R
N
A
 le
ve
ls
- + +- - - + CK2
PRH PRH 
(CC)
PRH 
(EE)
1 2 3 4 5 6 7
expression of Vegf in control cells (figure 5.5 [A] - lane 1). However, when PRH and 
CK2 are co-expressed PRH no longer represses Vegf expression (figure 5.5 [A] - 
lane 3). Vegf gene expression is also reduced in cells expressing PRH S163C,S177C 
(figure 5.5 [A] - lane 4) to a similar level as observed in cells expressing PRH (figure 
5.5 [A] - lane 2). Yet, when PRH S163C,S177C and CK2 are co-expressed (figure 5.5 
[A] - lane 5) there is no significant difference in repression of Vegf expression when 
compared to PRH S163,S177C  alone (figure 5.5 [A] - lane 4). Additionally, cells 
expressing PRH S163E,S177E alone (figure 5.5 [A] - lane 6) or cells expressing PRH 
S163E,S177E  and CK2 (figure 5.5 [A] - lane 7) have unchanged Vegf expression 
compared to control cells (figure 5.5 [A] - lane 1). This suggests that the serine 
residues 163 and 177 within the homeodomain are vital for CK2 dependent 
antagonism of PRH repression at the Vegf gene. 
Analysis of Vegfr1 gene expression in the same experiment shows that Vegfr1 is 
repressed when PRH is expressed, (figure 5.5 [B] - lane 2) when compared to the 
expression of Vegfr1 in control cells (figure 5.5 [B] - lane 1). However, when PRH and 
CK2 are co-expressed, repression of Vegfr1 expression is no longer observed (figure 
5.5 [B] - lane 3) compared to the control cells (figure 5.5 [B] - lane 1). Cells 
expressing PRH S163C,S177C  (figure 5.5 [B] - lane 4) also have repressed Vegfr1 
gene expression compared to the control (figure 5.5 [B] - lane 4). Yet, cells 
expressing PRH S163C,S177C and CK2 (figure 5.5 [B] - lane 5) have no significant 
difference in Vegfr1 expression compared to PRH S163,S177C alone (figure 5.5 [B] - 
lane 4). Furthermore, expression of PRH S163E,S177E alone (figure 5.5 [B] - lane 6) 
or PRH S163E,S177E and CK2 (figure 5.5 [B] - lane 7) has no effect on expression 
(figure 5.5 [B] - lane 1). These data demonstrate that CK2 antagonizes PRH 
repression of Vegfr1 expression through the phosphorylation of serine residues 163 
and 177 within the homeodomain of PRH.
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5.4 CK2 phosphorylation of PRH regulates DNA binding of the Vegf 
and Vegfr1 promoters.
To investigate the whether CK2 phosphorylation inhibits DNA binding of PRH in vivo, 
chromatin immuno-precipitation assays were carried out with cells expressing; PRH, 
PRH S163C,S177C, or PRH S163E,S177E alone or co-expressing CK2. K562 cells 
were transfected with pMUG1 vectors expressing Myc-PRH (PRH, PRH 
S163C,S177C, or PRH S163E,S177E) alone or with CK2α and CK2β  expression 
vectors. ChIP was performed as outlined in Chapter 3. PRH binds to the Vegfr1 
promoter, as described in section 3.4, at multiple sites across a 10kb region. As 
previously observed, in cells expressing PRH alone enrichment of the upstream 
-3000 and -1000 regions (figure 5.6 [A] - black bars at -3000 and -1000) and the 
region covering the ATG (figure 5.6 [A] - black bar at 0) are observed compared to 
the input (total pool of DNA fragments)(figure 5.6 [A] - white bars at -3000, -1000, and 
0). In addition there is moderate enrichment of the upstream -5000 and downstream 
+1700 regions (figure 5.6 [A] - black bars at -5000 and +1700) when compared to the 
input DNA (figure 5.6 [A] - white bars at -5000 and +1700). No enrichment is 
observed at the distal upstream promoter region of  Vegfr1, -7500bp from the ATG, in 
cells containing PRH alone (figure 5.6 [A] - black bar compared to white bar at 
-7500). However, in cells expressing PRH and CK2, no significant enrichment is 
observed across the entire 7.5kb regulatory region for Vegfr1 (figure 5.6 [B]). For 
cells containing PRH S163C,S177C (figure 5.6 [C]), a similar pattern of enrichment is 
observed as for wild-type PRH (figure 5.6 [A]). Substantial enrichment is observed for 
regions of Vegfr1 at distances of -3000, -1000 and 0bp  from the ATG (figure 5.6 [C] - 
black bars compared to white bars). There is also some enrichment observed for the 
-5000 and +1700 regions of the Vegfr1 promoter, but there is no enrichment at the 
-7500bp upstream region (figure 5.6 [C] - black bars compared to white bars), as 
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Figure 5.6 - CK2 phosphorylation controls PRH binding to the Vegfr1 promoter. 
[A] Chromatin Immuno-precipitation of Myc-PRH from K562 cells transfected with 5 µg 
pMUG1 Myc-PRH. Enrichment levels were determined by using the purified DNA in a qPCR 
reaction using promoter specific primers and comparing to qPCR reactions for the Gapdh 
promoter. Values are taken from a single immuno-precipitation and SD of 3 qPCR reactions. 
[B] As for panel A with cells transfected with 5µg pMUG1 Myc-PRH, 3µg pRc/CMV-CK2α-
HA, and 5µg pRc/CMV-HA-CK2β. [C] As for panel A with cells transfected with 5µg pMUG1 
Myc-PRH S163C,S177C. [D] As for panel A with cells transfected with 5µg pMUG1 Myc-
PRH S163C,S177C, 3µg pRc/CMV-CK2α-HA, and 5µg pRc/CMV-HA-CK2β. [E] As for panel 
A with cells transfected with 5µg pMUG1 Myc-PRH S163E,S177E.
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observed for PRH (figure 5.6 [A]). Expression of CK2 along with PRH S163C,S177C 
(figure 5.6 [D]) also results in binding across the promoter as observed for PRH 
S163C,S177C alone (figure 5.6 [C]). PRH S163C,S177C  is bound to the -5000, 
-3000, -1000, and 0 bp upstream from the ATG site of Vegfr1 in the presence of CK2, 
although there is no binding at the -7500 and +1700 regions of the promoters. No 
binding of PRH S163E,S177E is observed across the Vegfr1 promoter (figure 5.6 
[E]). This data was collected from one set of chromatin, a further repeat that only 
analyzed the -1000bp  region upstream of the TSS was performed and confirmed the 
observation that CK2 activity disrupts PRH binding but does not affect PRH 
S163C,S177C DNA binding activity (figure 5.7 [A]). PRH DNA binding to the Vegf 
gene promoter was also analyzed from these chromatin samples. Enrichment of the 
-5.5kb  region of the Vegf gene promoter is observed in immuno-precipitations of PRH 
from cells expressing PRH alone (figure 5.7 [B] - lanes 1-3). However, in cells 
expressing PRH and CK2 no enrichment is observed (figure 5.7 [B] - lanes 4-6). As 
observed at the Vegfr1 gene promoter, PRH S163C,S177C binds to the Vegf gene 
promoter in cells expressing PRH S163C,S177C alone (figure 5.7 [B] - lanes 7-9) or 
in cells expressing PRH S163C,S177C and CK2 (figure 5.7 [B] - lanes 10-12). The 
PRH S163E,S177E does not associate with the Vegf gene promoter (figure 5.7 [B] - 
lanes 13-15). These data show that CK2 phosphorylation of PRH can inhibit DNA 
binding in vivo and that the serine residues 163 and 177 within the homeodomain are 
the targets of this CK2 phosphorylation. 
5.5 CK2 phosphorylation of PRH regulates cell growth and 
apoptosis.
To investigate the role of CK2 phosphorylation of PRH in controlling growth potential, 
K562 cells were transfected with empty vector (pMUG1) or PRH (pMUG1 Myc-PRH) 
alone or PRH with the CK2 subunits α and β, or PRH with the β subunit and a 
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Figure 5.7 - CK2 phosphorylation of PRH inhibits DNA binding at Vegfr1 and Vegf.
CK2 phosphorylation controls PRH binding to the [A] Vegfr1 promoter and [B] Vegf 
promoter. Chromatin Immuno-precipitation of Myc-PRH from K562 cells transfected with 5 
µg pMUG1 vector containing (Myc-PRH, Myc-PRH S163C,S177C, Myc-PRH S163E,S177E) 
with or without 3µg pRc/CMV-CK2α-HA, and 5µg pRc/CMV-HA-CK2β. Enrichment levels 
were determined by  using the purified DNA in a qPCR reaction using promoter specific 
primers and comparing to qPCR reactions for the Gapdh promoter. Values are taken from a 
single immuno-precipitation and SD of 3 qPCR reactions. Data representative of 3 sets of 
extracted chromatin.
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mutated α subunit of CK2, or PRH with the β subunit of CK2 only. 24 hours after 
transfection viable cells were counted using trypan blue exclusion staining and cells 
were diluted to equal starting concentrations. After 72 hours the cells were re-
counted. In the cells expressing PRH alone (figure 5.8 - lane 2) a reduction in the 
total number of cells after 72 hours was observed compared to the control cells 
(figure 5.8 - lane 1). However, the growth of cells expressing both subunits of CK2, 
as well as PRH (figure 5.8 - lane 3) is unaffected compared to the control cells (figure 
5.8 - lane 1). Yet, for cells expressing PRH with the β subunit alone (figure 5.8 - lane 
5) or the β subunit and a mutated CK2α subunit (figure 5.8 - lane 4), reduced growth 
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Figure 5.8 - CK2 antagonizes PRH induced cell growth.
CK2 antagonises PRH repression of growth. K562 cells were transfected with 5µg pMUG1 
Myc-PRH alone, or with 3µg pRc/CMV-CK2α-HA and 5µg pRc/CMV-HA-CK2β, or with 3µg 
pRc/CMV-CK2α-K68M-HA and 5µg pRc/CMV-HA-CK2β, or with 5µg pRc/CMV-HA-CK2β. 
K562 cells transfected with 5µg pMUG1 was used as a control. Populations were set to 
equal numbers of cells and counted after 72 hours by  trypan blue exclusion. Values are 
means and SD (n=3).
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is still observed in comparison to the growth of control cells (figure 5.8 - lane 1). This 
suggests that phosphorylation of PRH by CK2 antagonizes growth inhibition by PRH.
To determine whether phosphorylation within the PRH homeodomain is essential for 
the CK2 dependent antagonism of growth inhibition by PRH, K562 cells expressing 
GFP or GFP with PRH or PRH S163C,S177C or PRH S163E,S177E with or without 
expression of CK2 α and β were used. 24 hours post-transfection viable cells were 
counted in the presence of trypan blue dye as described above. Cells expressing 
PRH alone (figure 5.9 [A] - lane 2) have a reduction in the total number of cells after 
72 hours compared to the control cells (figure 5.9 [A] - lane 1), as previously 
observed. However, for cells expressing PRH and both subunits of CK2 (figure 5.9 
[A] - lane 3) no change in the growth of these cells is observed when compared to the 
control cells (figure 5.9 [A] - lane 1). Expression of PRH S163C,S177C in K562 cells 
(figure 5.9 [A] - lane 4) results in a reduction in the total number of cells after 72 
hours, similar to that seen with PRH expressing cells (figure 5.9 [A] - lane 2). In 
contrast to wild type PRH and CK2, the expression of CK2 has no effect on PRH 
S163C,S177C (figure 5.9 [A] - lane 5). The growth of cells expressing PRH 
S163E,S177E (figure 5.9 [A] - lane 6) is similar to control cells (figure 5.9 [A] - lane 1) 
and co-expression of PRH S163E,S177E and CK2 (figure 5.9 [A] - lane 7) has no 
effect on the growth of the cells. These results suggest that the CK2 phosphorylation 
sites within the homeodomain of PRH are vital for CK2 dependent antagonism of 
PRH activity in relation to cell growth.
Chapter 4 showed that PRH inhibits growth by increasing apoptosis. To determine 
whether CK2 antagonises PRH induced apoptosis, K562 cells were transfected as 
described above and stained with PI and Annexin V APC 24 hours post-transfection 
and analyzed using flow cytometry. Transfected cells were identified through 
expression of EGFP. EGFP positive cells were examined by staining with PI and 
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Figure 5.9 - The effect of CK2 on PRH induced cell apoptosis.
CK2 antagonizes PRH repression of growth and induction of apoptosis. [A] K562 cells were 
transfected with 2µg pEGFP and 5µg pMUG1 or 2µg pEGFP and 5µg pMUG1 vector 
containing (Myc-PRH, Myc-PRH S163C,S177C, Myc-PRH S163E,S177E) with or without 
3µg pRc/CMV-CK2α-HA and 5µg pRc/CMV-HA-CK2β. Populations were set to equal 
numbers of cells and counted after 72 hours by  trypan blue exclusion. Values are means and 
SD (n=3). [B] Cells as described for panel A were stained with propidium iodide and an anti-
Annexin V APC antibody after 24 hours. Fold change in total apoptosis compared to the 
EGFP control. Values are means and SD (n=3).
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Annexin V APC. As observed in previous experiments, cells expressing PRH (figure 
5.9 [B] - lane 2) have approximately double the total number of cells in apoptosis 
(early and late) compared to the control cells (figure 5.9 [B] - lane 1). However, cells 
co-expressing PRH and CK2 (figure 5.9 [B] - lane 3) have an equal number of cells 
undergoing apoptosis compared to the control cells (figure 5.9 [B] - lane 1). In cells 
expressing PRH S163C,S177C (figure 5.9 [B] - lane 4) the total number of cells 
undergoing apoptosis is increased in comparison to the control cells (figure 5.9 [B] - 
lane 1) to a similar level as cells expressing the wild-type PRH (figure 5.9 [B] - lane 
2). Co-expression of PRH S163C,S177C and CK2 in K562 cells (figure 5.9 [B] - lane 
4) is still elevated when compared to the control cells (figure 5.9 [B] - lane 5). 
Expression of PRH S163E,S177E alone (figure 5.9 [B] - lane 6) or with CK2 (figure 
5.9 [B] - lane 7) has no effect on cell apoptosis compared to the control cells (figure 
5.9 [B] - lane 1). Since CK2 cannot block PRH induced apoptosis when PRH is 
mutated at serines 163 and 177 it can be concluded that the PRH induced apoptosis 
observed in K562 cells is antagonized by CK2 phosphorylation at these positions 
within the homeodomain of PRH.
5.6 BCR-ABL1 increases CK2 phosphorylation of PRH.
K562 cells are derived from a patient diagnosed with CML, and they contain the 
Philadelphia chromosome that encodes for the p210 BCR-ABL1 fusion protein, which 
drives proliferation (Lozzio and Lozzio, 1975). Imatinib is a small molecule inhibitor of 
ABL1 that is used to treat CML patients who have the Philadelphia chromosome. 
Imatinib binds to the ATP pocket of the ABL1 moiety and stabilizes the inactive form 
(O'hare et al., 2007). Dasatinib  is a second generation BCR-ABL1 inhibitor, which 
binds only to the active conformation of the ATP binding pocket of ABL1 (O'hare et 
al., 2007). Imatinib  and Dasatinib  are not structurally related molecules. Inhibition of 
p190 BCR-ABL1 in lymphoid cells using Imatinib  results in inhibition of CK2 activity 
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and this is proposed to occur through the direct interaction of BCR-ABL1 and the 
CK2α subunit (Mishra et al., 2003). Since direct inhibition of CK2 with DMAT 
increases transcriptional repression of VSP genes when PRH is present, I wanted to 
determine whether inhibition of CK2 activity indirectly through inhibition of BCR-ABL1 
activity  would have the same effect. K562 cells were therefore treated with the BCR-
ABL1 inhibitors, Imatinib  or Dasatinib, or an equivalent volume of DMSO for 8 hours. 
Whole cell protein extracts were made, equal amounts of protein were separated on 
a SDS-PAG, and the proteins were transferred onto an Immobilon P membrane. 
Western blot analysis was performed by staining the membrane with a rabbit anti-
PRH antibody (figure 5.10 - top  panel) for phosphorylated PRH. The blot was 
stripped of antibody and re-probed with a mouse anti-PRH antibody (figure 5.10 - 
upper middle panel) for unphosphorylated PRH, or an anti-pXRCC1 antibody (figure 
5.10 - lower middle panel), or an anti-Lamin A/C antibody which was used as a 
loading control (figure 5.10 - bottom panel). In DMSO treated K562 cells, a strong 
band can be observed at 36kDa (figure 5.10 - top panel, lane 1), which correlates to 
full-length pPRH. The pPRH band is markedly reduced in K562 cells treated with 
100µM Imatinib  (figure 5.10 - top panel, lane 2). In addition, K562 cells treated with 
the more potent BCR-ABL1 inhibitor Dasatinib (30µM) also show reduced pPRH 
levels (figure 5.10 - top panel, lane 4) compared to DMSO treated K562 cells (figure 
5.10 - top  panel, lane 3). However, the level of unphosphorylated PRH protein is 
unchanged by either treatment (figure 5.10 - middle panel, lanes 1-4). In K562 cells 
treated with either Imatinib  or Dasatinib, antibody staining for CK2 phosphorylated 
XRCC1, an unrelated CK2 target, was also substantially reduced (figure 5.10 - lower 
middle panel, lanes 2 and 4) indicating that CK2 activity is reduced in cells treated 
with BCR-ABL1 inhibitors. These data show that inhibition of BCR-ABL1 activity 
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results in decreased phosphorylation of the unrelated CK2 target proteins PRH and 
XRCC1.
To determine whether inhibition of BCR-ABL1 activity  affects the regulation of VSP 
genes, RNA was extracted from PRH KD and control cells that were treated as 
described above. Expression of the Vegf gene was analyzed using qPCR as 
described previously. In control cells treated with Imatinib the level of Vegf expression 
was reduced approximately 35% when compared to the level of Vegf expression for 
cells treated with DMSO (figure 5.11 [A] - lane 2 and 1). For control cells treated with 
Dasatinib the level of Vegf expression was more robustly repressed to almost 50% 
compared to the levels observed for K562 cells treated with DMSO (figure 5.11 [A] - 
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Figure 5.10 - Inhibition of BCR-ABL1 decreases CK2 phosphorylation of PRH.
K562 cells were treated with 100µM Imatinib (lane 2) or 30µM Dasatinib  (lane 4) or the 
equivalent volume of DMSO (lanes 1 and 3). Proteins were then separated by  SDS-PAGE 
and western blotted for endogenous phosphorylated PRH using a rabbit anti-PRH antibody 
(top panel), unphosphorylated PRH using a mouse anti-PRH antibody  (upper middle panel), 
pXRCC1 (lower middle panel) and Lamin A/C was used as a control (bottom panel). Data 
representative of three independent experiments.
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lane 3 and 1). However, in PRH KD cells treated with Imatinib  Vegf expression was 
unchanged compared to the DMSO treated PRH KD cells (figure 5.11 [A] - lane 5 and 
4). The level of expression of Vegf in PRH KD cells treated with Dasatinib was slightly 
reduced compared to PRH KD cells treated with DMSO (figure 5.11 [A] - lane 6 and 
4), however, this decrease is not significant. This demonstrates that inhibition of the 
p210 BCR-ABL1 fusion protein activity decreases the expression of the PRH target 
gene, Vegf. 
To investigate the regulation of Vegfr1 gene expression by p210 BCR-ABL1 activity, 
qPCR analysis was performed as above except using Vegfr1 specific primers. The 
level of Vegfr1 expression was reduced to almost 50% in control cells treated with 
Imatinib when compared to the level of Vegf expression for cells treated with DMSO 
(figure 5.11 [B] - lane 2 and 1). In control cells treated with Dasatinib, Vegfr1 
expression was repressed to approximately 65% of the level observed for control 
cells treated with DMSO (figure 5.11 [B] - lane 3 and 1). Conversely, in PRH KD cells 
treated with Imatinib, the level of Vegfr1 expression is unchanged from PRH KD cells 
treated with DMSO (figure 5.11 [B] - lane 5 and 4). Furthermore, the level of Vegfr1 
expression is unaffected by Dasatinib treatment of PRH KD cells when compared 
with PRH KD cells treated with DMSO (figure 5.11 [B] - lane 6 and 4). This shows 
that the expression level of two PRH target genes, Vegf and Vegfr1, are both 
controlled through the activity of the p210 BCR-ABL1 fusion protein. 
To determine whether PRH plays a role in Dasatinib induced cell death of BCR-ABL1 
positive cells, PRH KD and control cells were treated with 30µM Dasatinib  for 16 
hours. Cell numbers were determined using MTT assays, starting with equal 
numbers of cells as described previously. Data shown is the mean and standard error 
from a single experiment performed in quadruplicate and is representative of three 
independent experiments. Dasatinib treatment of control cells reduces cell number 
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Figure 5.11 - Inhibition of BCR-ABL1 reduces Vegf and Vegfr1 expression.
[A] PRH knockdown (PRH KD) and Control (CON) cells were treated with 100µM Imatinib or 
30µM Dasatinib or the equivalent volume of DMSO for 24 hours. RNA was extracted and 
cDNA was reverse transcribed. mRNA levels were determined by  using the synthesized 
cDNA in a qPCR reaction using Vegf specific primers and comparing to qPCR reactions for 
Gapdh. Values are means and standard deviations (SD) (n = 3). [B] As for panel A, except 
using Vegfr1 specific primers.
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after 16 hours of treatment when compared to control cells treated with DMSO (figure 
5.12 - lanes 2 and 1). PRH KD cells treated with Dasatinib are also significantly 
reduced compared to PRH KD cells treated with DMSO (figure 5.12 - lanes 4 and 3) 
However, there is a significant increase in the number of PRH KD cells treated with 
Dasatinib compared to control cells treated with Dasatinib  (p=0.001) (figure 5.12 - 
lanes 4 and 2). These data show that PRH plays a role in the cell death processes 
induced by the BCR-ABL1 inhibitor, Dasatinib.
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Figure 5.12 - Absence of PRH reduces BCR-ABL1 inhibitor potency in K562 cells.
Control and PRH KD cells were treated with 30µM Dasatinib (bars 2 and 4) or an equal 
volume of DMSO  (bars 1 and 3) for 16 hours. An MTT assay  was then used to calculate cell 
numbers. Values are means and SD (n = 4). Data representative of three independent 
experiments.
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5.7 Phosphorylation of PRH reduces proteasome dependent protein 
stability and nuclear localization.
Previous studies have demonstrated a role for CK2 in the regulation of degradation 
for specific proteins. This regulation can be positive or negative depending on the 
target protein. For example, CK2 phosphorylates the tumour suppressor PML and 
specifically targets this protein for degradation by the proteasome (Scaglioni et al., 
2006). However, CK2 phosphorylation of c-myc is vital for the proliferation of T-cell 
lymphomas and pharmacological inhibition or knock-down of CK2 reduces the 
stability of c-myc (Channavajhala and Seldin, 2002). Thus alteration of protein 
stability is a feature of some CK2 target proteins.
In K562 cell extract full length pPRH (36kDa) detected by rabbit pPRH antibody is 
always accompanied by a 27kDa product and this product is present even in DMAT 
treated cells, although there is a small reduction over 24 hours (figure 5.1 [A]). To 
determine whether the endogenous 27kDa PRH band observed in figure 5.1 [A] is a 
CK2 dependent cleavage product of full-length PRH, K562 cells or cells expressing 
PRH with or without co-expression of the α and β subunits of CK2 were harvested 
after 24 hours and whole cell protein extracts were made. Proteins were separated 
by SDS-PAG, transferred to a PVDF membrane and stained with an anti-Myc 
antibody. The membrane was stripped of antibody and re-stained with the rabbit anti-
PRH antibody or an anti-Tubulin antibody, which was used as a loading control 
(figure 5.13 - lower panel). The Myc antibody detects a strong 36kDa band and a 
weak 27 kDa band for PRH from cells transfected with Myc-PRH alone (figure 5.13 - 
top panel, lane 2). In cells expressing Myc-PRH and CK2, the Myc antibody detects a 
stronger band at 27kDa (figure 5.13 - top panel, lane 3) compared to the 27kDa band 
observed in cells expressing Myc-PRH alone (figure 5.13 - top panel, lane 2). Re-
probing of the membrane with the rabbit anti-PRH antibody confirms that a 36kDa 
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and a 27kDa band are present in cells alone (figure 5.13 - middle panel, lane 1). In 
cells expressing Myc-PRH, the myc tag slightly retards the mobility of the 36kDa and 
27kDa PRH proteins, therefore bands corresponding to the exogenous Myc-PRH 
protein are observed at 37kDa and 28kDa (figure 5.13 - middle panel, lane 2). In cells 
expressing Myc-PRH and CK2, the 28kDa PRH band (figure 5.13 - middle panel, 
lane 3) is stronger than in cells expressing Myc-PRH alone (figure 5.13 - middle 
panel, lane 2). However, the 36kDa PRH species is equally expressed in the 
presence or absence of CK2 (figure 5.13 - middle panel, lanes 2 and 3). This 
suggests that elevated CK2 expression increases the presence of the 27kDa PRH 
band. It can be concluded that the 27kDa PRH species is a C-terminal truncation of 
PRH because the Myc-tag is attached at the N-terminal domain (see figure 3.6). 
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Figure 5.13 - CK2 phosphorylation increases cleavage of PRH.
Untransfected K562 cells (lane 1) or cells transfected with 5µg pMUG1 Myc-PRH (lanes 2) 
or cells transfected with 5µg pMUG1 Myc-PRH, 3µg pRc/CMV-CK2α-HA and 5µg pRc/CMV-
HA-CK2β. The cells were harvested and whole cell protein was extracted. Proteins were 
separated on a SDS-PAG and transferred to a PVDF membrane that was stained with a 
anti-Myc (top panel), or a rabbit anti-PRH antibody  (middle panel), or an anti-Tubulin 
antibody (lower panel). Data representative of two independent experiments.
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Therefore, from this point forwards the 27kDa PRH species will be referred to as 
pPRHΔC.
To further investigate the presence of pPRHΔC, K562 cells were transfected with 
empty vector, PRH or the series of PRH mutants described in Chapter 3 (Myc-PRH 
LL23,24AA, Myc-PRH F32E, Myc-PRH N187A, Myc-PRH SS163,177EE, and Myc-
PRH SS163,177CC). The cells were harvested after 24 hours and whole cell protein 
extracts were made. Proteins were separated by SDS-PAG, transferred to a PVDF 
membrane and stained with an anti-Myc antibody. The membrane was stripped of 
antibody and re-stained with anti-Tubulin antibody, which was used as a loading 
control (figure 5.14 [A] - lower panel). As described above, the Myc antibody detects 
a strong 36kDa band and a weak 27 kDa band for PRH from cells transfected with 
Myc-PRH alone (figure 5.14 [A] - top panel, lane 2). In cells expressing proteins with 
mutations that inhibit the interaction of PRH with eIF4E (PRH LL23,24AA) (figure 
5.14 [A] - top panel, lane 3), or inhibit the interaction of PRH with TLE (PRH F32E) 
(figure 5.14 [A] - top panel, lane 4), the levels of expression of pPRHΔC are 
equivalent to the expression seen with wild-type Myc-PRH (figure 5.14 [A] - top 
panel, lane 2). However, the expression of pPRHΔC in cells expressing Myc-PRH 
N187A (figure 5.14 [A] - top panel, lane 5) appears slightly reduced compared to cells 
expressing wild-type Myc-PRH (figure 5.14 [A] - top  panel, lane 2). Interestingly, 
higher levels of pPRHΔC are observed in cells expressing the Myc-PRH 
SS163,177EE mutant of PRH, which mimics CK2 phosphorylation of PRH (figure 
5.14 [A] - top panel, lane 6), when compared to cells expressing the wild-type Myc-
PRH protein (figure 5.14 [A] - top panel, lane 2). In addition, no pPRHΔC is observed 
in cells expressing the Myc-PRH SS163,177CC  mutant of PRH, which inhibits CK2 
phosphorylation of PRH (figure 5.14 [A] - top  panel, lane 7). These data suggest that 
CK2 phosphorylation of PRH targets full-length PRH for cleavage and increases the 
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Figure 5.14 - CK2 phosphorylation increases cleavage of PRH.
[A] Western blot of Myc-PRH expression in K562 cells 48 h after transfection with 10 µg 
pMUG1 (lane 1, Control) or pMUG1 vectors expressing Myc-tagged PRH (PRH [lane 2], 
LL23,24AA [lane 3], F32E [lane 4], N187A [lane 5], SS163,177EE [lane 6], or SS163,177CC 
[lane 7]). Whole-cell extracts were separate by  SDS-PAGE and transferred to a PVDF 
membrane that was stained with anti-Myc (top panel) and anti-Tubulin antibodies (lower 
panel). [B] As for [A] except extracts are from control cells (lane 1) or cells expressing PRH 
(lane 2), PRH F32E (lane 3), PRH LL23,24AA (lane 4), or PRH N187A (lane 5). A Lamin A/C 
antibody  was used as a loading control. Data representative of three independent 
experiments.
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production of pPRHΔC.
To further confirm there is a reduction in pPRHΔC production from the PRH N187A 
mutant, extract from cells expressing PRH, PRH F32E, PRH LL23,24AA, or PRH 
N187A were separated by  SDS-PAGE and transferred to a PVDF membrane as 
described above for western blot analysis. The membrane was probed with an anti-
Myc tag antibody (figure 5.14 [B] - top  panel), to detect PRH. The membrane was 
then stripped and reprobed with an anti-Lamin A/C antibody, as a loading control 
(figure 5.14 [B] - lower panel). As described above, for cells expressing Myc-PRH, 
Myc-PRH F32E, or Myc-PRH LL23,24AA, a strong 36kDa band for PRH and a weak 
27 kDa band for pPRHΔC is detected (figure 5.14 [B] - top panel, lanes 2-4). In 
contrast, for cells expressing Myc-PRH N187A, only a band at 36 kDa is observed 
(figure 5.14 [B] - top panel, lane 5). This confirms that DNA binding has a role in the 
production of pPRHΔC expression.
Anisomycin is a protein translation inhibitor that blocks the translation of mRNAs in 
the cell. With no new protein translation, the stability  of a protein is entirely a 
consequence of its degradation rate and the half-life of a protein can be determined. 
To investigate the stability of endogenous full-length PRH and the pPRHΔC cleavage 
product, K562 cells were treated with 40µM anisomycin for 0, 4, 8 and 24 hours. The 
cells were harvested and whole cell protein extracts were made. Proteins were 
separated by SDS-PAG, transferred to a PVDF membrane and stained with a mouse 
anti-PRH antibody. The membrane was stripped of antibody and re-stained with a 
rabbit anti-PRH antibody or an anti-Lamin A/C antibody, which was used as a loading 
control (figure 5.15 - lower panel). Over 24 hours of treatment with anisomycin the 
level of un-phosphorylated PRH is unchanged (figure 5.15 - top  panel). The rabbit 
anti-PRH antibody gives two specific PRH bands, one at 36 kDa for full-length PRH 
and another at 27 kDa that corresponds to endogenous pPRHΔC, as demonstrated 
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Figure 5.15 - CK2 phosphorylation reduces PRH stability.
[A] K562 cells were treated with 40µM anisomycin for 0, 4, 8, and 24 hours (lanes 1-4 
respectively). The cells were harvested and whole cell protein was extracted. Proteins were 
separated on a SDS-PAG and transferred to a PVDF membrane that was stained with a 
mouse anti-PRH (top panel), or a rabbit anti-PRH antibody (middle panels), or an anti-Lamin 
A/C antibody  (lower panel). Data representative of three independent experiments. [B] 
Graphical representation of the expression of PRH (blue line), pPRH (black line) and 
pPRH∆C (red line) over 24 hours treatment with 40µM anisomycin, determined by 
densitometric analysis of three independent Western blots.
0 4 8 24 Hours Anisomycin Treatment
PRH (Mo.)
PRH (Rab) 36kDa
PRH (Rab) 27kDa
Lamin A/C
1 2 3 4
[A]
240 4 8 12 16 20
140
0
20
40
60
80
100
120
Pe
rc
en
ta
ge
 E
xp
re
ss
ion
Hours Anisomycin Treatment
PRH
pPRH∆C
pPRH
[B]
in figure 5.1. The rabbit anti-PRH antibody preferentially binds to the phosphorylated 
form of PRH. However, the phosphorylated form of PRH (figure 5.15 - upper middle 
panel) is substantially less stable than the unphosphorylated form (figure 5.15 - top 
panel). Using densitometric analysis of three independent experiments, full-length 
phosphorylated PRH has a half-life of approximately 100 minutes (figure 5.15 [B] - 
black line). The half-life for the full-length unphosphorylated PRH could not be 
quantified because it is stable over the 24 hour time period assayed (figure 5.15 [B] - 
blue line). The half-life for the pPRHΔC protein also could not be quantified because 
it accumulates prior to degradation (figure 5.15 [B] - red line). However, pPRHΔC is 
more stable than full-length pPRH and accumulates around 4 hours of treatment, 
after which pPRHΔC is degraded (figure 5.15 - lower middle panel). These data 
suggest that phosphorylation of PRH by CK2 destabilizes the protein and targets it 
for degradation or cleavage into pPRHΔC prior to degradation.
Endogenous PRH is known to be present in the nucleus and the cytoplasm of cells. 
Biochemical fractionation of cells, as outlined in the Materials and Methods, results in 
two fractions: a post-nuclear fraction consisting of the cytoplasm and loosely held 
nuclear proteins, and a nuclear fraction consisting of tightly held nuclear proteins. To 
investigate the localization of PRH, full-length pPRH and pPRHΔC and their relative 
stabilities in the post-nuclear and nuclear compartments, K562 cells were treated with 
40µM anisomycin for 0, 4, 8, 24 hours, harvested and fractionated into post-nuclear 
and tightly held nuclear protein fractions. Protein extracts were separated by SDS-
PAGE and transferred onto a PVDF membrane for antibody staining. The membrane 
was probed with the mouse anti-PRH antibody. The membrane was then stripped of 
antibody and re-probed using the rabbit anti-PRH antibody, or an anti-Tubulin, or anti-
Lamin A/C antibody, as fractionation and loading controls (figure 5.16 - lower panel 
and lower middle panel respectively). Unphosphorylated PRH is present in both the 
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Figure 5.16 - Stability of endogenous PRH and CK2 phosphorylated PRH in nuclear 
and post-nuclear cellular fractions.
K562 cells were treated with 40µM anisomycin for 0, 4, 8, and 24 hours. The cells were 
harvested and fractionated into post-nuclear and nuclear protein extracts. Proteins were 
separated by SDS-PAGE and transferred to a PVDF membrane that was stained with a 
mouse anti-PRH (top panel), or a rabbit anti-PRH antibody  (upper and central middle 
panels), or an anti-Lamin A/C antibody  (lower panel), or an anti-Tubulin (lower middle panel). 
Data representative of three independent experiments.
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Figure 5.17 - Stability of endogenous PRH and CK2 phosphorylated PRH in nuclear 
and post-nuclear cellular fractions in the presence of proteasome inhibitors.
[A] K562 cells were treated with 40µM anisomycin and 10µM MG132 for 0, 4, 8, and 24 
hours. The cells were harvested and fractionated into post-nuclear and nuclear protein 
extracts. Proteins were separated by SDS-PAGE and transferred to a PVDF membrane that 
was stained with a mouse anti-PRH (top panel), or a rabbit anti-PRH antibody (upper and 
central middle panels), or an anti-Lamin A/C  antibody  (lower panel), or an anti-Tubulin (lower 
middle panel). Data representative of three independent experiments. [B] As for panel A 
except K562 cells were treated with 40µM anisomycin and 10µM lactacystin for 0 and 24 
hours. Data representative of two independent experiments.
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nuclear and post-nuclear fractions and it can be seen over 24 hours (figure 5.16 - top 
panel). In contrast although full-length pPRH is present in both the post-nuclear and 
nuclear fractions at the 0 hour time point, it is completely lost from both fractions after 
24 hours (figure 5.16 - upper middle panel). Therefore just as observed previously in 
whole cell extracts (figure 5.15), pPRH protein (figure 5.16 - upper middle panel) has 
a shorter half-life than the unphosphorylated PRH (figure 5.16 - top  panel). 
Interestingly, pPRH in the nuclear fraction has a shorter half-life than pPRH in the 
post-nuclear fraction (figure 5.16 - upper middle panel). After 4 hours of treatment 
with anisomycin the pPRH band in the nuclear fraction is no longer observed (figure 
5.16 - upper middle panel, lanes 5-8), however the pPRH band persists in the post-
nuclear fraction until 8 hours after treatment (figure 5.16 - upper middle band, lanes 
1-4). Notably, pPRHΔC is located exclusively in the post-nuclear extract (figure 5.16 - 
central middle panel) and it accumulates until 8 hours after treatment (figure 5.16 - 
central middle panel, lanes 1-3), yet by 24 hours the band appears reduced 
compared to the 8 hour time point (figure 5.16 - central middle panel, lanes 4 and 3). 
One possible reason for these observations is that phosphorylation of PRH reduces 
its nuclear retention, thus the cleavage of PRH to produce pPRHΔC only  occurs in 
the post-nuclear compartment. Alternatively  pPRHΔC  could be produced in the 
nucleus but is not retained in the nuclear compartment. In conclusion pPRH has a 
short half-life relative to PRH and both pPRH and pPRHΔC  are not tightly  retained in 
the nucleus.
PRH has been shown to interact with the HC8 subunit of the proteasome(Bess et al., 
2003), however, the role of this interaction in vivo is unknown. CK2 phosphorylation 
of PML induces proteasome-dependent degradation of PML (Scaglioni et al., 2006). 
To investigate whether the proteasome is important for degradation of PRH protein, 
K562 cells were treated with anisomycin and the proteasome inhibitor, MG132, for 0, 
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4, 8 and 24 hours. MG132 is a specific small reversible proteasome inhibitor, which 
specifically inhibits the chymotrypsin-like activity  of the 20S proteasome (Chen et al., 
1995). The treated cells were harvested and fractionated into post-nuclear and 
nuclear protein fractions as before. Protein extracts were separated by  SDS-PAGE 
and transferred onto a PVDF membrane for antibody staining. The membrane was 
stained with the mouse anti-PRH antibody and was then stripped of antibody and re-
probed using the rabbit anti-pPRH antibody, or an anti-Tubulin, or anti-Lamin A/C 
antibody. It can be seen that the level of unphosphorylated PRH (figure 5.17 [A] - top 
panel) is not affected by anisomycin treatment over 24 hours in either the post-
nuclear or the nuclear fractions (figure 5.16). However, in the presence of both 
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Figure 5.18 - CK2 phosphorylation mutants of PRH have reduced nuclear retention.
K562 cells transfected with pMUG1 containing Myc–PRH, Myc-PRH S163C,S177C and 
Myc–PRH S163E,S177E were fractionated into post-nuclear and nuclear extracts. Proteins 
were separated by  SDS-PAGE and transferred to a PVDF membrane. Proteins were stained 
with anti-Myc (top panel), anti-Tubulin (middle panel) and anti-Lamin A/C (bottom panel) 
antibodies. Data representative of two independent experiments.
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anisomycin and MG132 pPRH is stabilized in both post-nuclear and nuclear fractions 
(figure 5.17 [A] - upper middle panel). Additionally, pPRHΔC present in the post-
nuclear fraction only, is now stable over 24 hours (figure 5.17 [A] - central middle 
panel), and does not fluctuate over time compared to cells treated with anisomycin 
alone (figure 5.16). These results suggest that CK2 phosphorylation of PRH targets 
PRH for cleavage and degradation by the proteasome, yielding a 27kDa product that 
is not tightly held in the nucleus.
To confirm that the degradation is specific to the proteasome, K562 cells were treated 
with 40µM anisomycin and 10µM lactacystin for 0 and 24 hours. Lactacystin is an 
irreversible inhibitor of proteasome activity and is active against the trypsin-like and 
chymotrypsin-like proteolytic activity of the 20S proteasome (Jensen et al., 1995). 
The treated cells were then harvested and fractionated into post-nuclear and nuclear 
extracts. Protein extracts were run on a SDS-PAG before transferring the proteins to 
a PVDF membrane for antibody staining. The membrane was stained as described 
above. Unphosphorylated PRH (figure 5.17 [B] - top panel) is stable over 24 hours of 
treatment with anisomycin and lactacystin. pPRH is stabilized compared to cells 
treated with anisomycin alone (figure 5.16 - upper middle panel). In cells treated with 
anisomycin alone, pPRH is not present after 24 hours in either the post-nuclear or 
nuclear fraction (figure 5.16 - upper middle panel, lanes 4 and 8), however, when 
cells are treated with lactacystin and anisomycin, pPRH can be seen (figure 5.17 [B] - 
upper middle panel, lanes 2 and 4). The pPRHΔC protein is also stabilized in 
lactacystin and anisomycin treated cells (figure 5.17 [B] - central middle panel) 
compared to cells treated with anisomycin alone (figure 5.16 - central middle panel). 
This confirms that CK2 phosphorylation of PRH is a signal for proteasome cleavage 
of full-length PRH protein to a 27 kDa intermediate, pPRHΔC, before complete 
degradation.
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To confirm that CK2 phosphorylation of PRH affects the nuclear retention of PRH, 
K562 cells were transfected with PRH, or PRH S163C,S177C, or PRH 
S163E,S177E. 24 hours after transfection the cells were harvested and fractionated 
into post-nuclear and nuclear extracts. Proteins were separated on a SDS-PAG and 
transferred to a PVDF membrane. The membrane was stained using an anti-Myc 
antibody to detect the expression of the transfected Myc-PRH proteins. Subsequently 
the membrane was stripped of antibody and stained with antibodies against Tubulin 
or Lamin A/C, which were used as loading and fractionation controls. PRH (figure 
5.18 - top  panel, lanes 1 and 4) and PRH S163C,S177C (figure 5.18 - top panel, 
lanes 2 and 5) can be detected in the post-nuclear and nuclear fractions. In contrast 
PRH S163E,S177E is predominantly  observed within the post-nuclear fraction (figure 
5.18 - top panel, lane 3) and is very weakly held in the nuclear fraction (figure 5.18 - 
top panel, lane 6) when compared to Myc-PRH or Myc-PRH S163C,S177C (figure 
5.18 - top panel, lanes 4 and 5 respectively). It can be concluded that 
phosphorylation of PRH within the homeodomain by CK2 reduces the nuclear 
retention of the pPRH species.
5.8 Discussion.
Previous chapters have identified PRH as a key regulator of cell survival through the 
VSP in haematopoietic cells. In vitro experiments by Soufi et al demonstrated that 
DNA binding by PRH is blocked through CK2 phosphorylation of two serine residues 
within the homeodomain (Soufi et al., 2009). This work suggested that PRH function 
could be perturbed by the stress activated regulator of survival CK2. However, the 
significance of this phosphorylation in cells was not demonstrated. In this chapter 
PRH is shown to be phosphorylated by  CK2 in cells. This phosphorylation blocks 
transcriptional repression of Vegf and Vegfr1 by PRH. This finding supports previous 
data that shows phospho-mimic mutants of PRH are unable to repress an artificial 
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reporter construct (Soufi et al., 2009). I demonstrate here that CK2 phosphorylation 
of PRH inhibits DNA binding at the Vegfr1 promoter and the Vegf promoter. CK2 
inhibition of transcription factor DNA binding has been demonstrated for another 
group  of homeodomain containing proteins, the Cut homeodomain proteins 
(Coqueret et al., 1998b). Cut homeodomain containing proteins are distinct from PRH 
and most other homeodomain containing proteins because they also contain three 
other DNA binding regions called Cut repeats. This work by Coqueret et al showed 
that CK2 could phosphorylate a key serine residue in each of these Cut repeats. 
Phosphorylation of these sites reduced transcriptional repression by mCut (Coqueret 
et al., 1998a). Cut homeodomain protein is a regulator of differentiation, cell growth 
and developmental processes (Nepveu, 2001). For example, Cut is a transcriptional 
repressor of c-Myc expression and therefore CK2 can promote growth through 
inactivation of Cut and this consequently leads to c-Myc activation (Dufort and 
Nepveu, 1994). CK2 appears to play a role in regulating many transcriptional 
repressors. In addition to blocking DNA binding by  PRH and Cut, CK2 
phosphorylation has been shown to alter the activity of the transcription factor, CTCF, 
from a transcriptional repressor into an activator of transcription (El-Kady and 
Klenova, 2005). CK2 phosphorylation of insect Hox proteins, of the UBX ortholog 
class, inhibits the repression of Distal-less (Dll) transcription, although this is thought 
to be mediated through sites C-terminal to its homeodomain (Taghli-Lamallem et al., 
2008). Furthermore, there are multiple examples of CK2 phosphorylation of co-
repressors. This includes the co-repressor and tumour suppressor PML, which is 
phosphorylated by CK2 and targeted for degradation by the proteasome (Scaglioni et 
al., 2006). Other targets include TLE (Nuthall et al., 2004) (which will be discussed 
further below) and SMRT (Zhou et al., 2001). However, these phosphorylation events 
appear to be linked to developmental processes rather than stress activated 
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Figure 5.19 - Role of PRH truncation after CK2 phosphorylation.
Schematic diagram proposing a model for PRH degradation through ubiquitin-dependent or 
ubiquitin-independent pathways, and a role for PRH truncation by  the proteasome in 
response to CK2 phosphorylation. 
responses.
Another feature of proteins phosphorylated by CK2 is that the phosphorylation event 
can alter the stability or turn-over rate of the protein. The tumour suppressor protein 
PML is phosphorylated by CK2 at multiple sites with the major phosphorylation site 
serine 517 within the degron domain of PML (Scaglioni et al., 2006). There are also 
other phosphorylation sites, with phosphorylation of serine 517 priming 
phosphorylation of serine 514, as well as other minor CK2 phosphorylation sites 
within the downstream PEST domain (Scaglioni et al., 2006). Phosphorylation of 
serine 517 is critical for ubiquitin-mediated proteasomal degradation of PML 
(Scaglioni et al., 2006). Other proteins that have reduced stability  after CK2 
phosphorylation include, IκB (McElhinny et al., 1996), and SAG (He et al., 2007). In 
contrast, c-myc is a good example of how CK2 can reduce protein turnover and 
thereby increase protein stability (Channavajhala and Seldin, 2002). In the case of 
PRH, phosphorylation by CK2 appears to target PRH for proteasomal degradation 
producing a truncated cleavage product pPRHΔC, which appears to be more stable 
than the full length pPRH protein. At present it is unknown whether the proteasomal 
degradation of full-length PRH occurs through a ubiquitin dependent degradation 
pathway (figure 5.19). It is possible that the observed cleavage of PRH and 
subsequent degradation is independent of ubiquitin conjugation because it has 
previously been shown that PRH interacts with the HC8 subunit of the proteasome 
(Bess et al., 2003). This study by Bess et al demonstrated that despite the interaction 
there was little effect of the proteasome on the half-life of full length 
unphosphorylated PRH either in vitro or in vivo. However, these studies did not 
examine the effect of the proteasome on phosphorylated PRH. Interestingly, they did 
observe that partially degraded PRH is a better substrate for the 20S and 26S 
proteasomes than the full length PRH, and that degradation is mediated through a 
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ubiquitin-independent mechanism (Bess et al., 2003). As shown in this chapter, CK2 
phosphorylated full length PRH is rapidly cleaved to form pPRHΔC, which retains the 
N-terminal domain and homeodomain of PRH. It is possible that CK2 phosphorylation 
of PRH may alter the conformation of PRH making it a better substrate for the 
proteasome or that phosphorylation may facilitate ubiquitylation and subsequent 
cleavage. Since the pPRHΔC product is relatively stable, compared to the full-length 
pPRH in vivo, it may very  well have some role in other cellular processes in the 
cytoplasm. Although this product still contains the homeodomain it is very unlikely 
that it can bind DNA as it will be phosphorylated within the homeodomain. However, 
pPRHΔC could still bind to unphosphorylated PRH in the cytoplasm, as it retains the 
N-terminal domain that is necessary  for PRH dimerization/oligomerization. Therefore, 
it is possible that pPRHΔC could alter the post-transcriptional regulation activity of 
PRH, because the eIF4E interaction site, also within the N-terminal domain, is 
retained. Alternatively, this pPRHΔC  protein may disrupt PRH oligomer formation or it 
may sequester TLE, reducing TLE availability  for full-length unphosphorylated PRH. 
Notably, pPRHΔC  is not tightly held in the nuclear compartment, so it is unlikely to 
have direct transcriptional functions, although there could be indirect consequences 
on transcription through sequestration of TLE or other co-factors. Further 
experiments will be required to determine the role of this form of PRH. 
Both PRH and PML are rapidly  degraded upon CK2 phosphorylation (Scaglioni et al., 
2006). PRH associates with PML and is a constituent of PNBs (Topisirovic et al., 
2003a; Topcu et al., 1999). PNBs are nuclear matrix associated structures 
(Lallemand-Breitenbach and de Thé, 2010). PRH is also found at the nuclear matrix 
(P-S Jayaraman, unpublished observations). CK2 is a well established nuclear matrix 
factor that can re-localize to the nuclear matrix in response to growth factor 
stimulation (Guo et al., 1999; Faust and Montenarh, 2000). Therefore, CK2 
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phosphorylation of PRH and PML could be occurring within the nuclear matrix 
compartment. In support of this idea, proteasome and ubiquitin E3 ligases necessary 
for PML degradation have been observed to co-localize with PNBs (Lallemand-
Breitenbach et al., 2008; Lallemand-Breitenbach et al., 2001). Similarly, PRH 
cleavage and production of pPRHΔC could also be occurring at PNBs in association 
with the nuclear matrix and may represent a mechanism for the removal of PRH from 
DNA and the nuclear matrix. 
Not only does CK2 phosphorylation of proteins affect the transcriptional activity, DNA 
binding activity and stability of target proteins but it can also alter their sub-cellular 
localization. I have shown that the nuclear retention of the PRH protein is affected by 
CK2 phosphorylation. There are clear parallels between PRH and Ikaros in their 
function and regulation in general terms. For example, Ikaros is important for the 
regulation of haematopoiesis, with key roles in the differentiation of myeloid 
(Dumortier et al., 2003) and lymphoid (Wu et al., 1997) lineages, and is thought to 
have tumour suppressor functions (Winandy et al., 1995). Ikaros can also act as a 
transcriptional repressor or activator, like PRH. Work by Gurel et al demonstrated that 
Ikaros DNA binding capacity is negatively  regulated by CK2 (Gurel et al., 2008). 
Furthermore, they showed that CK2 phosphorylation of Ikaros reduced its 
pericentromeric heterochromatin (PC-HC) localization (Gurel et al., 2008). This 
chapter shows that the sub-cellular localization of PRH is effected by CK2 
phosphorylation in a similar way to Ikaros. Reduced nuclear retention of PRH is 
observed for the CK2 phospho-mimic mutant of PRH. Additionally, the endogenous 
full length pPRH protein is predominantly present in the post-nuclear fraction. There 
is a small amount of pPRH that is present in the nuclear fraction but it is lost from the 
nuclear fraction within four hours of treatment with anisomycin. Since the half-life of 
CK2 is very short it is likely that four hours after treatment CK2 activity has been lost 
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and there is no further phosphorylation of PRH by  CK2 taking place in the cell 
(Lüscher and Litchfield, 1994). Therefore, the more rapid loss of pPRH from the 
nuclear compartment suggests that PRH is phosphorylated in the nuclear 
compartment. This phosphorylation then reduces nuclear retention and the pPRH 
remains only in the post-nuclear compartment. Thus, CK2 phosphorylation of PRH 
could be reducing PRH transcriptional repression activity through both reduction of 
DNA binding and through altered sub-cellular localization. Increased pPRH and its 
degradation product in the post-nuclear compartment could potentially enhance other 
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Figure 5.20 - PRH controls a component of BCR-ABL1 induced cell survival.
Schematic diagram proposing a model for how BCR-ABL1 and CK2 regulate VSP gene 
expression through PRH. 
interactions or functions of PRH in the post-nuclear compartment. PRH and Ikaros 
are not the only  examples of altered sub-cellular localization through CK2 
phosphorylation. CK2 phosphorylation can either favour nuclear export, such as for 
S6 kinase 1 II (S6K1 II) (Panasyuk et al., 2006), or block nuclear export, such as for 
CDC34 (Block et al., 2001), demonstrating the diversity of outcome from CK2 
phosphorylation.
CK2 is activated in response to stress signals such as osmotic shock or UV radiation. 
These signals activate p38 MAPK which can directly interact with CK2 and stimulates 
CK2 activities (Sayed et al., 2000). Stress-induced CK2 activation has been shown to 
be important for the induction of the NF-κB pathway. NF-κB is a pro-inflammatory 
transcription factor that is negatively regulated through an interaction with IκB. CK2 
can phosphorylate the C-terminal domain of IκB and cause degradation of IκB, thus 
activating NF-κB nuclear translocation and transcriptional activity  (Kato et al., 2003). 
PML phosphorylation and degradation (Scaglioni et al., 2006; Scaglioni et al., 2008), 
and p53 phosphorylation at serine 392 (Sayed et al., 2000) have also been observed 
in response to osmotic stress or UV radiation. Currently, it is unknown whether PRH 
responds to extracellular signals and although it has not been investigated in this 
thesis, PRH activity is very likely to also be regulated as a response to stress.
The role of CK2 in response to stress stimuli and the evolutionary conservation of the 
CK2 proteins suggests that they are fundamental for cell survival. Therefore, it is 
unsurprising that aberrant CK2 activity is a feature of many malignant diseases. One 
of the most obvious links to cancer is through the interaction of CK2 with the BCR-
ABL1 fusion protein that is found in acute lymphoblastic leukaemia (ALL) and chronic 
myelogenous leukaemia (CML). The CK2α subunit was identified as a binding 
partner of the BCR moiety of the BCR-ABL1 oncogene (Mishra et al., 2003) and it is 
thought to be phosphorylated by the kinase activity  of ABL1 (Hériché and Chambaz, 
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1998). Interestingly, in p190 BCR-ABL1 lymphoblastic leukaemia cells, monotherapy 
by a CK2 inhibitor (DMAT), has been shown to substantially reduce viability of these 
cells, suggesting that CK2 plays a critical role in BCR-ABL1 dependent 
transformation. However, although CK2 activity was shown to be increased in 
patients with CML in blast crisis (Phan-Dinh-Tuy et al., 1985), a role for CK2 in a 
CML model has not been clearly demonstrated. K562 cells are derived from a CML 
patient in blast crisis and contain the Philadelphia chromosome that encodes the 
p210 BCR-ABL1 fusion protein. In this chapter, phosphorylation of PRH by  CK2 is 
significantly decreased when K562 cells are treated with either Imatinib or Dasatinib, 
two BCR-ABL1 inhibitors. Furthermore, target genes of PRH are repressed to a 
greater extent. Importantly however, increased repression of target genes is only 
observed in the presence of PRH. This evidence indicates that CK2 activity is a 
feature of BCR-ABL1 molecular biology and it likely highlights the significance of 
PRH regulation by CK2. Transcriptional repression of the VSP by PRH is a key 
process in the regulation of K562 cell survival. Therefore it can be concluded that 
dysregulation of PRH through CK2 and the consequent increased survival, through 
up-regulation of VSP genes, is a feature of p210 BCR-ABL1 CML.
Similar to DMAT treatment, Dasatinib  also has no effect on repression in the absence 
of PRH. Dasatinib has a less potent effect on cell survival in the absence of PRH 
also. This suggests that there is a pathway from BCR-ABL1 inhibition by Dasatinib, to 
CK2 inhibition, increased PRH activity, observed as increased repression of multiple 
VSP genes and increased cell death. It can be inferred that increased CK2 activity as 
a consequence of BCR-ABL1 activities and consequent inactivation of PRH activity 
could be a contributor to BCR-ABL1 molecular biology (figure 5.20).
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General Discussion
6 General Discussion.
6.1 General Discussion.
This thesis has demonstrated that PRH is a direct transcriptional repressor of three 
VSP genes, Vegf, Vegfr1, and Vegfr2. PRH directly binds to the promoter regions of 
these genes and recruits TLE proteins to bring about transcriptional repression. PRH 
expression can alter the sub-cellular localization of TLE and also induce 
phosphorylation of TLE (Desjobert et al., 2009). The role of PRH expression on cell 
growth and the induction of an apoptotic response has been investigated. Expression 
of the VSP genes that PRH regulates have been shown to be important for cell 
survival. Furthermore, post-translational modification of PRH has been demonstrated 
to be a key regulatory feature of PRH activity. Finally, a role for dysregulation of PRH 
function in CML, through altered CK2 phosphorylation, has been demonstrated. 
As well as having a role in haematopoietic diseases, the direct regulation of the VSP 
genes by PRH could be important for embryonic development. As summarized in the 
introduction (see section 1.2.4) PRH expression is lost in the vascular system. 
However, PRH is required for the formation of the angioblast (Guo et al., 2003). It is 
likely  that PRH expression must be lost in the haemangioblast for the angioblast to 
form due to direct repression of key endothelial lineage genes, such as Vegfr2 and 
Vegf. This is supported by work from Nakagawa et al, who reported that PRH 
regulates a number of other endothelial genes although the mechanism of regulation 
for these genes was not investigated (Nakagawa et al., 2003). Therefore PRH is 
involved in lineage commitment of HSCs and angioblasts and this maybe partially 
through the direct regulation of the VSP genes.
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Chapter 3 identified a role for TLE as a transcriptional repressor of Vegf and Vegfr1 
expression, through an interaction with PRH. TLE, like PRH, is phosphorylated by 
CK2. Nuthall et al demonstrated that the DNA-binding protein Hes-1, induced hyper-
phosphorylation and increased the nuclear retention of TLE (Nuthall et al., 2002a) 
and that CK2 phosphorylation of serine residue 239 within the CcN domain of TLE 
was required. As demonstrated in chapter 3 PRH over-expression increases  nuclear 
retention of endogenous TLE and is known to induce hyper-phosphorylation of TLE, 
although it is unknown whether this occurs in a CK2 dependent fashion. Interestingly, 
CK2 phosphorylation of TLE increases the transcriptional repression activity of TLE, 
whereas CK2 phosphorylation of PRH reduces transcriptional activity. Therefore, 
there appears to be conflicting outcomes of CK2 activity  on transcription, where it 
both promotes and inhibits expression of PRH and TLE target genes. It is worth 
noting that in experiments performed by Nuthall et al, they used HEK293 cells, a cell 
line derived from human embryonic kidney cells, and not K562 cells, so there may be 
cell type differences or other kinases that can hyper-phosphorylate TLE. More likely 
however, is that this is a ʻself-regulatingʼ mechanism (figure 6.1). If CK2 activation is 
thought of as a survival response to stress, then there needs to be a point at which 
the cell can overcome this survival response and undergo apoptosis. In a steady 
state situation, there are low levels of TLE in the nucleus and some PRH bound at 
promoters of target genes repressing transcription. If a stress response is induced, 
then CK2 activity  is increased and PRH activity  is reduced, resulting in increased cell 
survival. However, if PRH expression becomes elevated and recruits TLE then CK2 
may preferentially phosphorylate TLE instead of PRH, therefore increasing 
transcriptional repression. The outcome of this mechanism would be determined by 
the threshold of PRH. Up  to a point, the level of expression of PRH would not be 
sufficient to recruit enough TLE to inhibit CK2 phosphorylation of PRH and increase 
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Figure 6.1 - Model for PRH versus TLE phosphorylation by CK2.
Schematic diagram showing how the levels of CK2 activity  or the expression levels of PRH 
or TLE may favour PRH phosphorylation instead of TLE phosphorylation by CK2.
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transcriptional repression, but once the threshold is surpassed the level of 
transcriptional repression would increase, promoting apoptosis (figure 6.1).
This thesis has demonstrated a role for PRH regulation in K562 CML cells. Figure 6.2 
presents a model for the role of PRH within the regulation of this disease state and 
how it is manipulated to favour the progression of malignant phenotypes. This model 
shows that PRH, as an oligomer, recruits TLE and binds to regulatory sequences 
within the promoter regions of the VSP genes, Vegf, Vegfr1, and Vegfr2. It can be 
assumed that further proteins are also recruited to this repression complex, such as 
HDACs which are associated with TLE proteins. Transcriptional repression of the 
Vegf, Vegfr1 and Vegfr2 genes reduces the expression of the protein products of 
these genes. Subsequently there is a decrease in survival signalling through the VSP. 
In this system PRH acts as a regulator of cell survival through the VSP. However, 
CK2 is able to regulate PRH activity. Inappropriate expression or up-regulation of 
CK2 leads to direct restriction of PRH function through phosphorylation. CK2 inhibits 
DNA binding by  PRH and induces proteolytic cleavage and degradation of PRH by 
the proteasome. Furthermore, CK2 restricts the nuclear localization of PRH. 
Consequently, this leads to increased expression of the VSP genes and enhanced 
survival signalling. 
In addition to the implied role of CK2 in CML and ALL, CK2 activity has also been 
linked with a number of other haematopoietic diseases. AML is a heterogenous 
disease with no single dominant mutation that characterizes the disease. Recent 
work by Kim et al identified CK2 expression as a marker for a poor prognosis in AML 
patients (Kim et al., 2007). They found that CK2 expression correlated with a 
significant reduction in patient survival. Over-expression of CK2 also results in 
increased levels of key survival or anti-apoptotic genes (Kim et al., 2007). One of 
these genes is Bcl-2, a negative modulator of apoptosis, and interestingly, this gene 
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Figure 6.2 - Model of PRH dysregulation in K562 cells.
Schematic diagram showing how PRH dysregulation through elevated CK2 activity, in K562 
cells (B), can drive cell survival through inhibition of PRH function and targeted degradation 
of PRH protein compared to a normal myeloid progenitor cell (A).
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is also induced through VEGF signalling in haematopoietic cells (Dias et al., 2002), 
and is vital for VEGF survival signalling. Expression of PRH is reduced or PRH 
protein is mis-localized in a subset of AML patient samples, and CML patients in blast 
crisis (Topisirovic et al., 2003b). PRH regulates VEGF expression in haematopoietic 
cells. Interestingly, neo-vascularization of the bone marrow is an associated 
pathology of AML (Hussong et al., 2000; Padró et al., 2000; Matuszewski et al., 2007; 
Shih et al., 2009). It has been demonstrated that bone marrow samples taken from 
AML patients have significantly increased micro-vessel counts, whereas these 
decrease to control levels in patients undergoing chemotherapy or in patients that are 
in complete remission (Padró et al., 2000). In addition, it has been shown that the 
release of soluble mediators from AML cells stimulates increased proliferation of 
microvascular endothelial cells (Hatfield et al., 2009). VEGF is a potent endothelial 
cell mitogen and critical for angiogenesis (Leung et al., 1989; Ferrara et al., 1996). 
Reduced PRH expression results in elevated VEGF production. It is therefore 
possible that PRH levels in cells taken from AML patients may correlate with bone 
marrow neo-vascularization. It is worth noting that once CML has progressed to the 
blast crisis phase of the disease it behaves like an AML. For this reason K562 cells, 
derived from a patient CML in blast crisis, has also been described as a model of 
AML (Peinert et al., 2010; Tiziani et al., 2009). With the evidence demonstrated in this 
thesis, it is reasonable to hypothesize that PRH function could be altered in many 
more AML cases than the subsets previously analyzed. It is highly likely that PRH 
activity  may also be perturbed in AML patients where the activity or expression of 
CK2 is high. High CK2 activity was found in over 30% of AML cases tested, this 
suggests that suppression of PRH function by CK2 may be a major contributor to 
AML. Since, PRH activity can also be affected when it is poorly expressed or mis-
localized, this suggests that the role for PRH in AML may be significantly greater than 
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initially anticipated. Furthermore, the antibody against pPRH could potentially be 
used as a diagnostic tool, to identify AML patients with elevated CK2 activity and 
reduced transcriptional function of PRH. 
In conclusion, PRH is a pleiotropic transcription factor, that can be dysregulated 
during normal haematopoiesis, resulting in aberrant survival signalling through the 
VSP. PRH is an interesting model of gene regulation within the haematopoietic 
compartment due to its oligomeric properties and relaxed binding specificity. 
However, further investigation is required to fully understand the mechanism through 
which PRH represses gene expression. One unanswered question is whether the 
relative position of binding sites compared to the TSS or the number of regions, 
within a promoter, bound by PRH determine high and low affinity  gene targets of 
PRH. For example there are interesting differences in the regulation of the VSP 
genes by PRH. The Vegfr1 gene is bound by PRH in the proximal promoter and at 
sites as far away as -5.6 kb upstream of the TSS. However, for the Vegf gene PRH 
binds in the distal promoter region, weak binding by PRH has been reported around 
-3.5 kb and -4.5 kb upstream of the TSS and promoter reporter assays further 
confirmed that the proximal promoter region of Vegf is not regulated by PRH (Noy et 
al., 2010). This could suggest differential cross-talk with other transcription factors 
bound to these promoters. For example, the distal regulation at Vegf may 
demonstrate weaker repression of some transcription factors, such as those that bind 
at the TSS compared to those that bind to upstream sites. Whereas PRH regulation 
of Vegfr1 may be stronger for proximal bound transcription factors compared to distal 
ones. Additional investigation would be required to clarify this sort of cross-talk 
between different regulatory factors bound at a specific gene. It is also possible that 
the relative position that PRH binds compared to the TSS is irrelevant because of the 
three dimensional positioning of chromatin structure. For example, binding of PRH to 
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the Vegf promoter may induce looping so that these distal regions interact and induce 
a similar mechanism of regulation to genes where PRH binds to the proximal 
promoter, such as Vegfr1 and Vegfr2. The use of chromatin conformation capture 
(3C) would be ideal for elucidating the mechanism of PRH induced transcriptional 
repression at Vegf and Vegfr1 (Dekker et al., 2002). For 3C cells are formaldehyde 
cross-linked, thereby binding associated regions of chromatin together. This is 
followed by enzymatic digestion, leaving two DNA fragments bound by  the 
formaldehyde cross-linker, and intramolecular ligation, so the two associated 
fragments are ligated together. Finally, PCR can be performed on the ligation 
product, with one primer annealing to each of the annealed fragments. If used with 
ChIP data, this technique could be utilized to determine whether PRH bound 
promoter regions are associated with the TSS of the Vegf and Vegfr1 genes. 
This thesis has also demonstrated the importance of post-translational regulation of 
PRH by CK2 and suggests that other post-translational modifications will also alter 
PRH functionality. Although the molecular basis of CK2 regulation of PRH has been 
investigated and discussed at length in this thesis there is still further work required to 
fully understand the significance of CK2 phosphorylation in disease. CK2 has a role 
in cancer for many tissues (Ruzzene and Pinna, 2010). Thus, CK2 phosphorylation of 
PRH may be relevant in other tissues where PRH is expressed. In the 
haematopoietic compartment, CK2 has also been observed to be highly  up-regulated 
in AML patients with a poor survival prognosis (Kim et al., 2007). It is known that 
reduced PRH expression or activity is a feature of some AMLs (Topisirovic et al., 
2003b; Jankovic et al., 2008). Therefore, AML patients with elevated CK2 activity  may 
have reduced PRH activity without affecting PRH expression or the potential 
functionality of PRH. However, this work suggests that PRH is an important protein in 
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maintaining the homeostasis of myeloid progenitor cells, which may be relevant to a 
number of other cell types.
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